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ABSTRACT 
Mycosamine-containing polyene macrolides represent a large family of natural products 
with antifungal activity, of which amphotericin B (AmB) is an important member. Several of 
these clinically vital but toxic agents have been proposed to exert their biological activity 
through ion channel formation and thus represent small molecules with the capacity to perform a 
protein-like function. This function and the dose-limiting toxicity of AmB are thought to be 
dependent upon the presence of sterols in the cellular membrane, but the precise role of sterols in 
this mechanism and even whether channel formation and antifungal activity are causatively 
linked has remained unclear. An advanced understanding of this mechanism thus stands to 
enable the development of new antifungals with improved therapeutic index, as well as small 
molecule prosthetics which can replicate the function of missing or dysfunctional proteins for the 
treatment of human disease. 
All members of this family contain a conserved structural motif bearing a carboxylic acid 
and the rare aminosugar mycosamine. These groups are proposed to form polar interactions 
which stabilize the putative ion channel complex, anchor these compounds to the lipid bilayer, 
and/or promote an interaction with sterol. We employed a series of AmB derivatives lacking 
each of these functional groups to test these contested and unresolved hypotheses. We found that 
mycosamine is necessary for promoting a direct binding interaction with sterol, and that deletion 
of mycosamine abolishes sterol binding, channel formation, and antifungal activity.  
The C35 hydroxyl group of AmB has also been proposed to be critical for ion channel 
formation. We synthetically removed this group, and the resulting derivative had no membrane 
permeabilizing activity but retained the ability to bind ergosterol. This compound exhibited 
fungicidal activity like that of natamycin, another mycosamine-containing polyene macrolide 
which binds ergosterol and does not permeabilize membranes. Removal of mycosamine from 
natamycin also abolished its antifungal activity. Collectively, these results led us to conclude that 
mycosamine-mediated sterol binding is the primary mechanism of action of these natural 
products, and that channel formation represents a complementary mechanism which further 
increases drug potency. 
Given the functional importance of the conserved substructure of mycosamine-containing 
polyene macrolides, we synthesized a building block containing this motif with the potential for 
application to a general platform for small molecule synthesis based on iterative cross-coupling. 
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This synthesis was enabled by the development of a new type of diastereotopic group-selective 
lactonization and a new directing group for the challenging installation of the mycosamine sugar. 
This building block may help enable the modular synthesis of these natural products and their 
derivatives not readily accessible via degradation. Additionally, the discovery that mycosamine-
mediated sterol binding is the primary mechanism of action of polyene macrolides may inform 
future efforts to improve the therapeutic index of these compounds and to develop small 
molecule prosthetics for the treatment of human disease. 
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CHAPTER 1  
 
Mycosamine-Containing Polyene Macrolides 
 
1-1 BIOLOGICAL ACTIVITY AND STRUCTURE OF MYCOSAMINE-CONTAINING 
POLYENE MACROLIDES 
Invasive fungal infections represent a current and growing threat to human health. 
Infections stemming from the pathogenic yeast Candida albicans represent the fourth most 
common cause of hospital-acquired bloodstream infections,
1
 and the mortality rate for these 
infections is extremely high (30-80%).
2
 The resulting estimated costs to the healthcare system of 
the United States approaches $1 billion annually,
3
 and the increasing number of 
immunocompromised patients is expected to further exacerbate the occurrence of these 
infections.
4
 Additionally, the emergence of microbial resistance challenges the current arsenal of 
treatment options available for systemic mycoses and more generally represents a global health 
problem of immediate concern.
5,6 
Prior to 1950, the prognosis for patients with fungal infections was extremely grim. With 
a mortality rate of nearly 100%, new treatments for these diseases were desperately needed.
7
 In 
1944, microbiologist Elizabeth Hazen discovered a strain of bacteria, Streptomyces noursei, that 
produced an agent with potent antifungal activity but which was inactive against bacteria. This 
profile was unique compared to other known antibiotics at the time. In 1950, working with 
chemist Rachel Brown, Hazen reported the isolation of this new antibiotic, which they named 
fungicidin.
8,9,10
 To avoid confusion with another compound of the same name, the drug was 
renamed nystatin (pronounced “nye-state-in” by Hazen and Brown) after the New York State 
Division of Laboratories and Research in which Hazen and Brown collaborated. In 1954, 
nystatin was licensed by Squibb & Sons Pharmaceuticals and became the first broad-spectrum 
commercial antifungal agent.
10
 The remarkable activity of this compound against C. albicans, 
coupled with its relative lack of oral and topical toxicity, marked a paradigm shift in the 
treatment of fungal infections. The subsequent frenzy of active research in the field led to the 
isolation of several other antifungal agents
11
 from actinomycetes over the next decade: 
rimocidin
12
 in 1951, perimycin
13
 in 1952, candicidin
14
 and candidin
15
 in 1953, amphotericin
16
 in 
1955, and natamycin
17
 in 1957.  
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Soon after their isolation, efforts to characterize the chemical structure of these 
compounds began to shed light on some features common to this family of natural products. UV 
spectroscopy led to the conclusion by Taber and coworkers that they contained conjugated 
polyene units ranging from four to seven double bonds and were thus distinct from other known 
antibiotics such as agrocybin which contained poly-yne or -eneyne subunits.
18
 Chemical 
degradation suggested the presence of a new sugar identified by Walters, Dutcher, and 
Wintersteiner as D-mycosamine,
19
 as well as a gross “macrolide” structure, a term coined by 
Woodward during his classic studies of erythromycin.
20
 However, many of these antibiotics 
existed as complex mixtures of structurally related compounds which were inseparable using the 
technology available at the time.
21
 The assumption that antibiotic samples represented 
homogeneous single components greatly complicated their analysis. In fact, nystatin was 
regarded as a pure compound during its first 14 years of clinical use before it was reported that it 
contained as much as 30% of another unknown component.
22
 
Because of these confounding factors, the first correct structural proposal of a polyene 
macrolide was not advanced until 1966 when Rickards and coworkers
23
 corrected the originally 
proposed structures of natamycin
24,25
 through a combination of mass spectrometry, UV 
spectroscopy, and chemical degradation. Further highlighting the challenge of structural 
characterization, the full stereochemical assignment of natamycin was not completed until 
1990,
26
 more than 30 years after its discovery. The use of X-ray crystallography has also proved 
valuable, and a crystal structure of N-iodoacetylamphotericin B in 1970 by Schaffner and 
coworkers
27
 established the absolute stereochemistry of amphotericin B and, by extension, most 
other members of the family. 
Since the discovery of nystatin, over 200 members of this class of natural products have 
been reported, although structural characterization remains a challenge, and it is likely that at 
least some of these reports are redundant.
28
 As of 2012, 36 members of this class of natural 
products have been structurally characterized to a reasonable degree of certainty (Figures 1.1 to 
1.3). Tables 1.1 to 1.3 list these compounds with references pertinent to their structural 
determination. Though the members of this class possess a variety of different chemical 
functionality, the similarity of their overall architecture stems from the common biosynthetic 
manifold used by the organisms that produce them. 
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Figure 1.1. Mycosamine-containing tetraene macrolides. 
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Figure 1.1. (cont.) Mycosamine-containing tetraene macrolides. 
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Figure 1.2. Mycosamine-containing pentaene macrolides. 
 
 
Figure 1.3. Mycosamine-containing heptaene macrolides. 
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Figure 1.3. (cont.) Mycosamine-containing heptaene macrolides. 
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Figure 1.3. (cont.) Mycosamine-containing heptaene macrolides. 
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Figure 1.3. (cont.) Mycosamine-containing heptaene macrolides. 
 
Tetraene Structural determination reference 
amphotericin A 29 
arenomycin B 28 
CE-108 30 
etruscomycin 31 
HA-2-91 32 
natamycin 26 
nystatin A1 33 
nystatin A2 34 
nystatin A3 35 
polyfungin B 28 
rimocidin 36 
tetramycin A 37 
tetramycin B 37 
tetrin A 37 
tetrin B 37 
tetrin C 37 
YS-822A 38 
 
Table 1.1. Structural references for mycosamine-containing tetraene macrolides. 
 
Pentaene Structural determination reference 
eurocidin D 39 
eurocidin E 39 
 
Table 1.2. Structural references for mycosamine-containing pentaene macrolides. 
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Heptaene Structural determination reference 
3874 H1 40 
3874 H2 40 
3874 H3 40 
67-121-A 41 
amphotericin B 27 
candicidin D 42 
candidin 43 
candidoin 43 
FR-008-IV 44 
hamycin A 28 
levorin A0 45 
levorin A3 46 
mycoheptin 47 
particin A 48 
trichomycin A 49 
trichomycin B 49 
vacidin A 50 
 
Table 1.3. Structural references for mycosamine-containing heptaene macrolides. 
 
Polyene macrolides are synthesized via modular type I polyketide synthase (PKS) 
machinery in a manner similar to fatty acid synthesis.
51
 The iterative Claisen condensation of 
acetate-type units is mediated by the β-ketoacyl ACP synthase (ketosynthase or KS) module, 
which joins the starter unit to an extender unit linked to an acyl carrier protein (ACP). Other 
starter units can include carbon chain homologues of acetate such as propionate or butyrate, or p-
aminobenzoate in the case of the aromatic heptaenes.
52
 Three sequential and discrete steps 
transform the resulting β-ketoacyl subunit into a saturated chain. First, reduction by β-ketoacyl 
ACP reductase (ketoreductase or KR) generates a secondary hydroxyl group, and dehydration by 
dehydratase (DH) generates an α,β-unsaturated acyl group. Final conversion to the fully 
saturated chain is accomplished by enoyl reductase (ER). Inactivation of KR, DH, or ER shunts 
the pathway to generate a ketone, alcohol, or olefin, respectively, in the final macrolide. Once 
this sequence is complete, the chain enters the KS domain and begins another cycle of 
condensation with the next extender unit. After the last cycle, the chain is released and cyclized 
by a thioesterase (TE) domain.
51
 The resulting macrolides are then substantially modified 
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through dedicated tailoring enzymes (Figure 1.4). Attachment of mycosamine to the free 
hydroxyl group allylic to the polyene defines this subclass of polyene macrolides. Mycosamine 
attachment always co-occurs with the cytochrome P450-mediated oxidation of an exocyclic 
methyl group to the corresponding carboxylic acid, although the order of these two modifications 
are not dependent upon each other.
53
 
 
Figure 1.4. Post-PKS tailoring enzyme modifications to generate amphotericin B. 
 
The ubiquitous nature of mycosamine in polyene macrolides is striking given its rarity in 
other natural products.
54
 The only other characterized natural products known to contain 
mycosamine are the fluviricins, antifungal macrolactams isolated independently by workers at 
Bristol-Myers Squibb
55
 and Schering-Plough;
56,57
 and vancoresmycin, an antibacterial tetramic 
acid derivative.
58
 Additionally, the oxidation of the exocyclic methyl group in the same region as 
the mycosamine sugar is another rare event in natural products.
54
 Caffrey and coworkers
59
 have 
proposed that the co-occurrence of these two unique modifications may arise from the co-
evolution of the enzymes which install them. In the biosynthesis of mycosamine, GDP-D-
mannose is dehydrated at C4 and C6 by GDP-D-mannose 4,6-dehydratase to give GDP-4-keto-
6-deoxy-D-mannose. A 3,4 isomerization to give GDP-3-keto-6-deoxy-D-mannose followed by 
transamination then generates GDP-D-mycosamine.
51
 Based on analysis of the amphotericin, 
nystatin, and natamycin gene clusters,
54
 no gene has been found which is likely to encode for this 
putative GDP-6-deoxy-4-ketomannose-3,4-isomerase. However, homologous genes from 
organisms which produce other amino sugars that require 3,4-isomerization are very similar to 
cytochrome P450 monooxygenases such as AmphN which oxidizes the C41 methyl group in 
amphotericin B. The structure of the anomalous polyene macrolide perimycin
60
 (1.38) also 
suggests that such a link may exist (Figure 1.5). This macrolide contains the aminosugar 
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perosamine which does not require a putative 3,4-isomerase for its biosynthesis. Strikingly, the 
nearby methyl group remains unoxidized in this compound, supporting the hypothesis that the 
3,4-isomerase and P450 monooxygenase enzymes are related.
59
  
 
 
Figure 1.5. The anomalous polyene macrolide perimycin. This natural product contains the aminosugar perosamine, 
which does not require a 3,4-isomerase for its biosynthesis. Also, the nearby methyl group remains unoxidized. 
 
The co-occurrence of these rare modifications and a polyene motif in all members of this 
family led us to hypothesize that the mechanism of action of these compounds may be closely 
tied to the structural elements which are most highly conserved. This type of analysis is common 
in protein science where the comparison of amino acid sequences often leads to the identification 
of functionally critical residues.
61,62,63
 An application of this strategy is found in studies of the 
KcsA potassium ion channel by MacKinnon and coworkers.
64
 As shown in Figure 1.6, analysis 
of several potassium ion channels produced by very different organisms identified an amino acid 
sequence which was highly conserved. Structural characterization revealed that these residues 
formed the “selectivity filter” and “gating hinge” which are critical for the voltage-gated 
potassium-selective channel function of this ubiquitous type of protein. The discovery of these 
elements contributed to an atomistic understanding of the function of an entire class of molecules 
with important biological activity and stands as a classic example of structure-function homology 
in protein science.
65
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Figure 1.6. (A) Sequence homology of potassium ion channels from a variety of species. The conserved selectivity 
filter is highlighted in orange, and the glycine residue critical for gating is highlighted in red. (B) These features are 
highlighted in the intracellular pore of the MthK potassium ion channel crystal structure. Figure adapted from 
reference 64. 
 
Inspired by this work and with the goal of identifying the structural features of 
mycosamine-containing polyene macrolides which might be critical for their mechanism of 
action, we have performed the same type of analysis on the members of this family for which 
reasonable structural information is available (Figures 1.1 to 1.3 and Tables 1.1 to 1.3). Each 
macrolide ring was analyzed as its corresponding linear chain. Similar to the single letter codes 
used to identify amino acid residues and nucleotide bases, we have developed a series of single 
letter codes to identify the functional group present at each carbon of the linear macrolide. In this 
way, each mycosamine-containing polyene macrolide may be identified by a unique sequence of 
letter codes which describe not only its PKS-based synthesis but also the post-PKS modifications 
which lead to the final product. The resulting sequences were then aligned with respect to the 
common site of mycosamine attachment. 
The results of this analysis are shown in Figure 1.7. Strikingly, the region surrounding the 
mycosamine attachment point shows a highly conserved pattern of functional groups. This 
encompasses the “eastern” portion of these molecules and contains a 6-membered hemiketal, the 
aforementioned carboxylic acid and mycosamine, and a portion of the polyene. Interestingly, the 
biosynthetic gene cluster which encodes this portion of the macrolide structure has been 
proposed to arise via horizontal gene transfer amongst Streptomyces species and thus may confer 
some advantage to those organisms which retain it.
66
 This analysis suggests that the functionality 
contained within this highly conserved motif may be critical to the mechanism of action of this 
entire class of natural products. Additionally, this type of analysis may be more broadly 
applicable to the identification of structural motifs which are critical for the diverse functions 
performed by other classes of small molecules.  
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Figure 1.7. Conservation of the hemiketal/mycosamine-containing motif in all structurally characterized members 
of this family. The substructure above represents the portion highlighted in blue and shows 100% homology. The 
structural abbreviations are defined as shown. 
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O
A H A
M
OE OE OE OE OE OE OZ OZ OZ OZ OE OE OE OE M AL M H H A H PM
3874 H3 L H A H A H H H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OZ OZ OE OE OE OE OE M AL M H H A H K OE OE OE OE H
67-121-A L H A H A H A H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H H A H PM
candicidin D L H K H H H K H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H M A H PA
FR-008-IV L H K H A H K H H H A H H H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H M A H PA
hamycin A L H A H A H A H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H H A H PA
levorin A0 L H K H H H K H A H H H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H M A H PA
levorin A3 L H A H H H K H A H A H A H K H A M
O
A H A
M
OE OE OE OE OZ OZ OZ OZ OE OE OE OE OE OE M AL M H M A H PA
partricin A L H A H K H A H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OZ OZ OZ OZ OE OE OE OE M AL M H M A H PM
trichomycin A L H K H A H A H H H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H H A H PA
trichomycin B L H K H H H A H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OE OE OE OE OE OE OE OE M AL M H H A H PA
vacidin A L H A H K H A H A H A H A H K H A M
O
A H A
M
OE OE OE OE OE OE OZ OZ OZ OZ OE OE OE OE M AL M H M A H PA
ketone K ethyl E acid MO
alcohol A propyl R mycosamine AM
E olefin OE butyl B keriose A
K
Z olefin OZ lactone carbonyl L jannose A
J
CH2 H lactonized alcohol AL epoxide from E olefin OE
E
methyl M aminophenone PA epoxide from Z olefin OZ
E
methylaminophenone PM
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1-2 CURRENT MECHANISTIC UNDERSTANDING 
As the clinical use of mycosamine-containing polyene macrolides became more 
widespread, efforts to understand the mechanism of action of these natural products intensified. 
This field of study remains highly active and of great importance to current efforts towards 
improving human health. Strikingly, despite almost 60 years of use, minimal clinically relevant 
resistance has developed against any of the mycosamine-containing polyene macrolides.
5,67
 This 
stands in stark contrast the rapid emergence of resistance to most new antibiotics which is 
typically observed within a few years of their introduction and currently represents a global 
public health crisis. This lack of resistance is thus unique among pharmaceuticals in use today. 
Unfortunately, all members of this class exhibit serious dose-limiting side effects when 
administered intravenously to treat systemic mycoses, and AmB is the only member which 
remains in use for systemic infections. A thorough mechanistic understanding of this class of 
natural products thus stands to not only enable the rational design of antimycotics with improved 
therapeutic indices, but also may lead to the development of other resistance-refractory 
antibiotics and thereby combat the growing threat of resistance to the modern pharmaceutical 
arsenal. 
The first studies
11
 of the mechanism of action of these natural products began with the 
demonstration by Osteux and coworkers in 1958 that nystatin induced leakage of low molecular 
weight cellular contents from C. albicans, but that larger solutes were retained.
68
 The ability of 
these natural products to permeabilize membranes has subsequently been the mechanistic 
manifold most often implicated in the mode of action and toxicity of these compounds.
51,69,70
 
Electrophysiology experiments utilizing planar black lipid bilayers (BLM) demonstrated 
unequivocally that both AmB and nystatin form discrete single ion channels.
7,71
 This was in 
contrast to other membrane active polyenes such as filipin which do not contain mycosamine and 
cause global disruption of membrane integrity rather than discrete ion channel formation.
72
 To 
investigate the size of the pores formed by AmB, Andreoli and coworkers examined the relative 
permeability of the AmB channel to solutes of increasing size and estimated a channel diameter 
of between 7 and 10 Å.
73
 
These experiments collectively led to the proposal of the now-classic barrel-stave model 
for AmB ion channel formation (Figure 1.8).
72,74,75
 In this model, a collection of eight AmB 
monomers is proposed to self-assemble into a complex in which the hydrophilic polyol regions 
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form the interior of the pore and allow the passage of hydrated ions. The hydrophobic polyenes 
line the exterior of the channel complex and engage in van der Waals interactions with the 
hydrophobic lipid tails in the interior of the membrane. Two leading mechanisms propose 
different ways in which this complex spans the lipid bilayer. The single barrel model predicts 
that this aggregate spans a dimpled bilayer, and the double barrel model predicts a dimerization 
of two octomeric complexes, each spanning one-half of the lipid bilayer.
76
 
 
Figure 1.8. Barrel-stave model for AmB ion channel formation. (A) Bird's eye view of the proposed octomeric pore 
of AmB. (B) The single (center) and double (right) barrel models for AmB pore formation. Figure adapted from 
reference 132. 
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The formation of discrete ion channels by nystatin and AmB represents a rare example of 
a protein-like function performed by a small molecule. Harnessing this ability represents a 
potential strategy for developing new treatments for diseases which result from a lack of protein 
ion channel function, such as cystic fibrosis.
77,78,79
 An atomistic understanding of this self-
assembly and channel formation process thus stands to enable not only an improved 
understanding of the mechanism of action of these natural products, but also the development of 
small molecules which may collectively perform protein-like functions in the context of living 
systems and thereby replace missing or dysfunctional proteins in human disease. 
 
 
Figure 1.9. Three types of interactions involving the C41 carboxylate and C19 mycosamine of AmB predicted to be 
critical for channel formation. (A) Intermolecular polar interactions between these groups is predicted to stabilize 
the ion channel complex. (B) Polar interactions of these groups with phospholipid head groups are predicted to 
anchor AmB to the membrane. (C) Polar interactions of these groups with membrane-embedded sterol are predicted 
to be critical for ion channel formation. Figure adapted from reference 131. 
 
Several specific functional group interactions have been proposed to be critical for a 
channel-based mechanism of action.
80
 The majority of these proposals invoke functional groups 
which are incorporated within the conserved hemiketal/mycosamine-containing motif common 
to all members of this family (Figure 1.9).
70
 Specifically, the carboxylic acid and amine 
functionalities have been proposed to be important in three different types of interactions. In the 
first proposal, polar interactions between these functional groups on adjacent AmB monomers 
are predicted to stabilize the putative barrel-stave channel complex (Figure 1.9A).
81,82,83,84
 In the 
second proposal, polar interactions of these functional groups with the phospholipid head groups 
17 
 
are predicted to anchor these compounds to the membrane (Figure 1.9B).
82,83
 Third, both of these 
groups are predicted to interact with membrane-embedded sterol via the C3-β-OH of the A ring 
in ergosterol and cholesterol (Figure 1.9C).
80,81,82,83,85,86,87
 An alternative model has been 
proposed in which indirect effects of sterols on global membrane properties, rather than any 
direct binding interactions, are responsible for the impacts of membrane sterol on the biological 
activity of AmB.
 88,89
  
The first studies to indicate that the biological activity of polyene macrolides is affected 
by the presence of sterols were performed by Herbert Carter and coworkers at the University of 
Illinois in Urbana-Champaign in 1958. They reported that the addition of exogenous sterols 
inhibited the activity of many polyene macrolides against yeast, but the role of sterols in this 
mechanism was unclear.
90
 In 1965, Feingold reported that the organism Mycoplasma laidlawii, 
which is naturally devoid of sterol and insensitive to polyene macrolides, can become sensitive 
to AmB when exogenous cholesterol is incorporated into its cellular membrane.
91
 The yeast 
Schizosaccharomyces japonicus was utilized by Bulder to demonstrate the importance of 
ergosterol, the main sterol found in fungi, in the mechanism of action of natamycin.
92
 The 
normal production of ergosterol in Sch. japonicus under aerobic conditions can be prevented by 
growing the yeast under anaerobic conditions. Sch. japonicus grown under anaerobic conditions 
and thus lacking ergosterol was insensitive to natamycin, but cultures grown under aerobic 
conditions were as sensitive as S. cerevisiae to this polyene macrolide. A body of literature was 
thus growing which strongly suggested an important role for sterols and membrane 
permeabilization in the activity of mycosamine-containing polyene macrolides, but the 
mechanistic underpinnings of their involvement were still unclear. 
As stated above, two hypotheses were proposed to account for the role of sterol in the 
mechanism of action of polyene macrolides. The first hypothesis, proposed by Hsuchen and 
Feingold in 1973, states that indirect effects of sterol on global membrane properties is 
responsible for enabling membrane permeabilization by these natural products.
88,89
 Supporting 
this model, increasing quantities of cholesterol
88,93
 or ergosterol
94
 in phospholipid membranes 
have in some cases led to a decrease in membrane permeabilization by AmB, and AmB can 
permeabilize some model membranes in the absence of sterol.
95,96,97
 An alternative hypothesis 
proposed by Medoff states that these compounds instead directly bind membrane-embedded 
sterol en route to channel formation.
98
 The selective toxicity of AmB to fungal cells over 
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mammalian cells was proposed to result from the relative affinity of AmB to membranes 
containing ergosterol or cholesterol. Thus, determination of the relative importance of the global 
membrane properties imparted by these different sterols vs. a direct binding interaction has 
important implications for improving the therapeutic index of these natural products. 
Efforts to probe these interactions have traditionally relied on covalent modification of 
the amine and carboxylate functional groups. However, interpretation of the results of such 
experiments is complicated by the introduction of new steric interactions in the corresponding 
derivatives which may disrupt putative intermolecular contacts and/or the potential retained 
capacity to form compensatory polar interactions.
86
 To overcome these limitations, Palacios and 
coworkers reported the development of an approach based on functional group deletion to probe 
the role of the C41 carboxylate and C19 mycosamine in the mechanism of action of AmB.
99
 To 
this end, AmB derivatives AmdeB, MeAmB, and MeAmdeB (Figure 1.10) were prepared, and 
the impact of these functional group deletions on the biological activity of AmB was explored. 
Strikingly, deletion of the C41 carboxylate had no effect on the antifungal activity of AmB, but 
derivatives lacking mycosamine were completely inactive. These results indicated that either the 
proposed polar interactions were not required to form ion channels, or that ion channel formation 
was not required to kill yeast. Mycosamine was clearly required for biological activity, but its 
precise role remained unclear. 
 
 
Figure 1.10. Functional group-deficient derivatives prepared by Palacios et al. Figure adapted from reference 99. 
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Finally, several studies have demonstrated a separation between the membrane 
permeabilizing ability of polyene macrolides and their biological activity,
100,101
 and the question 
of whether channel formation is causatively linked to antifungal activity has been debated. It has 
been proposed that the activity of AmB may be alternatively derived from the promotion of 
oxidative damage to lipid bilayers induced by the polyene motif.
69,102
 However, AmdeB retains 
the putatively redox-active polyene core but shows no biological activity.
99
 Te Welscher and 
coworkers have reported that natamycin exhibits antifungal activity at concentrations much 
lower than those required for membrane permeabilization, leading to the proposal that natamycin 
operates via directly binding ergosterol in a mechanism which “sets [it] apart from other polyene 
antibiotics studied so far.”103 Thus, the relative contribution of sterol binding and channel 
formation to the overall mechanism of action of these natural products remained unclear at the 
outset of our studies.  
 
1-3 SYNTHESIS OF MYCOSAMINE-CONTAINING POLYENE MACROLIDES 
Efforts to understand the role(s) of these mechanisms and/or improve the therapeutic 
index of polyene macrolide antibiotics has led to numerous synthetic efforts to access these 
compounds and their derivatives. The synthesis of polyene macrolides is made challenging not 
only because of their structural complexity but also because of their sensitivity to light, oxygen, 
protic acid, and insolubility in most organic solvents.
99
 Consequently, the only reported total 
synthesis of any mycosamine-containing polyene macrolide is that of AmB by Nicolaou and 
coworkers in 1987.
104,105,106,107
 This remains a classic in the field and illustrates many of the 
challenges associated with the synthesis of these natural products. 
The retrosynthesis employed by Nicolaou is shown in Figure 1.11. Notably, this and all 
other reported synthetic efforts towards this class of natural products involves glycosylation as 
the first retrosynthetic transform, with subsequent transforms separating the polyene and polyol 
fragments of the aglycone. Horner-Wadsworth-Emmons (HWE) olefination was used by 
Nicolaou as the primary method of carbon-carbon bond formation, with the application of HWE 
transforms eventually leading to building blocks 1.45, 1.46, 1.47, 1.48, and 1.49. Sharpless 
asymmetric epoxidation was the primary methodology used to install the stereochemistry of the 
polyol in building blocks 1.46 and 1.48, and several of the stereocenters in building blocks 1.45 
20 
 
and 1.49 were derived from diethyl tartrate. Assembly of these building blocks then generated 
protected amphoteronolide.  
 
 
Figure 1.11. Retrosynthesis of AmB by Nicolaou and coworkers. 
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Traditionally in the synthesis of polyene macrolides, the final glycosylation process has 
represented a formidable synthetic challenge.
108,109
 These natural products contain a β-1,2-cis 
glycosidic linkage, arguably the most challenging type to form stereoselectively.
110,111
 The 
nomenclature of this linkage is derived from the relationship of the exocyclic anomeric oxygen 
atom to both the C5 methyl group (same face of a 6-membered ring, therefore β) and the adjacent 
C2 hydroxyl group (same face of the ring, therefore cis) (Figure 1.12A). It is also referred to as a 
β-mannose linkage, as this is the simplest sugar which contains this type of glycosidic bond. 
  
 
Figure 1.12. Mycosamine stereochemistry and challenges associated with direct installation. (A) Nomenclature for 
β-1,2-cis linkage. (B) Steric and stereoelectronic challenges associated with forming this linkage by direct attack 
onto an oxocarbenium ion intermediate. 
 
The challenges associated with forging this glycosidic bond are summarized in Figure 
1.12B. Most glycosylation strategies rely on ionization of an appropriate glycosyl donor to 
generate the corresponding oxocarbenium ion, which is then intercepted by a nucleophilic 
acceptor, usually a free hydroxyl group. This method is challenging to employ directly in the 
case of a β-1,2-cis glycosidic linkage, which requires an equatorial approach of the incoming 
nucleophile. This trajectory engenders unfavorable steric interaction with the C2 hydroxyl group 
on the same side of the ring. Additionally, the anomeric effect stabilizes an axial nucleophile via 
donation of the ring oxygen lone pair into the incipient C-O σ* orbital in the transition state of 
axial attack. Both factors disfavor a direct glycosylation strategy for the formation of β-1,2-cis 
glycosidic linkages, and the application of this approach usually leads to poor or no selectivity 
for the desired β-1,2-cis linkage. 
Several important strategies have been developed to address these issues. One approach, 
pioneered by Barresi and Hindsgaul,
112
 is known as intramolecular aglycone delivery (Figure 
1.13A). In general, this approach involves tethering of the glycosyl donor and acceptor via the 
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substituent at C2 of the donor and effecting an intramolecular transfer of the acceptor to the 
anomeric position, thereby utilizing the stereochemistry at C2 to selectively deliver the acceptor 
to the desired face of the donor. This process may be performed with or without isolation of the 
tethered intermediate. Removal of the tether at C2 either during the course of glycosylation or as 
a separate step then gives the desired product.
110
 Several types of tethers have been utilized 
successfully in intramolecular aglycone delivery and can be organized by their method of 
formation. Mixed ketals or acetals are most common and can be installed through acid catalysis 
as in the original report from Barresi and Hindsgaul,
112
 oxidation of activated benzylic ethers as 
developed by Ito,
113
 or attack on an iodonium generated from the corresponding vinyl ether as 
developed by Fairbanks.
114
 Mixed silicon tethers have also been developed by Stork.
115
  
 
 
Figure 1.13. Two strategies for forming β-1,2-cis glycosidic linkages. (A) Intramolecular aglycone delivery. (B) 
Anchimeric assistance followed by stereocenter inversion. 
 
Intramolecular aglycone delivery has been explored previously by Rychnovsky in their 
efforts towards the synthesis of rimocidin.
116,117
 Mycosamine donors were prepared and tethered 
to the rimocidin aglycone using the Stork silyl linkage (Figure 1.14). Though these intermediates 
could be formed successfully, subsequent transfer was not possible due to the poor 
nucleophilicity of the rimocidin aglycone, as well as chemical incompatibility of the 
functionalized macrolide with the conditions necessary for glycosylation. As a result of these 
difficulties, the total synthesis of rimocidin remains incomplete. 
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Figure 1.14. Packard and coworkers’ efforts towards the installation of mycosamine onto the rimocidin aglycone via 
intramolecular aglycone delivery.  
 
Another strategy widely employed for the synthesis of β-1,2-cis glycosidic linkages 
involves anchimeric assistance from an appropriate directing group at C2 to first install a β-1,2-
trans glycosidic linkage, followed by removal of the directing group and inversion of 
configuration at C2 (Figure 1.13B).
111
 This process allows for stereospecific attack of the 
nucleophilic acceptor onto an activated intermediate where axial approach is blocked by the 
neighboring group at C2. A common byproduct of this strategy is competitive attack on the 
acetoxonium carbon of the directing group to generate an orthoester, which may exist in 
equilibrium with the desired product and may in some cases represent the thermodynamically 
favored product. 
Many elaborated esters have been used as directing groups, as shown in Figure 1.15. 
These may incorporate steric bulk proximal to the carbonyl center to disfavor orthoester 
formation, as in 1.53, which can also complicate the removal of these directing groups after 
glycosylation.
118,119
 To address these problems, sterically bulky directing groups have been 
designed incorporating protected or latent functionality which aids in subsequent deprotection. 
The 2,2-dimethylbut-3-enoate directing group (1.55) developed by Crimmins and coworkers and 
can be removed by hydroboration/oxidation and lactonization.
118
 Similarly, the 4-acetoxy-2,2-
dimethylbutyrate directing group (1.56) developed by Ensley and coworkers is removed by 
saponification and lactonization.
119
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Figure 1.15. Examples of some directing groups used in the anchimeric-assistance strategy for glycosylation. 
Increasing steric bulk proximal to the acetoxonium ion in the activated intermediate has been proposed to disfavor 
orthoester formation. 
 
An alternative chlorodimethylacetate group (1.54) was developed by Carreira and 
coworkers in the formal total synthesis of AmB and several derivatives.
108,109,120
 This group 
contains a gem-dimethyl moiety to sterically disfavor orthoester formation, while incorporating a 
chloride substituent to increase the lability of the directing group after glycosylation. The 
development of this group arguably represented the state of the art in polyene macrolide 
glycosylations at the outset of our studies. Figure 1.16 shows the glycosylation of the AmB 
aglycone 1.57 with mycosamine donors 1.58 and 1.59 prepared by the Nicolaou
107
 and 
Carreira
108,109
 groups, respectively. Use of a simple acetate directing group gave a 20% yield of 
the desired product in a 1:1 ratio with the corresponding orthoester. The performance of the 
chlorodimethylacetate directing group was significantly improved, giving a 43% yield of the 
desired product in a 1.9:1 ratio with the orthoester. Notably, the orthoester byproduct could not 
be converted to the desired product in either case. To the best of our knowledge, these remain the 
only two successful examples of glycosylation to synthesize mycosamine-containing polyene 
macrolides. 
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Figure 1.16. Glycosylation of protected amphoteronolide (1.57) by Nicolaou and Carreira. 
 
The construction of the aglycones of several other members of this family has also been 
explored. Recognizing the conserved hemiketal/mycosamine motif, Rychnovsky and coworkers 
set out to develop a general synthesis platform for this family of natural products.
121,122
 This 
approach relied on iterative cyanohydrin acetonide alkylation to assemble the polyol fragments 
of candidin, nystatin, and rimocidin. However, difficulties in the glycosylation of these 
aglycones prevented the synthesis of the final product containing mycosamine.
116
 Smith and 
coworkers developed another iterative approach to the rimocidin polyol, employing the addition 
of lithiated dithianes to epoxides.
123
 However, the alkylations employed by both Rychnovsky and 
Smith require strong base (LDA or t-BuLi) and subsequent deprotections use either strong acid 
(6 N HCl for cyanohydrin) or oxidants (PhI(O2CCF3)2 for dithiane), conditions which limit the 
generality of this approach in the synthesis of small molecules which may contain sensitive 
functionality. 
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1-4 A GENERAL PLATFORM FOR THE SYNTHESIS AND STUDY OF MYCOSAMINE-
CONTAINING POLYENE MACROLIDES 
To enable a more systematized approach towards complex small molecule synthesis 
under mild conditions, Gillis and coworkers reported in 2007 the development of a synthesis 
strategy based upon the concept of iterative cross-coupling (ICC).
124,125
 In this platform, complex 
small molecules are constructed via the recursive application of the Suzuki-Miyaura cross-
coupling reaction to precisely assemble bifunctional haloboronic acid building blocks protected 
as the corresponding N-methyliminodiacetic acid (MIDA) boronate esters (Figure 1.17). 
Importantly, complexation of a boronic acid with MIDA renders the resulting boron center inert 
to Suzuki-Miyaura cross-coupling conditions, as well as a variety of other common synthetic 
transformations, thus allowing boron-containing intermediates to be carried through multiple 
synthetic steps.
126
 Additionally, these MIDA boronate complexes are generally free-flowing 
crystalline solids that can be easily purified by column chromatography and stored under 
ambient benchtop conditions without decomposition. Despite this stability, MIDA boronates can 
be deprotected under mild aqueous basic conditions to give free boronic acids or transformed to 
the corresponding pinacol boronic esters, both of which can then undergo subsequent cross-
coupling with another bifunctional building block and thereby iterate the C-C bond formation 
process. This strategy has been utilized in the synthesis of a number of polyene natural products, 
including ratanhine,
124
 retinal,
127
 parinaric acid,
127
 crocacin C,
126
 peridinin,
128
 and 
synechoxanthin,
129
 as well as the polyene cores of AmB
127
 and vacidin A.
130
 
 
 
Figure 1.17. Synthesis of complex molecules from simple building blocks. (A) Iterative amide bond formation to 
synthesize peptides from protected amino acids. (B) Iterative Suzuki Miyaura cross-coupling to synthesize small 
molecules from bifunctional halo-MIDA boronates. Figure adapted from reference 125. 
27 
 
We recognized that this strategy might enable a general and highly modular synthesis of 
mycosamine-containing polyene macrolides. Specifically, the design of a building block 
incorporating the conserved hemiketal/mycosamine motif identified in Figure 1.7 could allow for 
the introduction of this ubiquitous structural element as a single unit and thereby represent the 
cornerstone of a modular synthetic strategy to access this family of complex small molecules. 
This approach could potentially provide access to derivatives not readily accessible through a 
top-down degradative route. The following chapters describe our development of an atomistic 
understanding of the role of this substructure in the mechanism of action of these natural 
products
131,132
 and the synthesis of a universal MIDA boronate building block for the 
incorporation of this motif into a modular ICC-based approach for the generation of targeted 
derivatives not readily accessible from a top-down degradative approach. 
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CHAPTER 2  
 
Discovery of the Mycosamine-Mediated Sterol Binding of Amphotericin B 
 
Despite more than 50 years of study, the role of sterol binding in the ion channel and 
antifungal activities of mycosamine-containing polyene macrolides had remained unclear. This 
chapter describes the application of an isothermal titration calorimetry (ITC) assay to AmB and a 
collection of functional group-deficient derivatives to probe this putative interaction and its 
predicted underpinnings. Collectively, our results are consistent with the conclusions that 
mycosamine is critical for promoting a direct binding interaction between AmB and both 
ergosterol and cholesterol, and that the direct binding of AmB and ergosterol is required for both 
forming ion channels and killing yeast cells. These results, in addition to the complete 
conservation of the mycosamine and polyene motifs in all members of this family of natural 
products, led us to hypothesize that mycosamine in combination with a polyene is a universal 
binding element for sterol, and that sterol sequestration and membrane permeabilization may 
represent two distinct mechanisms of action of mycosamine-containing polyene macrolides. 
MeAmB, AmdeB, and MeAmdeB were prepared by Dr. Dan Palacios and Brandon 
Wilcock. MIC and liposome incorporation assays were performed by Dr. Dan Palacios and Dave 
Siebert. Potassium efflux studies, BLM experiments, and ITC experiments with natamycin were 
performed by Dr. Dan Palacios. Portions of this chapter were adapted from Palacios, D. S.; 
Dailey, I.; Seibert, D. M.; Wilcock, B. C.; Burke, M. D. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 
6733-6738. 
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2-1 BACKGROUND  
As described in Chapter 1, a functional group deletion strategy was developed by Dr. Dan 
Palacios and Tom Anderson to investigate the role of the C41 carboxylic acid and C19 
mycosamine in the mechanism of action of AmB.
1
 Specifically, three hypotheses have been 
proposed for the role of these functional groups (Figure 2.1). First, in the barrel-stave ion channel 
model, these groups are predicted to form intermolecular polar interactions between adjacent 
AmB molecules that are required to stabilize the AmB ion channel (Figure 2.1A).
2,3,4,5
 Second, 
these groups are predicted to form polar interactions with phospholipid head groups and thereby 
anchor AmB to the membrane (Figure 2.1B).
3,4
 Third, these groups are predicted to promote the 
binding of AmB with membrane-embedded sterols (Figure 2.1C).
2,3,4,6,7,8,9
  
 
 
Figure 2.1. Three types of interactions involving the C41 carboxylate and C19 mycosamine of AmB predicted to be 
critical for channel formation. (A) Intermolecular polar interactions between these groups is predicted to stabilize 
the ion channel complex. (B) Polar interactions of these groups with phospholipid head groups are predicted to 
anchor AmB to the membrane. (C) Polar interactions of these groups with membrane-embedded sterol are predicted 
to be critical for ion channel formation. Figure adapted from reference 42. 
 
The precise role of sterols in the mechanism of action of AmB has remained ambiguous. 
Some of the earliest studies with AmB recognized a connection between its activity and the 
presence of sterols,
10
 and this has been supported by numerous other 
data.
2,3,4,6,7,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35
 For example, the presence of 
sterols is typically required for AmB to form ion channels,
12,13,14,36
 and, albeit very rare, strains 
34 
 
of yeast that are resistant to AmB in vitro usually have substantially modified membrane sterol 
content.
11,37
 Two hypotheses have been advanced to account for these findings. The first 
hypothesis states that global membrane properties mediated by sterol content are responsible for 
the activity of AmB.
19,20,21,22,23,24,25,26,27
 This model has been invoked to rationalize observations 
that, although AmB is typically most potent in membranes that contain sterols, increasing 
quantities of cholesterol
19,20
 or ergosterol
21
 can decrease the degree of membrane 
permeabilization induced by AmB. Further supporting this model, some artificial membranes can 
be permeabilized by AmB in the absence of sterols.
22,23,24,25,26
  
The second hypothesis states that direct binding of AmB to sterols in the lipid bilayer is 
critical for forming ion channels.
12,13,14,15
 Specifically, the C41 carboxylate and/or mycosamine 
appendages of AmB are proposed to form key polar interactions with the 3-β-hydroxyl group of 
a sterol and thereby stabilize a putative AmB/sterol complex (Figure 2.1C).
6,7,8,28,29,30,31,32
 Studies 
designed to probe this putative interaction in solution or in liposomes have traditionally relied on 
UV/vis and/or CD spectroscopy.
17
 However, it has been theorized that differences in these 
spectra may reflect changes in AmB aggregation states rather than a discrete AmB/sterol binding 
interaction.
16,29
 In a particularly interesting study, Rychnovsky and coworkers synthesized 
enantiomeric cholesterol and found that the electrophysiological properties of AmB ion channels 
in membranes containing either cholesterol or ent-cholesterol were different, consistent with the 
formation of diastereomeric AmB/cholesterol complexes.
33
 However, other studies by Murata,
29
 
Pieringer,
38
 and Bolard
39
 have led these authors to propose that AmB and cholesterol do not 
directly interact. Recent solid-state NMR experiments by Murata have concluded that AmB and 
ergosterol form complexes based on their similar mobilities in lipid bilayers, but that the 
mobilities of AmB and cholesterol are dissimilar.
35
 In other solid-state NMR studies, through-
space dephasing expected for a binding interaction was not observed between 
13
C-labeled AmB 
and 6-fluoroergosterol.
29
 This interaction could be observed in a covalently tethered dimer of 
AmB and ergosterol (2.1); however, this conjugate lacked antifungal activity.
28,29
 Thus, despite 
these and other investigations, the precise role of sterol in the activity of AmB has remained 
unclear.  
 
35 
 
 
Figure 2.2. Covalent dimer of AmB and ergosterol prepared by Murata and coworkers. This compound displayed 
through-space dephasing consistent with a binding interaction but was not biologically active.  
 
Given the aforementioned complications and resulting lack of clarity associated with 
covalent modifications, an alternative experimental strategy was pursued by Dr. Dan Palacios 
and Tom Anderson which involves synthetically deleting protic functional groups appended to 
the polyene macrolide skeleton, verifying retention of macrolide conformation, and determining 
the biological and biophysical consequences of these functional group deletions.
1
 Albeit more 
synthetically challenging, a functional group deletion approach circumvents the inherent 
complications associated with the sensitivity of small-molecule self-assembly to steric 
perturbations that may be introduced by covalent modification.
40,41
 Also, in contrast to 
experiments based on perturbing membrane components, the same probe reagents can be 
employed both in vitro and in vivo, thereby directly linking structure/function relationships 
determined via biophysical studies to the consequences of perturbing such functions in living 
cells.  
Studies performed by Dr. Dan Palacios, Tom Anderson, and Dave Siebert
42
 utilizing the 
functional group-deficient probes MeAmB, AmdeB, and MeAmdeB (Figure 2.3) unambiguously 
determined that, in contrast to two leading proposals (Figure 2.1A and B), polar interactions 
between the C41 carboxylate and C19 mycosamine are not required for channel formation or 
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antifungal activity, nor are they required for binding to phospholipid bilayers. Alternatively, the 
presence of the C19 mycosamine is necessary for ion channel formation and antifungal activity. 
The contribution of these functional groups to sterol binding remained untested using this 
platform, and we undertook efforts to develop an assay which could probe the putative 
interaction of AmB with membrane-embedded ergosterol. 
 
 
Figure 2.3. Functional group-deficient derivatives prepared by Palacios et al. Figure adapted from reference 1. 
 
2-2 ISOTHERMAL TITRATION CALORIMETRY 
The non-covalent binding of two chemical species is ubiquitous and critical for a vast 
number of processes, ranging from complex multimeric interactions of biomolecules necessary 
for the fundamental activities of life to the coordination of a ligand to a metal catalyst in 
common organic transformations.
43,44
 As such, the development of techniques to study these 
interactions has been critical to the understanding and utilization of these processes. One of the 
most valuable techniques for measuring the binding of two chemical components is isothermal 
titration calorimetry (ITC). This method can be extremely useful for studying the 
thermodynamics of binding interactions as it can potentially characterize all thermodynamic 
parameters of the system in a single experiment. 
A basic experimental setup is shown in Figure 2.4. The ITC instrument contains a sample 
cell and a reference cell surrounded by an adiabatic chamber. The sample and reference cells are 
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maintained at a constant temperature through the continuous application of a small current to the 
cell heaters. The sample cell is filled with a solution of one binding partner, while the reference 
cell contains a buffer solution or water. Using a syringe controlled by computer software, a 
solution of the other binding partner is injected into the sample cell in controlled amounts. If this 
results in a heat change in the sample cell, the instrument adjusts the power applied to the sample 
cell heater to ensure the temperature difference between the sample cell and the reference cell 
remains constant. The application of power over time is recorded, and integration of this plot 
gives the enthalpy (ΔH) of the titration. Thus, ΔH of the interaction is directly measured. By 
fitting the titration exotherm to a binding model, the binding constant K and the binding 
stoichiometry n can be determined. Once K and ΔH are known, ΔG and ΔS can be calculated. In 
this way, all thermodynamic binding parameters for a binding interaction can be determined 
from a single ITC experiment. 
 
 
Figure 2.4. ITC instrument schematic. Controlled injections of a solution of one binding partner are made via a 
computer-controlled syringe into a sample cell containing a solution of the other binding partner. The instrument 
measures the power required to maintain both the sample cell and reference cells at a constant temperature. The 
evolution or absorption of heat in the sample cell changes the power required to maintain the sample and reference 
cells at the same temperature. The instrument records this change, and an integration of the resulting power signal 
over time gives the enthalpy of the interaction within the sample cell. Figure adapted from reference 43. 
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In the context of polyene macrolides, ITC has been employed once before by te Welscher 
and coworkers to study the interaction of natamycin (1.6) with membrane-embedded sterols.
45
 
Importantly, natamycin was found to exert antifungal activity under conditions that did not 
permeabilize the membrane, leading to the hypothesis that natamycin acts via a different 
mechanism than other polyene macrolides which cause membrane permeabilization. To 
investigate the role of sterols in this mechanism, natamycin was titrated with large unilamellar 
vesicles (LUVs) containing no sterol, 10% cholesterol, or 10% ergosterol (Figure 2.5). Very little 
exotherm was observed for LUVs containing no sterol or 10% cholesterol (Figure 2.5A and B). 
Strikingly, a large exotherm was observed for LUVs containing 10% ergosterol. Based on this 
observed enthalpy difference, the authors concluded that natamycin binds ergosterol in cell 
membranes. Further biological studies led to the proposal that natamycin exerts antifungal 
activity via binding of ergosterol, and that “this novel mechanism sets natamycin apart from 
other polyene macrolides studied so far.”45  
 
 
Figure 2.5. ITC thermograms obtained by te Welscher and coworkers by titrating a solution of natamycin with 
LUVs containing (A) no sterol, (B) 10% cholesterol, and (C) 10% ergosterol. A large increase in exotherm was 
observed for titration with ergosterol-containing LUVs, leading to the conclusion that natamycin binds membrane-
embedded ergosterol. Figure adapted from reference 45. 
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Encouraged by these results, we set out to adapt this technique to the study of AmB, its 
mechanism of action, and the role of the C41 carboxylate and C19 mycosamine in sterol 
binding.
42
 We recognized that our functional group deletion strategy could stand to clarify the 
role of these functional groups by circumventing the complicating effects of steric perturbation 
inherent to an approach based upon covalent modification. Coupling this approach with ITC 
could thus represent a general strategy for the study of the sterol-binding capacity of polyene 
macrolides and thereby help illuminate the mechanistic underpinnings of this entire family of 
natural products. 
 
2-3 COMBINATION OF ITC AND FUNCTIONAL GROUP-DEFICIENT PROBES REVEALS 
MYCOSAMINE-DEPENDENT STEROL BINDING 
First, we set out to test the hypothesis that AmB binds membrane-embedded ergosterol. 
As discussed above and in Chapter 1, this question has been debated in the literature for decades. 
The results of our studies are shown in Figure 2.6. A solution of AmB was first titrated with 
sterol-free POPC LUVs, and a small net exotherm was observed (-18.1 ± 4.1 μcal). Importantly, 
when this experiment was repeated using POPC LUVs containing 10% ergosterol, a substantially 
larger exotherm was observed (-37.3 ± 4.4 μcal). To determine whether this increase in exotherm 
was due to a direct binding interaction between AmB and ergosterol or alternatively to indirect 
sterol-mediated changes in global membrane properties, the same set of titrations was repeated 
using POPC LUVs containing 10% lanosterol. Extensive solid-state NMR studies have 
demonstrated that the global membrane properties of POPC LUVs containing either lanosterol or 
ergosterol are very similar.
46,47,48
 Thus, if the observed exotherms were due to changes in global 
membrane properties, LUVs containing either ergosterol or lanosterol would be expected to 
behave similarly in ITC. However, titration with lanosterol-containing POPC LUVs showed only 
a small exotherm identical to that of sterol-free LUVs (-14.0 ± 6.0 μcal). Collectively, these data 
indicate the observed increase in exotherm observed with ergosterol-containing LUVs is a result 
of a direct binding interaction of AmB with ergosterol rather than a nonspecific interaction of 
AmB with the membrane. 
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Figure 2.6. Representative ITC thermograms obtained by titrating a solution of AmB with POPC LUVs containing 
(A) no sterol, (B) 10% ergosterol, and (C) 10% lanosterol. A large increase in exotherm was observed with 
ergosterol-containing LUVs. The global membrane properties of ergosterol- and lanosterol-containing POPC LUVs 
are very similar, yet the overall exotherm for the titration of AmB with lanosterol-containing LUVs is different than 
that for ergosterol-containing LUVs. This data is consistent with the conclusion that the observed exotherms are the 
result of a direct binding interaction between AmB and ergosterol. All values represent the mean ± the standard 
deviation of at least three experiments. Figure adapted from reference 42. 
 
With a direct binding interaction established and this ITC assay in hand, we determined 
whether MeAmB, AmdeB, and MeAmdeB had a similar capacity to bind ergosterol and thus 
probe the roles of the C41 carboxylate and C19 mycosamine in this interaction. The same set of 
ITC experiments was performed with these compounds in egg PC LUVs, and the results are 
summarized in Figure 2.7. AmB again showed a substantial net increase in exotherm with 
ergosterol-containing egg PC LUVs compared to sterol-free egg PC LUVs (-29.2 ± 7.9 μcal). 
Titration of MeAmB with sterol-free followed by 10% ergosterol-containing egg PC LUVs 
showed a substantial net increase in exotherm similar to that of AmB (-25 ± 10 μcal), indicating 
that oxidation at C41 is not necessary for binding to ergosterol. In stark contrast, titration of 
AmdeB and MeAmdeB with sterol-free followed by 10% ergosterol-containing egg PC LUVs 
showed no net change in exotherm. These results revealed that the mycosamine appendage is 
required for AmB to bind to membrane-embedded ergosterol.  
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Figure 2.7. Differences in net exotherms for AmB, MeAmB, AmdeB, and MeAmdeB titrated with sterol-free 
followed by 10% ergosterol-containing egg PC LUVs. All values represent the mean of at least three experiments, 
and error bars represent the standard deviation of these experiments. These results reveal that the mycosamine 
appendage is required for binding ergosterol. * P = 0.005. ** P = 0.006. Figure adapted from reference 42. 
 
To determine if mycosamine-mediated sterol binding is a more general phenomenon, 
similar experiments were performed utilizing cholesterol-containing LUVs. The direct 
interaction of AmB with cholesterol, the primary sterol in mammalian membranes, has also 
remained controversial but may underlie the toxicity of AmB in clinical applications.
19,49,50
 In 
contrast to the dramatic effects observed with ergosterol, initial experiments with cholesterol 
under the same conditions were inconclusive due to the small and irreproducible exotherm 
observed. We hypothesized that the binding interaction of AmB with cholesterol may be more 
difficult to detect given the sensitivity of the ITC instrument and the statistical error associated 
with the averaging of multiple experiments. To improve the sensitivity of our experiment, we 
developed a modified assay with a higher signal-to-noise ratio. Specifically, the concentrations 
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of LUVs and AmB were increased 1.5- and 3-fold, respectively, with the goal of increasing the 
overall measureable enthalpy. To validate these more robust conditions, AmB was again titrated 
with sterol-free and 10% ergosterol-containing POPC LUVs (Figure 2.8), and a dramatic 
increase in exotherm was observed (-79.0 ± 20.2 μcal), consistent with the results obtained above 
under more dilute conditions (Figure 2.7). With this optimized assay, titration of AmB with 
POPC LUVs containing 10% cholesterol indeed showed a substantial increase in exotherm 
relative to the sterol-free control (-24.6 ± 8.2 μcal). Additionally, when these experiments were 
repeated with AmdeB, no increase in exotherm was observed. These results indicate that AmB 
also directly binds cholesterol, and that this interaction is mycosamine-dependent, just as in the 
case of ergosterol. This finding has important implications for the toxicity of AmB. 
 
 
Figure 2.8. Differences in net exotherms for AmB and AmdeB titrated with sterol-free followed by 10% sterol-
containing egg PC LUVs using ITC conditions with improved sensitivity. All values represent the mean of at least 
three experiments, and error bars represent the standard deviation of these experiments. These results reveal that 
AmB binds membrane-embedded cholesterol in a mycosamine-dependent manner. * P = 0.0066. ** P = 0.0011.  
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Because derivatives lacking mycosamine also lack the ability to form ion channels and 
kill yeast cells, these results suggest that an AmB/sterol binding interaction is required for both 
the channel-forming and antifungal activities of AmB. These observations, in combination with 
those reported for natamycin,
45
 led us to propose that mycosamine in combination with a polyene 
may serve as a general sterol-binding motif. As noted in Figure 1.7, this motif is conserved in all 
mycosamine-containing polyene macrolides. Interestingly, although natamycin contains this 
motif, binds ergosterol, and exerts antifungal activity, it does not permeabilize membranes at 
relevant concentrations and is less potent than AmB. These findings have led us to propose a 
model in which AmB exerts its antifungal effects via two distinct and complementary 
mechanisms: sterol sequestration and membrane permeabilization, both of which require 
mycosamine-mediated sterol binding (Figure 2.9).
42
 A similar pair of killing mechanisms has 
been demonstrated to underlie the activity of the antimicrobial peptide nisin, which binds lipid II 
and subsequently forms membrane ion channels.
51
 Thus, this two-mechanism model may 
represent a common strategy convergently evolved in both peptide and small molecule 
antimicrobials and may explain the antifungal activities of many mycosamine-containing 
polyene macrolide natural products. A similar hypothesis has more recently been proposed by te 
Welscher and coworkers,
52
 and Chapter 3 will detail the synthesis and study of other probe 
reagents to test the relative contributions of these mechanisms to the antifungal activity of 
mycosamine-containing polyene macrolides. 
 
Figure 2.9. A proposed unifying model for AmB antifungal activity involving two complementary mechanisms of 
action that both require mycosamine-mediated binding to sterols: (A) sterol sequestration and (B) membrane 
permeabilization. Adapted from reference 42. 
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2-4 SUMMARY 
Using a set of functional-group deficient derivatives of AmB, we have demonstrated that 
polar interactions involving the C41 carboxylic acid and C19 mycosamine are not required for 
forming ion channels, binding to lipid membranes, or killing yeast. Alternatively, the 
mycosamine appendage is strictly required for promoting a direct binding interaction with both 
ergosterol and cholesterol, and the loss of this capacity for binding results in complete loss of 
antifungal activity. These results led us to hypothesize that mycosamine-containing polyene 
macrolides operate via two distinct mechanisms: sterol sequestration and membrane 
permeabilization, both of which require mycosamine-mediated sterol binding as enabled by the 
conserved structural motif found in all members of this family.  
The clarified picture of the functional groups critical for the ion channel activity of AmB 
helps build the foundation for the development of small molecules with the capacity to replace 
missing or dysfunctional protein ion channels in living systems. In addition, the conclusion that 
sterol binding is critical to the resistance-refractory mechanism of action of AmB may help guide 
the development of new antifungal agents. The discovery that AmB binds both ergosterol and 
cholesterol in a mycosamine-mediated fashion may help focus efforts to develop derivatives of 
AmB with improved therapeutic indices. Finally, these studies highlight the power of a 
functional group deletion strategy to illuminate the mechanistic underpinnings of complex small 
molecule function. 
 
2-5 EXPERIMENTAL SECTION 
Materials.  
Commercially available materials were purchased from Aldrich Chemical Co. 
(Milwaukee, WI), Fisher Scientific (Hampton, NH), and Avanti Polar Lipids (Alabaster, AL) and 
used without further purification unless otherwise noted. Amphotericin B was a generous gift 
from Bristol-Myers Squibb and was purified by preparative RP-HPLC using an Agilent (Santa 
Clara, CA) 1100 series HPLC system equipped with a Waters (Milford, MA) Sunfire Prep C18 30 
x 150 mm column as described previously. Ergosterol was recrystallized from ethyl acetate. 
Water was obtained from a Millipore (Billerica, MA) Gradient A10 water purification system. 
Amphotericin B derivatives were prepared as described.
1
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LUV Preparation. 
Egg yolk phosphatidylcholine (EYPC) was obtained as a 10 mg/mL solution in CHCl3 
from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 °C under an atmosphere of dry 
argon and used within 1 month. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at -20 °C under an atmosphere of dry argon. Prior to preparing a lipid film, 
the solutions were warmed to ambient temperature to prevent condensation from contaminating 
the solutions. A 13 x 100 mm test tube was charged with 1.6 mL EYPC and 230 μL of the 
ergosterol solution. The solvent was removed with a gentle stream of nitrogen and the resulting 
lipid film was stored under high vacuum for a minimum of 8 hours prior to use. The film was 
then hydrated with 1 mL of 150 mM KCl, 5 mM HEPES pH 7.4 (K buffer) and vortexed 
vigorously for approximately 1 minute to form a suspension of multilamellar vesicles (MLVs). 
The resulting lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and 
the syringe was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then 
passed through a 0.20 μm Millipore (Billerica, MA) polycarbonate filter 21 times, the newly 
formed large unilamellar vesicle (LUV) suspension being collected in the syringe that did not 
contain the original suspension of MLVs to prevent the carryover of MLVs into the LUV 
solution.  
  
Determination of Phosphorus Content. 
Determination of total phosphorus was adapted from the report of Chen and coworkers.
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The LUV solution was diluted tenfold with Na buffer and three 10 μL samples of the diluted 
LUV suspension were added to 3 separate 7 mL vials. Subsequently, the solvent was removed 
with a stream of N2. To each dried LUV film, and a fourth vial containing no lipids that was used 
as a blank, was added 450 μL of 8.9 M H2SO4. The four samples were incubated open to ambient 
atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 23 °C and 
cooled for 5 minutes. After cooling, 150 μL of 30% w/v aqueous hydrogen peroxide was added 
to each sample, and the vials were returned to the 225 °C heating block for 30 minutes. The 
samples were then removed to 23 °C and cooled for 5 minutes before the addition of 3.9 mL 
water. Then 500 μL of 2.5% w/v ammonium molybdate was added to each vial and the resulting 
mixtures were then vortexed briefly and vigorously 5 times. Subsequently, 500 μL of 10% w/v 
ascorbic acid was added to each vial and the resulting mixtures were then vortexed briefly and 
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vigorously 5 times. The vials were enclosed with a PTFE lined cap and then placed in a 100 °C 
aluminum heating block for 7 minutes. The samples were removed to 23 °C and cooled for 
approximately 15 minutes prior to analysis by UV/Vis spectroscopy. Total phosphorus was 
determined by observing the absorbance at 820 nm and comparing this value to a standard curve 
obtained through this method and a standard phosphorus solution of known concentration. 
  
Determination of Ergosterol Content. 
Ergosterol content was determined spectrophotometrically. The LUV solution was 
diluted tenfold with Na buffer, and 50 μL of the dilute LUV suspension was added to 450 μL 
2:18:9 hexane:isopropanol:water (v/v/v). Three independent samples were prepared and then 
vortexed vigorously for approximately 1 minute. The solutions were then analyzed by UV/Vis 
spectroscopy and the concentration of ergosterol in solution was determined by the extinction 
coefficient of 10400 L mol
-1
 cm
-1
 at the UVmax of 282 nm and was compared to the concentration 
of phosphorus to determine the percent sterol content. The extinction coefficient was determined 
independently in the above ternary solvent system. LUVs prepared by this method contained 
between 7 and 14% ergosterol. 
 
Isothermal Titration Calorimetry 
General Information. 
Experiments were performed using a VP-ITC isothermal titration calorimeter (MicroCal 
Inc., Piscataway, NJ). Solutions of the compounds to be tested were prepared by diluting a 5.0 
mM stock solution of the compound in DMSO to 50 μM with K buffer. The final DMSO 
concentration in the solution was 1% v/v. LUVs were prepared and phosphorus and ergosterol 
content was quantified as described in Section VI. Ergosterol and lanosterol were also 
incorporated into POPC LUVs. The LUV solutions were diluted with buffer and DMSO to give a 
final phospholipid concentration of 8.0 mM in a 1% DMSO/K buffer solution. Immediately prior 
to use, all solutions were degassed under vacuum at 17 °C for 10 minutes. The reference cell of 
the instrument was filled with a solution of 1% v/v DMSO/K buffer. 
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Titration Experiment. 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 1.4399 mL or 1.4495 mL) which contained the 50 μM solution of the 
compound in question at 25 °C. The volume of the first injection was 1 μL. Consistent with 
standard procedure,
54
 due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, forty 5 
μL injections of the LUV suspension were performed. The injection duration was 2.1 seconds 
and 10.3 seconds for the 1 μL and 5 μL injections, respectively. The spacing between each 
injection varied between 240 seconds and 480 seconds and was adjusted to allow the instrument 
to return to baseline before the next injection was made. The rate of stirring for each experiment 
was 300 or 310 rpm. 
 
Data Analysis. 
ORIGIN software (MicroCal, Inc.) was used for baseline determination and integration of 
the injection heats, and Microsoft Excel was used for subtraction of dilution heats and the 
calculation of overall heat evolved. To approximate the dilution heats, the final integrated heat 
from each run was subtracted from all the data for that particular experiment.
45
 The overall heat 
evolved during the experiment was calculated using the following formula: 
)(μcal
1



n
i
n
injection
i
injectionoverall hh  
where i = injection number, n = total number of injections, 
i
injectionh  = heat of the i
th
 injection, 
n
injectionh  = heat of the final injection of the experiment. 
 
Cholesterol Binding Experiments 
General Information. 
In order to detect the relatively weaker binding between AmB and cholesterol the 
concentrations of small molecule and LUVs were increased for these experiments. Solutions of 
AmB and AmdeB were prepared by diluting a 15.0 mM stock solution of the compound in 
DMSO to 150 μM with 5 mM HEPES (pH = 7.4) buffer. The final DMSO concentration in the 
solution was 1% v/v. LUVs were prepared and phosphorus content was quantified as described 
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above. Cholesterol content was assumed based upon the molar ratio of sterol to lipid in the 
preparation of the lipid films. The LUV solutions were diluted with 1% v/v DMSO/5 mM 
HEPES to give a final phospholipid concentration of 12.0 mM. Immediately prior to use, all 
solutions were degassed under vacuum at 17 °C for 10 minutes. The reference cell of the 
instrument was filled with a solution of 1% v/v DMSO/5 mM HEPES. 
 
Titration Experiment. 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 1.4399 mL or 1.4495 mL) which contained the 150 μM solution of 
AmB or AmdeB at 25 °C. The volume of the first injection was 1 μL. Consistent with standard 
procedure, due to the large error commonly associated with the first injection of ITC 
experiments,
54
 the heat of this injection was not included in the analysis of the data. Next, twenty 
10 μL injections of the LUV suspension were performed. The injection duration was 2.1 seconds 
and 20.6 seconds for the 1 μL and 10 μL injections, respectively. The spacing between each 
injection varied between 240 seconds and 360 seconds and was adjusted to allow the instrument 
to return to baseline before the next injection was made. The rate of stirring for each experiment 
was 300 or 310 rpm. 
 
Data Analysis. 
The data analysis for the cholesterol binding experiments was performed as described 
above for the ergosterol binding experiments.  
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CHAPTER 3  
 
Mycosamine-Mediated Sterol Binding Is the Primary Mechanism of Action of Polyene 
Macrolide Antibiotics 
 
Results of experiments using our functional group-deficient derivatives of AmB had led 
us to propose that sterol sequestration and membrane permeabilization may represent two 
distinct mechanisms of action of mycosamine-containing polyene macrolides, and that the 
conserved structural motif in this family represents a universal sterol binding element which is 
critical for this biological activity. However, the relative contributions of sterol sequestration and 
membrane permeabilization to the overall mechanism of action of these compounds remained 
unknown. To test the hypothesis that sterol binding is the primary mechanism of action, we 
synthesized a derivative of AmB, C35deOAmB, through a semisynthetic ICC-based approach. 
Importantly, this derivative retained the capacity to bind ergosterol but lacked the ability to 
permeabilize membranes. Similar to natamycin, another mycosamine-containing polyene 
macrolide which binds sterol and kills yeast but does not permeabilize membranes, the antifungal 
activity of C35deOAmB was only sixfold less than AmB. Additionally, removal of mycosamine 
from natamycin completely abolished the sterol binding and antifungal activities of this natural 
product. These results are consistent with the conclusion that mycosamine-mediated ergosterol 
binding is the primary mechanism of action of mycosamine-containing polyene macrolides, and 
that channel formation represents a complementary mechanism that further increases drug 
potency and rate of killing.  
C35deOAmB was prepared in collaboration with Dr. Kaitlyn Gray, Dr. Dan Palacios, 
Matt Endo, Brice Uno, Brandon Wilcock, and Prof. Marty Burke. Natamycin aglycone was 
synthesized by Dr. Kaitlyn Gray. ITC experiments with natamycin and natamycin aglycone were 
performed by Matt Endo. Liposome and yeast efflux experiments were performed by Matt Endo 
and Dr. Dan Palacios. MIC experiments were performed by Dr. Dan Palacios, Matt Endo, and 
Dr. Kaitlyn Gray. Killing kinetics studies were performed by Dr. Kaitlyn Gray. Ergosterol 
quantification was performed by Matt Endo and Dr. Dan Palacios. Portions of this chapter were 
adapted from Gray, K. C.; Palacios, D. S.; Dailey, I.; Endo, M. M.; Uno, B. E.; Wilcock, B. C.; 
Burke, M. D. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 2234-2239. 
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3-1 BACKGROUND  
As discussed in Chapter 2, our functional-group deletion strategy revealed that polar 
interactions between the C41 carboxylate and C19 mycosamine of AmB are not required for 
forming ion channels or killing yeast, and neither functional group is required for binding to 
phospholipid membranes.
1,2
 Strikingly, derivatives lacking mycosamine showed no ability to 
bind sterols, form ion channels, or kill yeast. We hypothesized based on these results and those 
obtained with natamycin,
3
 another mycosamine-containing antifungal agent which binds 
ergosterol but does not form ion channels, that mycosamine-containing polyene macrolides such 
as AmB may operate via two distinct and complementary mechanisms: sterol sequestration and 
membrane permeabilization, both of which are mediated by mycosamine.
2
  
Ergosterol has been proposed to participate in many critical cellular functions, including 
endocytosis,
4
 pheromone signaling,
5
 membrane compartmentalization,
6
 and the proper 
functioning of membrane proteins.
7
 Grote has shown that inhibition of yeast ergosterol 
biosynthesis by treatment with fluconazole inhibits membrane fusion during mating.
5
 
Remarkably, the same result was obtained upon exposure to the mycosamine-containing and 
channel-forming polyene macrolide nystatin. Ergosterol is also critical for proper yeast vacuole 
fusion, and this process is inhibited by both nystatin and natamycin, the latter of which binds 
ergosterol but does not form ion channels.
2,3,8
  
Albeit very rare, strains of yeast resistant to polyene macrolides usually have 
substantially modified membrane sterol content.
9,10
 Very importantly, structural modification 
and/or decreased expression of ergosterol via mutations in the sterol biosynthesis pathway 
substantially diminish fungal pathogenicity in vivo.
11
 Thus, it seems that that modification of 
such an important membrane component, while possibly conferring some resistance against 
polyene macrolides, reduces overall cell viability. This phenomenon may play a very important 
role in preventing the development of clinically significant microbial resistance to polyene 
macrolides.
12
 These observations combined with the fact that the mycosamine sugar is necessary 
for AmB to bind ergosterol and is conserved among all members of this class of natural products 
led us to hypothesize that mycosamine-mediated sterol binding is the primary mechanism by 
which all polyene macrolide antifungal agents operate, and that the channel forming capacity of 
some members represents a secondary mechanism that further increases potency.
2,12
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3-2 DESIGN OF PROBE REAGENTS 
Testing the hypothesis that sterol binding is the primary mechanism of action of AmB 
required the synthesis of a derivative which retains the ability to bind sterol but lacks the ability 
to form ion channels. Given the unknown structure of polyene macrolide/ergosterol complexes 
and the multimeric ion channels formed by many members of this family, the rational design of 
such a derivative represented a significant challenge. However, our earlier studies with AmB and 
its functional group-deficient derivatives were greatly informative in this respect.
1,2
 Given its 
critical role in ergosterol binding, it was clear that the mycosamine sugar should remain intact. 
Alternatively, as shown in Figure 3.1, the hydroxyl group at C35 of AmB is predicted to be 
important for channel formation by both leading models for the barrel stave complex. In the 
single barrel model, an aggregate of AmB monomers spans a dimpled membrane, and polar 
interactions of the C35 hydroxyl group with the phospholipid head group are predicted to be 
critical for this assembly.
13
 In the double barrel model, two single barrel units, each spanning 
half the length of the lipid bilayer, are predicted to dimerize through hydrogen bonding between 
the C35 hydroxyl groups of AmB monomers in opposing membrane leaflets.
13
 In both cases, the 
C35 hydroxyl group is proposed to play a critical role in AmB channel formation and thus 
represents an attractive target to perturb this self-assembly process.  
To investigate the role of this hydroxyl group in AmB channel formation, Carreira and 
coworkers synthesized a derivative of AmB in which the C35 hydroxyl group was removed and 
the C41 carboxylate was protected as a methyl ester.
14,15
 Supporting an important role for C35, 
this derivative showed weak potassium efflux from liposomes at a concentration of 10 μM and 
no efflux at a concentration of 1 μM. These authors also reported a 26-fold loss in antifungal 
activity relative to the methyl ester of AmB (AmE) against C. albicans. No investigation of 
sterol binding was reported for either compound. Thus, these authors observed both membrane 
permeabilizing and antifungal activity for the methyl ester of C35deOAmB, but only at 
concentrations an order of magnitude higher than that at which the same activities were observed 
for the methyl ester of AmB, and concluded, “Collectively, these results underscore the pivotal 
role of the C35-hydroxyl group for the biological mechanism of action as well as lend support 
for ion channel formation as a necessary condition for the fungicidal effect of amphotericin B.”15  
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Figure 3.1. (A) Structures of AmB and ergosterol. (B) Representations of two mechanisms for the antifungal 
activity of AmB: ergosterol binding and membrane permeabilization. (C) Representations of two leading models for 
the structure of the AmB ion channel. Both models predict that the hydroxyl group at C35 is critical for ion channel 
self-assembly. Figure adapted from reference 12. 
 
Based on results from our group (see below), we hypothesized that the weak efflux 
observed by Carreira and coworkers at elevated concentrations was likely an artifact of 1. unique 
biophysical properties resulting from the net positive charge of C41 methyl ester derivatives of 
AmB and/or 2. the increased sensitivity of liposomes to permeabilization relative to live yeast 
cells.
12
 Studies performed by Matt Endo demonstrated that the membrane permeabilizing 
properties of AmB (net neutral) and the methyl ester of AmB (AmE, net positive charge) can be 
very different (Figure 3.2). For example, consistent with ergosterol binding being required for 
AmB channel formation, no substantial potassium efflux is observed when AmB is added to 
sterol-free POPC LUVs even at the very elevated concentration of 30 μM. However, at 
concentrations of 10-30 μM, AmE causes significant efflux in these sterol-free LUVs (Figure 
3.2).
12
 Additionally, AmdeB, which does not bind sterol, has no antifungal activity, and does not 
permeabilize S. cerevisiae even at the elevated concentration of 30 μM, can cause potassium 
efflux from POPC LUVs at 10 or 30 μM, thus demonstrating that liposomes can be more 
sensitive to permeabilization than live yeast cells (Figure 3.3).
12
 Thus, with the goal of retaining 
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sterol binding, abolishing the capacity for membrane permeabilization, and enabling direct 
comparisons with the biophysical and biological properties of the zwitterionic natural product, 
we targeted the synthesis of C35deOAmB (3.2) which retains the C19 mycosamine, lacks a 
hydroxyl group at C35, and retains the anionic carboxylate group at C41 (Figure 3.4).  
 
 
Figure 3.2. AmB and AmE efflux in sterol-free POPC LUVs. AmB (net neutral) and AmE (net positive charge) can 
have distinct membrane permeabilizing properties. Figure adapted from reference 12. 
 
 
Figure 3.3. AmdeB potassium efflux in (A) S. cerevisiae and (B) POPC LUVs. AmdeB does not cause efflux from 
live yeast even at the elevated concentration of 30 μM. While at a low concentration, AmeB did not cause efflux in 
liposomes, at the elevated concentrations of 10 and 30 μM it caused significant efflux in this model membrane 
system, demonstrating that liposomes can be more sensitive to permeabilization than live yeast cells. Figure adapted 
from reference 12. 
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Figure 3.4. Targeted derivatives for investigating the relative contribution of sterol binding to the mechanism of 
action of mycosamine-containing polyene macrolides. 
 
To further evaluate the putatively general primary importance of ergosterol binding, we 
sought to investigate the hypothesis that the mycosamine sugar is responsible for the binding of 
polyene macrolides to ergosterol. To accomplish this goal, we targeted the synthesis of 
natamycin aglycone (3.1, Figure 3.4). The methyl ester of this compound had been previously 
reported by Masamune and was obtained via degradation of the natural product.
16
 Based on this 
work and our previous experience with the preparation of AmdeB, the synthesis of the fully 
deprotected natamycin aglycone was completed by Dr. Kaitlyn Gray.
12
 
 
3-3 SYNTHESIS OF C35deOAmB 
Execution of our functional group deletion strategy had previously relied on a top-down 
degradative approach for accessing MeAmB, AmdeB, and MeAmdeB.
1,2
 Preliminary 
investigations by Dr. Kaitlyn Gray demonstrated that the synthesis of C35deOAmB via a 
degradative approach was fraught with difficulty, and to date no successful degradative route to 
C35deOAmB has been identified.
14,15
 Thus, although a top-down degradative strategy was very 
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useful for the rapid generation of other targeted derivatives, these results highlighted some of the 
limitations in the modularity and flexibility of a top-down approach. 
 
 
Figure 3.5. Collection of building blocks for ICC-based access to C35deOAmB. 
 
To overcome this challenge, we expanded our synthesis platform to employ an ICC-
based
17,18
 semisynthesis strategy incorporating building blocks 3.3, 3.4, and 3.5 which could be 
assembled rapidly and under mild conditions through iterative Suzuki-Miyaura cross-coupling 
(Figure 3.5). For a detailed explanation of ICC, see Chapter 1. Based on pioneering studies by 
Nicolaou,
19,20,21
 Rychnovsky,
22
 and Murata,
23
 the synthesis of 3.3 via top-down degradation of 
AmB was developed by Dr. Kaitlyn Gray. Large amounts of material en route to this 
intermediate were synthesized in collaboration with Dr. Dan Palacios, Brice Uno, Matt Endo, 
and Brandon Wilcock via the route shown in Scheme 3.1. Briefly, beginning with the natural 
product, global protection of all protic functional groups gave intermediate 3.6. The polyene was 
then excised via ozonolysis, and the resulting bis-aldehyde was converted to the corresponding 
bis-iodide via double Takai olefination. Subsequent saponification of the western half of AmB 
(3.7) and cross-coupling with bis-borylated compound 3.8 gave 3.3. 
The installation of the polyene unit via 3.4 necessitated the synthesis of gram quantities 
of this bifunctional building block. The synthesis of this building block, shown in Scheme 3.2, 
was developed previously in our group by Dr. Suk Joong Lee based upon the use of the 
triethylgermanium group as a masking group for halides through a novel ICC manifold.
24
 This 
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strategy enabled the construction of a library of polyene building blocks encompassing all 
possible diene stereoisomers and proved useful in the construction of the polyene core of the 
macrolide vacidin A. The construction of each trans-olefin building block relies on the synthesis 
and coupling of bis-metalated building block 3.9.
25
 Thus, we recognized that the application of 
this approach to the synthesis of C35deOAmB and other polyene targets would benefit from the 
scalable and robust preparation of 3.9. 
 
 
Scheme 3.1. Synthesis of building block 3.3 via degradation of AmB. 
 
 
Scheme 3.2. Synthesis of polyene building block 3.4 as developed by Dr. Suk Joong Lee. 
 
The synthesis of 3.9 is shown in Scheme 3.3.
24,25
 Addition of ethynylmagnesium bromide 
to triethylgermanium chloride generated ethynyl triethylgermanium (3.12). Because of the 
relatively low boiling point of this intermediate (70-71°C at 65 Torr),
26
 previous protocols called 
for the isolation of the crude product from a THF solution by rotary evaporation from an ice 
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bath. Subsequent column chromatography also required cold rotary evaporation of the product 
from a solution of petroleum ether. Next, hydrostannylation with tributyltin hydride and AIBN 
afforded the desired product after column chromatography. 
 
 
Scheme 3.3. Synthesis of versatile bis-metalated olefin 3.9. 
 
Though a successful and efficient procedure on smaller scale, this route was not 
amenable to the >100 g scale required for the synthesis of C35deOAmB, as well as other 
concurrent synthetic efforts in the group. Thus, a procedure was developed in which the 
concentration of the alkynylation reaction was increased, workup volumes were decreased, and 
rotary evaporation was performed with a bath temperature of 15 - 20 °C as maintained by 
constant cold water circulation. This allowed the scaleup of this reaction to 30 grams 
triethylgermanium chloride. The crude ethynyl triethylgermanium (3.12) was then carried 
forward to the hydrostannylation reaction, which was also run at higher concentration on 
approximately 30 gram scale. Multiple batches of crude 3.9 were pooled and purified by rapid 
column chromatography with petroleum ether to give the product in 85% yield over 2 steps. 
More than 240 grams of this building block was easily generated in the span of one week using 
this approach. Development of this scalable procedure greatly enabled the synthesis of 
C35deOAmB, as well as other synthetic campaigns in the group. 
With this building block in hand, 3.4 was synthesized in collaboration with Brice Uno 
and Dr. Kaitlyn Gray according to Scheme 3.2.
12
 Compound 3.5 was prepared by Dr. Kaitlyn 
Gray.
12
 With all the requisite building blocks in hand, the macrolide skeleton of C35deOAmB 
was assembled in collaboration with Dr. Kaitlyn Gray as shown in Scheme 3.4.
12
 Conversion of 
3.3 to the corresponding pinacol boronic ester, followed by cross-coupling with 3.4 gave 
pentaene 3.13. In situ deprotection of the MIDA boronate and cross-coupling with 3.5, followed 
60 
 
by macrolactonization gave fully protected C35deOAmB (3.14). Subsequent deprotections 
developed by Dr. Kaitlyn Gray and Dr. Dan Palacios then afforded the final targeted derivative.
12
 
 
 
Scheme 3.4. Completion of the synthesis of C35deOAmB. 
 
3-4 BIOPHYSICAL STUDIES REVEAL STEROL BINDING AS THE PRIMARY 
MECHANISM OF MYCOSAMINE-CONTAINING POLYENE MACROLIDE 
ANTIBIOTICS 
With the desired probe reagents in hand, we first set out to determine the capacity of each 
compound to bind membrane-embedded ergosterol via isothermal titration calorimetry (ITC) as 
described in Chapter 2.
2
 Given the synthetic overhead required to generate C35deOAmB, we 
first sought to minimize the amount of compound required for ITC without compromising the 
sensitivity of the experimental conditions. Previous experiments utilized a MicroCal calorimeter 
with a sample cell volume of 1.45 mL but required the preparation of 2.2 mL of sample solution 
to achieve robust sample loading. Based on a solution concentration of 150 μM, a single ITC 
experiment required 250-300 μg of compound. To miniaturize our ITC assay, we utilized a 
NanoITC calorimeter with a sample cell volume of only 190 μL, requiring the preparation of just 
300 μL of sample solution. Based on the same concentration of 150 μM, this reduced the amount 
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of compound required by nearly tenfold (30-40 μg) which was critical for completing this study. 
Additionally, the volume of each liposome preparation was reduced by approximately fivefold. 
Together, these improvements greatly streamlined the ITC analysis process and allowed for 
much more efficient use of the highly valuable derivatives produced via semisynthesis. 
To validate these new ITC conditions, we first titrated AmB with sterol-free followed by 
10% ergosterol-containing POPC LUVs and observed a substantial increase in net exotherm (-
23.2 ± 14.8 μcal, Figure 3.6), consistent with our previous results and the conclusion that AmB 
directly binds ergosterol.
2
 Next, we performed the same set of experiments using AmdeB and 
observed no change in exotherm, again consistent with our previous results that this binding 
interaction is mycosamine dependent. Having validated this miniaturized ITC assay, the same 
series of titrations was performed with natamycin and its aglycone in collaboration with Matt 
Endo. Consistent with literature precedent,
3
 we observed a net increase in exotherm upon 
titration of natamycin with 10% ergosterol-containing POPC LUVs relative to the sterol-free 
control (-24.8 ± 7.0 μcal), indicating that natamycin binds membrane-embedded ergosterol. 
Importantly, repeating these experiments with natamycin aglycone showed no increase in 
exotherm, demonstrating for the first time that mycosamine is also required for natamycin to 
bind ergosterol. Finally, titration of C35deOAmB with sterol-free followed by ergosterol-
containing POPC LUVs showed an increase in exotherm identical to that of AmB (-20.6 ± 11.0 
μcal), indicating that the sterol-binding capacity of C35deOAmB was retained.  
Having determined the ability of these compounds to bind sterol, we next interrogated 
their ability to permeabilize lipid membranes. These studies were conducted by Dr. Dan Palacios 
and Matt Endo. The result of these studies are shown in Figure 3.7. Exposure of POPC LUVs to 
AmB at a concentration of 1 μM showed rapid and robust efflux of potassium ions. In contrast, 
exposure to AmdeB, natamycin, and natamycin aglycone all showed no potassium efflux, 
indicating these compounds do not permeabilize model lipid membranes at this concentration. 
Importantly, C35deOAmB was devoid of any significant permeabilizing activity; this was the 
case even at the elevated concentration of 10 μM. We next examined the ability of these 
compounds to permeabilize live S. cerevisiae cells (Figure 3.7B). AmB at 3 μM produced rapid 
and substantial efflux of potassium ions, whereas AmdeB, natamycin, and natamycin aglycone 
were completely inactive at this concentration. Most importantly, C35deOAmB also caused no 
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membrane permeabilization in this in vivo experiment, even at the extremely elevated 
concentration of 30 μM. 
 
 
Figure 3.6. Total exotherm, as measured by ITC, for solutions of each polyene macrolide titrated with either sterol-
free or 10% ergosterol-containing POPC LUVs. AmB, natamycin, and C35deOAmB all bind ergosterol, whereas the 
aglycones do not. All values represent the mean of at least three experiments, and error bars represent the standard 
deviation of these experiments. * P ≤ 0.035. Figure adapted from reference 12. 
 
 
Figure 3.7. Membrane permeabilizing ability of probe reagents in (A) POPC LUVs and (B) live S. cerevisiae cells. 
In both LUVs and live yeast cells, robust membrane permeabiliation is observed with Amb, whereas AmdeB, 
natamycin, natamycin aglycone, and C35deOAmB are all inactive. Figure adapted from reference 12. 
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Collectively, these results established that C35deOAmB retains the ability to bind 
ergosterol but lacks the capacity for membrane permeabilization. This derivative was thus a 
valuable tool for probing the relative contributions of sterol binding and channel formation to the 
mechanism of action of AmB and, more broadly, other polyene macrolides. Furthermore, the 
ability to abolish the sterol-binding activity of both AmB and natamycin by removal of 
mycosamine further enabled the evaluation of the putatively dominant and general role of sterol 
binding in the antifungal activity of polyene macrolide natural products. 
 
 
Figure 3.8. Antifungal activities of polyene macrolides. (A) MIC as measured by broth dilution. Relative to AmB 
against S. cerevisiae, C35deOAmB, which cannot permeabilize membranes but retains the ability to bind sterol, is 
only sixfold less active. Also, the MICs for C35deOAmB and natamycin are very similar. A similar set of results is 
observed with C. albicans. Killing kinetics of (B) S. cerevisiae and (C) C. albicans show that, in contrast to the 
fungistatic agent ketoconazole, AmB and C35deOAmB are powerful fungicidal agents. All compounds were tested 
at four times their MIC. CFU, colony forming unit. Figure adapted from reference 12. 
 
We therefore next determined the MIC of these derivatives against S. cerevisiae in 
studies performed by Dr. Dan Palacios and Dr. Kaitlyn Gray (Figure 3.8A). AmB, which binds 
sterol and forms ion channels, showed a MIC of 0.5 μM. The aglycones of AmB and natamycin, 
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which do not bind sterol or permeabilize membranes, were at least 1000-fold less active with no 
antifungal activity up to a concentration of 500 μM.1,2 Strikingly, natamycin and C35deOAmB, 
which both bind sterol but do not form ion channels, demonstrated very similar MICs of 2 and 3 
μM, respectively, only 4 and 6 times less active than AmB, respectively. A very similar set of 
results was obtained when these compounds were tested against the pathogenic yeast C. 
albicans. 
To further probe the capacity of these probes for fungicidal vs. fungistatic activity, a 
study of the yeast killing kinetics
27
 of AmB and C35deOAmB was performed by Dr. Kaitlyn 
Gray. These experiments demonstrated that, like AmB, C35deOAmB is fungicidal in both yeast 
strains with only a small decrease in killing rate (Figure 3.8 B). 
Finally, the hypothesis that sterol binding is the primary mechanism of action of these 
compounds would predict that a significant number of AmB molecules relative to ergosterol is 
present at the MIC. To test this hypothesis, the relative amount of AmB and ergosterol at the 
MIC for each yeast strain was determined by Matt Endo and Dr. Dan Palacios.
28
 As shown in 
Figure 3.9, these results showed that the amount of AmB present in solution at the MIC is an 
order of magnitude greater than the amount of ergosterol in both S. cerevisiae and C. albicans.  
 
 
Figure 3.9. The number of molecules of AmB and ergosterol, as determined by HPLC, per yeast cell employed in 
the broth dilution experiments. At the MICs for both S. cerevisiae and C. albicans, the amount of AmB exceeds the 
amount of ergosterol by an order of magnitude. P ≤ 0.0003. Figure adapted from reference 12. 
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Collectively, these results strongly support the conclusion that mycosamine-mediated 
sterol binding is the primary mechanism of action of polyene macrolides, and that channel 
formation represents a complementary mechanism that further increases potency and rate of 
yeast killing. Conservation of the mycosamine appendage in the large family of polyene 
macrolides combined with the finding that this subunit is required for the sterol binding and 
antifungal activities of both AmB and natamycin further suggests that mycosamine-mediated 
ergosterol binding accounts primarily for the antifungal activities of this entire family of natural 
products. 
 
3-5 SUMMARY 
Based on an ICC strategy, we have completed the semisynthesis of C35deOAmB and 
used this derivative to probe the relative contribution of sterol binding to the ion channel and 
antifungal activities of AmB. This derivative is unable to permeabilize membranes but retains the 
ability to bind ergosterol and demonstrates antifungal activity similar to natamycin, another 
mycosamine-containing polyene macrolide that binds ergosterol but does not form ion channels. 
As in the case of AmB, removal of mycosamine from natamycin also completely abolishes sterol 
binding and antifungal activity of this natural product. These results strongly support the 
conclusion that mycosamine-mediated sterol binding is the primary mechanism of action of 
mycosamine-containing polyene macrolides. This discovery has important implications in 
several areas. 
First, the rapid development of microbial resistance to antibiotics represents an emergent 
global public health crisis.
29,30
 Despite extensive use over the past 50 years, clinically significant 
resistance to mycosamine-containing polyene macrolides remains exceptionally rare.
31,32
 Thus, 
clinically relevant antimicrobial mechanisms that can evade resistance exist, and the mode(s) of 
action of these natural products is one of them. The discovery that these compounds act primarily 
by binding a functionally vital lipid suggests that this may represent an antimicrobial mode of 
action with substantial potential for evading resistance in the clinical setting. Additionally, the 
potential for many of these compounds to operate via a dual mode of action, i.e. sterol binding 
and membrane permeabilization, likely contributes to their resistance-refractory nature. This dual 
mechanism is paralleled by the peptide nisin, which also operates primarily by binding a vital 
66 
 
cellular lipid and secondarily induces membrane permeabilization,
33
 and thus may represent a 
strategy which has co-evolved in both peptide and small molecule antibiotics.
8
 
Second, extensive efforts to improve the therapeutic index of AmB have been guided by 
the classic mechanistic model in which membrane permeabilization is paramount to biological 
activity. Thus, these studies have focused primarily on promoting ion channel formation in 
fungal cells selectively over mammalian cells.
34,35,36,37
 The discovery that ergosterol binding is 
instead the primary mechanism of cell killing suggests that the optimization of binding of 
ergosterol relative to cholesterol could represent a more accessible strategy for improving the 
therapeutic index of AmB. 
Finally, the discovery that sterol binding rather than channel formation is the primary 
mechanism of action of mycosamine-containing polyene macrolides suggests that the cytocidal 
effects of these two processes may be separable. This has important implications for the 
development of small molecules to replace the function of missing or dysfunctional protein ion 
channels in human disease, as these compounds must demonstrate therapeutic ion channel 
activity with minimal corresponding toxicity. Derivatives of AmB that do not bind endogenous 
sterols yet maintain the ability to form ion channels now represent promising new targets to 
accomplish this goal. 
All of these important implications highlight the need for unfettered synthetic access to 
mycosamine-containing polyene macrolides and their derivatives to further understand and/or 
optimize the remarkable function of these natural products. Given the critical role of 
mycosamine, the conserved hemiketal/mycosamine motif identified in Chapter 1 represents an 
attractive synthetic target to introduce modifications in a flexible and efficient manner. 
Importantly, the semisynthetic and degradative strategies described above and in Chapter 2 do 
not allow for ready access to derivatives in which this subunit is modified. Thus, we set out to 
develop a synthesis of this universal sterol-binding motif which could potentially be incorporated 
into an ICC-based platform for the synthesis of all members of this class of natural products and 
their derivatives. The results of these efforts are detailed in Chapter 4.  
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3-6 EXPERIMENTAL SECTION 
Materials.  
Commercially available materials were purchased from Sigma-Aldrich, Alfa Aesar, 
Strem, Avanti Polar Lipids, or Fisher Scientific and were used without further purification unless 
stated otherwise. Amphotericin B was a generous gift from Bristol-Myers Squibb Company. All 
solvents were dispensed from a solvent purification system that passes solvents through packed 
columns according to the method of Pangborn and coworkers
38
 (THF, Et2O, CH2Cl2, toluene, 
dioxane, hexanes : dry neutral alumina; DMSO, DMF, CH3OH : activated molecular sieves). 
Water was obtained from a Millipore MilliQ water purification system.  
 
Reactions.  
All reactions were performed in oven- or flame-dried glassware under an atmosphere of 
argon unless otherwise indicated. Reactions were monitored by analytical thin layer 
chromatography performed using the indicated solvent on E. Merck silica gel 60 F254 plates 
(0.25mm). Compounds were visualized using a UV (λ254) lamp or stained by an acidic solution 
of KMnO4.  
 
Purification and Analysis.  
Flash chromatography was performed as described by Still and coworkers
39
 using the 
indicated solvent on E. Merck silica gel 60 230-400 mesh. 
1
H NMR spectra were recorded at 23 
°C on one of the following instruments: Varian Unity 400, Varian Unity 500, Varian Unity Inova 
500NB. Chemical shifts (δ) are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced internally to the residual protium in the NMR solvent (CHCl3, δ 
= 7.26) or to added tetramethylsilane. 
13
C spectra were recorded at 23 °C with a Varian Unity 
500. Chemical shifts (δ) are reported downfield of tetramethylsilane and are referenced to the 
carbon resonances in the NMR solvent (CDCl3, δ = 77.16, center line) or to added 
tetramethylsilane. High resolution mass spectra (HRMS) were obtained at the University of 
Illinois mass spectrometry facility. All synthesized compounds gave HRMS within 5 ppm of 
calculated values.  
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Isothermal Titration Calorimetry 
General Information. 
Experiments were performed using a NanoITC isothermal titration calorimeter (TA 
Instruments, Wilmington, DE). Solutions of the compounds to be tested were prepared by 
diluting a 15.0 mM stock solution of the compound in DMSO to 150 M with K buffer (5.0 mM 
HEPES/KHEPES, pH = 7.4). The final DMSO concentration in the solution was 1% v/v. POPC 
LUVs were prepared and phosphorus and ergosterol content was quantified as described below. 
The LUV solutions were diluted with buffer and DMSO to give a final phospholipid 
concentration of 8.0 mM in a 1% DMSO/K buffer solution. Immediately prior to use, all 
solutions were degassed under vacuum at 20 °C for 10 minutes. The reference cell of the 
instrument (volume = 0.190 mL) was filled with a solution of 1% v/v DMSO/K buffer. 
 
LUV Preparation.  
Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 20 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 C under an atmosphere 
of dry argon and used within 1 month. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4 C under an atmosphere of dry argon. Prior to preparing a lipid film, the 
solutions were warmed to ambient temperature to prevent condensation from contaminating the 
solutions. A 13 x 100 mm test tube was charged with 1.2 mL POPC and 350 L of the ergosterol 
solution. For sterol-free liposomes, a 13 x 100 mm test tube was charged with 1.2 mL POPC. 
The solvent was removed with a gentle stream of nitrogen and the resulting lipid film was stored 
under high vacuum for a minimum of eight hours prior to use. The film was then hydrated with 1 
mL of 5 mM HEPES pH 7.4 (K buffer) and vortexed vigorously for approximately 3 minutes to 
form a suspension of multilamellar vesicles (MLVs). The resulting lipid suspension was pulled 
into a Hamilton (Reno, NV) 1 mL gastight syringe and the syringe was placed in an Avanti Polar 
Lipids Mini-Extruder. The lipid solution was then passed through a 0.20 μm Millipore (Billerica, 
MA) polycarbonate filter 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  
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Determination of Phosphorus Content.  
Determination of total phosphorus was adapted from the report of Chen and coworkers.
40
 
Three 10 μL samples of the LUV suspension were added to three separate 7 mL vials. 
Subsequently, the solvent was removed with a stream of N2. To each dried LUV film, and a 
fourth vial containing no lipids that was used as a blank, was added 450 μL of 8.9 M H2SO4. The 
four samples were incubated open to ambient atmosphere in a 225 °C aluminum heating block 
for 25 min and then removed to 23 °C and cooled for 5 minutes. After cooling, 150 μL of 30% 
w/v aqueous hydrogen peroxide was added to each sample, and the vials were returned to the 
225 °C heating block for 30 minutes. The samples were then removed to 23 °C and cooled for 5 
minutes before the addition of 3.9 mL water. Then 500 μL of 2.5% w/v ammonium molybdate 
was added to each vial and the resulting mixtures were then vortexed briefly and vigorously five 
times. Subsequently, 500 μL of 10% w/v ascorbic acid was added to each vial and the resulting 
mixtures were then vortexed briefly and vigorously five times. The vials were enclosed with a 
PTFE lined cap and then placed in a 100 °C aluminum heating block for 7 minutes. The samples 
were removed to 23 °C and cooled for approximately 15 minutes prior to analysis by UV/Vis 
spectroscopy. Total phosphorus was determined by observing the absorbance at 820 nm and 
comparing this value to a standard curve obtained through this method and a standard 
phosphorus solution of known concentration. 
 
Determination of Ergosterol Content.  
Ergosterol content was determined spectrophotometrically. A 50 μL portion of the LUV 
suspension was added to 450 μL 2:18:9 hexane:isopropanol:water (v/v/v). Three independent 
samples were prepared and then vortexed vigorously for approximately one minute. The 
solutions were then analyzed by UV/Vis spectroscopy and the concentration of ergosterol in 
solution was determined by the extinction coefficient of 10400 L mol
-1
 cm
-1
 at the UVmax of 282 
nm and was compared to the concentration of phosphorus to determine the percent sterol content. 
The extinction coefficient was determined independently in the above ternary solvent system. 
LUVs prepared by this method contained between 7 and 14% ergosterol.  
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Titration Experiment. 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 0.191 mL) which contained the 150 M solution of the compound in 
question at 25 °C. The volume of the first injection was 0.23 μL. Consistent with standard 
procedure,
41
 due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, nineteen 
2.52 L injections of the LUV suspension were performed. The spacing between each injection 
was 240 seconds to ensure that the instrument would return to a stable baseline before the next 
injection was made. The rate of stirring for each experiment was 300 rpm.  
 
Data Analysis. 
NanoAnalyze software (TA Instruments) was used for baseline determination and 
integration of the injection heats, and Microsoft Excel was used for subtraction of dilution heats 
and the calculation of overall heat evolved. To correct for dilution and mixing heats, the heat of 
the final injection from each run was subtracted from all the injection heats for that particular 
experiment.
42
 By this method, the overall heat evolved during the experiment was calculated 
using the following formula: 
)(μcal
1



n
i
n
injection
i
injectionoverall hh  
Where i = injection number, n = total number of injections,

hinjection
i
 = heat of the i
th
 injection, 
and 

hinjection
n
 = the heat of the final injection of the experiment. Values represent the mean ± SD 
of at least three experiments. 
 
 
Triethyl(ethynyl)germane 3.12. A 1L round bottom flask with a stir bar was outfitted with a 
250 mL pressure-equalizing addition funnel with a gas adapter. The apparatus was flame-dried 
under vacuum, backfilling with Ar. The gas adapter was replaced with a rubber septum. Et3GeCl 
(25.5 mL, 154 mmol, 1.0 equiv.) was added via the addition funnel. The septum was removed, 
and THF (154 mL) was added to the reaction from a graduated cylinder via the addition funnel. 
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The septum was replaced, and the resulting solution was cooled to 0 °C and stirred. A solution of 
ethynylmagnesium bromide in THF (0.5 M, 340 mL, 169 mmol, 1.1 equiv.) was cannulated into 
the addition funnel and added dropwise to the reaction over 20 minutes. After addition was 
complete, the reaction was removed from the ice bath, the addition funnel was replaced with a 
reflux condenser with gas adapter, and the reaction was heated in a 70 °C oil bath with stirring 
for 4 hours. The reaction was allowed to cool to room temperature and poured into a separatory 
funnel containing 250 mL saturated aq. NH4Cl and 250 mL H2O. The layers were separated, and 
the aqueous phase was extracted with Et2O (400 mL). The combined organics were dried over 
MgSO4, filtered, and concentrated on a rotovap with a bath temperature of 15 - 20°C, maintained 
by constant tap water circulation. This afforded the crude product as a brown liquid which was 
used without further purification. 
 
All characterization data match the reported literature values.
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(E)-triethyl(2-(tributylstannyl)vinyl)germane 3.9. A 1 L 3-neck round bottom flask with a stir 
bar was outfitted with a reflux condenser with gas adapter and 2 rubber septa. One septum was 
removed, and the crude substrate (154 mmol assumed, 1.0 equiv.) was added through a funnel, 
followed by PhMe (385 mL) and AIBN(2.28 g, 13.9 mmol, 0.09 equiv.). The septum was 
replaced, and Bu3SnH (49.0 mL, 185 mmol, 1.2 equiv.) was added via syringe. The apparatus 
was purged with Ar for 3 minutes, then heated in a 100 °C oil bath with stirring for 18 hours. 
The reaction was allowed to cool to room temperature, the stir bar was removed, and the reaction 
was transferred to a 1 L round bottom flask and concentrated in vacuo. A stir bar was added, 
followed by CCl4 (150 mL). The solution was stirred at room temperature for 1 hour. Next, Et2O 
(200 mL), H2O (200 mL), and saturated aq. KF (200 mL) were added sequentially, and the 
mixture was stirred vigorously for 1 hour. The mixture was transferred to a separatory funnel, 
and the layers were separated. The aqueous phase was extracted with Et2O (400 mL). The 
combined organics were dried over MgSO4, filtered, and concentrated in vacuo to give a yellow 
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liquid. This was purified by SiO2 chromatography (petroleum ether, 9 cm diameter column 
packed with 12 - 14 cm SiO2 gel). After a 500 mL prefraction, the subsequent 1.5 L of eluent 
was collected. This was repeated for 3 batches of crude substrate, and the combined product-
containing eluents were concentrated to afford the product as a pale yellow liquid (241 g, 85% 
overall from triethylgermanium chloride). 
 
All characterization data match the reported literature values.
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CHAPTER 4  
 
A Universal Building Block for Mycosamine-Containing Polyene Macrolides 
 
As discussed in Chapters 2 and 3, our functional group deletion strategy has revealed that 
sterol binding is the primary mechanism of action of mycosamine-containing polyene 
macrolides. The potential implications of this result for the development of new resistance-
refractory antifungals with increased activity and therapeutic index, as well as other small 
molecules with the potential to replicate the function of missing or deficient protein ion channels, 
highlighted the need for a modular and flexible synthesis of these natural products. Despite their 
diverse architecture, all members of this family contain a conserved motif encompassing a 6-
membered hemiketal ring and mycosamine, which is essential for the sterol-binding and 
subsequent antifungal activity of these compounds. Importantly, our existing degradative and 
semisynthetic strategies for generating derivatives of AmB did not allow ready access to 
derivatives of this portion of the molecule. Thus, we developed the synthesis of a building block 
with the potential for introducing this conserved motif through an ICC-based strategy. 
Specifically, the development of a novel type of diastereotopic group-selective lactonization and 
a new tactic for the stereoselective installation of mycosamine enabled the completion of this 
work. 
The gram scale synthesis of allylic alcohol 4.67 was developed in collaboration with Dr. 
Justin Struble, David Knapp, and Jim Tucker. Mycosamine donors were synthesized in 
collaboration with David Knapp and Dr. Justin Struble.   
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4-1 BACKGROUND 
The total synthesis of polyene macrolide natural products has remained a very important 
challenge in the field of organic chemistry. To date, the only member of this class of natural 
products to succumb to the efforts of total synthesis is amphotericin B (AmB), reported in a 
series of publications by the Nicolaou group from 1987-1988.
1,2,3,4
 Partial, formal, and 
semisynthetic efforts have been reported for several members of this family, including 
AmB,
5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22
 natamycin,
23,24
 nystatin,
25,26,27,28,29,30,31,32,33
 candidin,
33
 
and rimocidin.
33,34,35
 Additionally, biosynthetic strategies have been employed to generate 
derivatives of several of these natural products,
36,37,38,39,40
 although in many of these cases the 
isolation of pure compounds for biological testing has proven difficult.
41,42,43
 The challenges of 
assembling and manipulating the complex and highly functionalized architecture of theses 
natural products has produced enduring and widely applicable synthetic methodology
5
 in the 
areas of carbon-carbon bond formation,
3,4,19,20,21,33,34,44 
enantio- and diastereoselective polyol 
synthesis,
 1,2,4,8,19,20,21,33,33
 and chemical glycosylation.
4,20,21,45
  
Despite these successes, synthetic efforts have primarily focused on the unique 
challenges associated with individual polyene macrolide targets and have not been generalized 
into a flexible synthetic platform. The recognition of a highly conserved and functionally critical 
subunit of this family of natural products (Figure 4.1) suggests that a strategy for the introduction 
of this fragment in a modular fashion under mild conditions may help illuminate in atomistic 
detail the mechanism(s) of action of mycosamine-containing polyene macrolides, optimize their 
pharmacological properties, and enable their transformation into functional mimics of deficient 
proteins that underlie currently incurable human diseases. 
 
 
Figure 4.1. The universally conserved structural motif in mycosamine-containing polyene macrolides. 
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4-2 ICC-BASED SYNTHESIS PLATFORM FOR POLYENE MACROLIDES 
To address this challenge, efforts in the Burke group have focused on the development 
and application of an iterative cross-coupling (ICC)-based strategy for the synthesis of small 
molecules.
46,47,48,49,50,51,52
 Paralleling the modular fashion in which peptides are constructed via 
the recursive application of a single reaction to assemble a collection of simple building blocks, 
this strategy employs the Suzuki-Miyaura cross-coupling of bifunctional MIDA-boronates to 
form carbon-carbon bonds iteratively under mild conditions. The application of such a strategy to 
mycosamine-containing polyene macrolides has the potential to enable the synthesis of this 
family of natural products and their derivatives in a highly modular fashion.  
As shown in Figure 4.2, all of the members of this family can be retrosynthetically 
disconnected via Suzuki-Miyaura transforms into four general building blocks: 
1. A polyol-containing motif, consisting primarily of a pattern of 1,3-diols with 
occasional occurrence of a 1,2-diol, ketone, or epoxide motif (BB1) 
2. A hemiketal/mycosamine-containing motif, which is conserved among all members 
of this class of natural products (BB2) 
3. A polyene core, ranging in length from 0 to 3 double bonds that may or may not be 
conjugated (BB3) 
4. A hydrophobic tail, containing a variety of alkyl and occasionally aryl substituents 
and completing the macrolactone ring (BB4) 
 
 
Figure 4.2. ICC-based retrosynthesis of mycosamine-containing polyene macrolides. A collection of much simpler 
building blocks could theoretically be used to access all members of this family of natural products, including 
unnatural analogs. BB2 is completely conserved throughout this family. 
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Enabled by the ICC strategy for small molecule synthesis,
47
 we envisioned a collection of 
building blocks in each of the four categories which, upon combination, will allow the synthesis 
of any of the members of this family of natural products, including many unnatural analogs.  
Among all of these building blocks, BB2 encompasses the conserved structural elements 
of this family of natural products and thus could be common to the synthesis of all members of 
this family via ICC. Importantly, it contains the mycosamine sugar, which we have demonstrated 
to be critical for the binding of these natural products to membrane-embedded sterols
53
 and is, in 
turn, primarily responsible for the antifungal activity of AmB and natamycin.
54
 As discussed in 
Chapter 3, we have proposed that this binding interaction is the primary mechanism by which all 
members of this family of natural products exert their biological activity.
54
 This building block 
thus represents the cornerstone of a modular ICC-based approach to potentially access all 
members of this class of natural products.  
 
4-3 BB2 DESIGN AND RETROSYNTHESIS 
Based upon the application of the above series of disconnections to AmB (Figure 4.3), we 
designed bifunctional building block BB2 to incorporate a ketene-acetal phosphate at C13 as the 
electrophile for a Csp
2
-Csp
3
 cross-coupling with 4.1.
55
 Ketene acetal phosphates are versatile 
pseudohalides for cross-coupling, as demonstrated by the Nicolaou
56
 and Sasaki
57
 groups in the 
synthesis of marine polyether natural products, and tend to be more stable than the corresponding 
triflates. This coupling reaction would forge the C-C bond between C12 and C13, resulting in a 
dihydropyran which could then be transformed into the corresponding hemiketal present in the 
natural product.
58
 This two-step sequence would thus represent a surrogate for a Csp
3
-Csp
3
 cross-
coupling, thus rendering the polyol portion of these natural products amenable to the ICC 
approach. BB2 also contains a dienyl MIDA boronate subunit for subsequent elaboration with 
via ICC with 3.4 and 4.2 into the remaining polyene core of these natural products. Previous 
experience with the synthesis of C35deOAmB developed by Dr. Kaitlyn Gray had demonstrated 
that ICC starting with this type of dienyl MIDA boronate is an effective method of constructing 
the polyene core of these natural products.
49,54 
78 
 
 
Figure 4.3. ICC-based retrosynthesis of AmB. 
 
Similar experience with other synthetic campaigns had highlighted the importance of 
protecting group choice when working with this class of natural products.
21,54,59
 Based on these 
results, a tert-butyldimethylsilyl ether was chosen to protect the alcohols at C15, C2’, and C4’. 
The C41 carboxylic acid was protected as the corresponding trimethylsilylethyl ester, and the 
C3’ amine was protected as an azide. Initial concerns regarding the stability of the azide to cross-
coupling conditions employing phosphine ligands were addressed by both literature 
precedent
60,61
 and successful model studies undertaken by Dr. Kaitlyn Gray and Pulin Wang in 
which polyene cross-couplings were performed with no degradation of a model azide included in 
the same reaction. 
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Having determined the protecting group choice for BB2, subsequent retrosynthesis 
afforded lactone 4.3, bis-metalated olefins
52,62
 4.5 and 3.9, and mycosamine donor 4.4 (Figure 
4.4). The retrosynthetic analysis and recognition of potential challenges for construction and 
combination of each of these intermediates is described in detail below.  
 
 
Figure 4.4. Retrosynthesis of BB2. 
 
4-4 DIASTEREOTOPIC GROUP-SELECTIVE LACTONIZATION 
Recognizing the symmetrical pattern of functional groups in lactone 4.3, we hypothesized 
that this key substructure might be accessible via a novel type of diastereotopic group-selective 
lactonization (see below) of pseudo-C2-symmetric intermediates such as 4.7 - 4.9, any of which 
might be prepared from L-(-)-arabitol (4.10, Figure 4.5). Such a synthetic strategy could allow 
for the construction of intermediates through bidirectional synthesis, thereby increasing 
efficiency through the execution of multiple synthetic steps simultaneously. 
 
 
Figure 4.5. Recognition of symmetry elements in the retrosynthesis of lactone 4.6. This substructure could 
potentially be efficiently constructed through bidirectional synthesis starting from the carbohydrate L-(-)-arabitol 
(4.10). 
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Bidirectional chain synthesis and terminus differentiation is a valuable strategy in the 
construction of natural products.
63,64,6566,67,68,69,70,71,72
 Several reviews have been published 
highlighting the principles and application of this approach.
73,74,75
 As summarized by Schreiber
73
 
and shown in Figure 4.6, bidirectional synthesis can be subdivided by the type of chain that 
undergoes elongation. Except in the case of a symmetric final target, some type of 
desymmetrization is always required to complete the bidirectional synthesis process and further 
elaborate the chain to the desired target structure. Each type of chain requires a specific 
desymmetrization manifold. In the case of achiral or meso chains, the termini are enantiotopic 
and can only be differentiated through the use of a chiral reagent. In the case of C2-symmetric 
chains, the termini are homotopic and are therefore not chemically distinguishable. The 
differentiation of homotopic groups is accomplished by monofunctionalization of the chain. In 
the case of pseudo-C2-symmetric chains, the termini are diastereotopic and can be differentiated 
through a diastereotopic group-selective reaction employing, in principle, either substrate- or 
reagent-controlled selectivity. 
 
 
Figure 4.6. Summary by Schreiber of different types of symmetrical chains and the methods required for their 
desymmetrization. Figure adapted from reference 73. 
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The term “pseudo-C2-symmetric” describes a chain which would be C2-symmetric if it 
did not contain a chirotopic nonstereogenic center along the C2 axis.
73
 This center is chirotopic 
because it is a point on a chiral molecule, yet it is nonstereogenic because it contains two 
equivalent groups.
76
 This center becomes stereogenic upon desymmetrization, allowing for both 
the installation of a new stereogenic center and the elaboration of the chain simultaneously. In 
the case of intermediates 4.7 – 4.9, all contain a chirotopic nonstereogenic center which becomes 
stereogenic during diastereotopic group-selective lactonization. 
 
 
Figure 4.7. Type 1 diastereotopic group selective lactonizations. (A) The chirotopic nonstereogenic center bears a 
substituent which participates in bond formation during lactonization. The stereodetermining element of a Type 1 
system will always reside at C5 in the lactone ring where, in a pseudoaxial position, it encounters a 1,3-diaxial 
interaction with the sbustituent at C3. (B) Type 1 system under kinetic control by Schreiber and coworkers (see 
reference 65). (C) Type 1 system under thermodynamic control by Hoye and coworkers (see reference 64).  
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Previous selected examples of diastereotopic group-selective lactonizations are shown in 
Figure 4.7 These include pioneering studies by Schreiber in the synthesis of FK506
65
 and Hoye 
in the synthesis of invictolide
64
 and peloruside.
63
 In all cases, the chirotopic nonstereogenic 
center bears a substituent which participates in selective bond formation with one diastereotopic 
terminus. We have termed this a Type I diastereotopic group-selective lactonization.  
The diastereoselectivity of Type I diastereotopic group-selective lactonizations is 
rationalized by involvement of transition state (kinetic control) or product ground state 
(thermodynamic control) structures in which the maximum number of ring substituents assume 
an equatorial or pseudoequatorial position (Figure 4.7).
63,64,65,72
 A notable exception to this 
rationale was reported by Hoye and coworkers
63
 in the context of their synthesis of peloruside 
(Figure 4.8). Base-catalyzed lactonization of 4.19 proceeded with selectivity for lactone 4.20 as 
rationalized by structure 4.21 in which the maximum number of substituents is pseudoequatorial. 
However, ozonolytic lactonization
77,78
 of the corresponding substrate 4.23 resulted in selective 
formation of lactone 4.24, which was proposed to proceed through intermediates such as 4.25 
containing an axial methoxymethyl ether. This reaction platform is thus diastereodivergent, and 
the disparity was rationalized by the stereoelectronic activation of the C-H bond at C1 in 
intermediates containing an adjacent axial methoxymethyl ether, potentially rendering these 
intermediates more reactive to oxidation by ozone (Figure 4.8B).
63
 
Interestingly, we recognized that the lactonization of substrates 4.7 - 4.9 would 
alternatively involve selective crossover of a substituent from one diastereotopic half of the 
molecule to react with the terminus of the other diastereotopic half, thereby rendering the 
bystanding chirotopic nonstereogenic center stereogenic. To the best of our knowledge, this 
represents a novel type of lactonization which we have termed a Type II diastereotopic group-
selective lactonization (Figure 4.9). In addition to opening up new opportunities for strategic 
disconnections in complex molecule synthesis, we recognized two potential advantages of Type 
II diastereotopic group-selective lactonizations over Type I. First, because of the topology of a 
Type II system, the substituent at the initially chirotopic nonstereogenic center will always reside 
at the 4 position of the lactone product or its precursors, where A-values are expected to be 
maximized through interaction with a substituent at the 2 position and the lone pair of the ring 
oxygen atom (Figure 4.9). Thus, in contrast to Type I systems,
64
 whether determined by the 
relative energies of the diastereomeric lactones (thermodynamic control) or the diastereomeric 
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transition states leading to their formation (kinetic control), Type II systems may lead to 
uniformly high stereoselectivities. Second, because the substituent at the chirotopic 
nonstereogenic center of a Type II system does not participate in new bond formation, it can 
easily be varied to increase flexibility in synthesis planning and/or readily provide access to 
targeted derivatives.
53
  
 
 
Figure 4.8. Diastereodivergent lactonizations developed by Hoye and coworkers. (A) Base-catalyzed kinetic 
lactonization of 4.19 gives lactone 4.20 as rationalized by transition state 4.21 in which the number of equatorial 
substituents is maximized. (B) Ozonolytic lactonization of analogous bis-olefin 4.23 shows a turnover in selectivity 
to give lactone 4.24. Hoye and coworkers propose this diastereodivergence arises from the stereoelectronic 
activation of hemiketal intermediates such as 4.25 which possess a C-O σ* orbital synperiplanar to the hemiketal C-
H bond. Figure adapted from reference 63. 
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Figure 4.9. Type 2 diastereotopic group selective lactonizations. (A) The chirotopic nonstereogenic center bears a 
substituent which does not participate in bond formation during lactonization. The stereodetermining element of a 
Type 1 system will always reside at C4 in the lactone ring where, in a pseudoaxial position, it encounters a 1,3-
diaxial interaction with the sbustituent at C2 and the lone pair of the lactone ring oxygen. (B) Lactonization of 
substrates 4.7 – 4.9 are predicted to proceed with selectivity for 4.27 under kinetic, thermodynamic, and ozonolytic 
conditions. 
 
4-5 DEVELOPMENT OF A NOVEL DIASTEREOTOPIC GROUP-SELECTIVE 
LACTONIZATION 
Initial synthetic efforts were focused on determining the feasibility of the proposed Type 
II diastereotopic group-selective lactonization through the preparation of model substrates 4.38 
and 4.39 from known alcohol 4.35 (Scheme 4.1).
79,80,81,82
 Briefly, methylation, deketalization, 
and epoxidation under Mitsunobu conditions
83
 (see below) afforded bis-epoxide 4.36. Opening 
with trimethylsilylcyanide
84,85
 afforded bis-nitrile 4.37. Nitrile hydrolysis and subsequent 
lactonization (see below), followed by methylation and lactone methanolysis gave bis-ester 4.38. 
Alternatively, opening of bis-epoxide 4.36 with vinylmagnesium bromide
65
 afforded bis-olefin 
4.39.  
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To accurately determine the d.r. of lactonization, we synthesized both possible lactone 
diastereomers and used them as GC standards for analysis of the model lactonization reactions. 
The synthesis of each is shown in Scheme 4.2. Configuration of the new stereogenic center in 
each case was verified by the NOE analysis shown in Figure 4.10. 
 
 
Scheme 4.1. Synthesis of model lactonization substrates 4.38 and 4.39. 
 
 
Scheme 4.2. Synthesis of lactone diastereomers 4.41 and 4.44 as standards for GC analysis. 
 
 
Figure 4.10. NOE analysis to confirm the configuration of the new stereogenic center (marked in blue) in lactones 
(A) 4.40, and (B) 4.44. 
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To explore the lactonization, we first cyclized bis-ester 4.38 under acidic conditions 
(Figure 4.11A, entry 1). Consistent with the analysis described in Section 4-4, diastereomer 4.40 
was formed with a high level of diastereoselectivity as determined by GC. This selectivity was 
robust and did not diminish over time (entry 2), suggesting its potential application to a practical 
synthetic process. In contrast to the diastereodivergent system described by Hoye,
63
 ozonolytic 
lactonization
77,78
 of bis-olefin 4.39 resulted in the diastereoconvergent formation of 4.40, also 
with high diastereoselectivity (entry 3). Despite this high level of stereoselectivity, extensive 
byproduct formation rendered the ozonolytic manifold impractical for application to the 
synthesis of BB2. Additionally, the manipulation of bis-ester 4.38 proved challenging as it 
exhibited poor chromatographic properties and was prone to lactonization and polymerization 
upon storage. Encouraged by the robustness of the acid-catalyzed lactonization, we recognized 
that a one-pot hydrolysis/lactonization of bis-nitrile 4.37 might allow for high levels of 
diastereoselectivity without the need to isolate potentially unstable intermediates. This was in 
fact realized with the one-pot hydrolysis/lactonization of 4.37 to give lactone 4.47 with high 
diastereoselectivity. Based on this result, the synthesis of BB2 was designed to incorporate a 
Type II diastereotopic group-selective lactonization utilizing this one-pot procedure. 
 
 
Figure 4.11. Results of model Type 2 diastereotopic group-selective lactonizations. (A) Lactonizations under acidic 
conditions show very high levels of diastereoselectivity that do not diminish over time. Ozonolytic lactonization is 
also highly diastereoselective. (B) A one-pot hydrolysis/lactonization of bis-nitrile 4.37 is very highly selective with 
the potential for practical and scalable application to the synthesis of BB2. 
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4-6 SYNTHESIS OF BB2-AGLYCONE 
To maximize the scalability of the synthesis of this building block, we sought to link 
multistep sequences without purification of the corresponding intermediates whenever possible. 
Transformation of L-(-)-arabitol into alcohol 4.35 had been previously reported by Linclau as 
shown in Scheme 4.3.
79,80
 The initial ketalization was reported on a 10 gram scale, with all 
subsequent reactions on 1 gram scale or smaller, and column chromatography was required after 
each step. Treatment of the crude reaction mixture from ketalization with succinic anhydride was 
utilized as a scavenging protocol by Linclau and coworkers to remove undesired internal ketal 
isomers via their selective acylation to give 4.50, which was removed through basic aqueous 
extraction.
79
 Application of the Parikh-Doering oxidation
86
 of alcohol 4.48 on large scale 
produced large quantities of the noxious byproduct dimethyl sulfide and introduced inorganic 
impurities which colored subsequent reactions and could not be removed except through 
chromatography. Wittig reaction afforded olefin 4.49, with chromatography required for removal 
of the stoichiometric triphenylphospine oxide byproduct.
79
 Finally, hydroboration and oxidation 
generated alcohol 4.35.
80
 
 
 
Scheme 4.3. Linclau and coworkers' route to alcohol 4.35 from L-(-)-arabitol. 
 
To improve the scalability and practicality of the synthesis of 4.35, an alternative route 
was developed as shown in Scheme 4.4. Selective ketalization of arabitol was performed without 
the subsequent scavenging workup procedure. As suggested and implemented by Dr. Justin 
Struble, the Parikh-Doering oxidation was replaced by an IBX-mediated oxidation.
87
 After the 
reaction was complete, the iodobenzoic acid byproduct was isolated via precipitation and 
88 
 
recycled by reaction with Oxone.
88
 In this way, iodobenzoic acid could be recycled several times 
with no decrease in activity. The resulting ketone was then transformed into olefin 4.49 via a 
Wittig olefination,
79
 and the crude reaction mixture was treated with hexanes to precipitate the 
stoichiometric triphenylphosphine oxide. The crude product was isolated after passing through a 
pad of silica gel. Hydroboration and oxidation
80
 then gave alcohol 4.35 without the need for any 
column chromatography through this entire sequence.  
This crude material next smoothly underwent benzylation and deketalization. The 
resulting tetraol 4.51 partitioned into the aqueous phase of the reaction workup, and successive 
washes with petroleum ether removed all other organic byproducts from the reaction. The crude 
tetraol was then isolated and converted to bis-epoxide 4.52 under Mitsunobu-type conditions
83
 
(see below), and the product was purified by column chromatography or distillation. This 
procedure has been employed in collaboration with Dr. Justin Struble and Jim Tucker to produce 
more than 150 g of this intermediate to date. 
 
 
Scheme 4.4. A robust and scalable synthesis of bis-epoxide 4.52. Replacement of the Parikh-Doering oxidation with 
an IBX-mediated oxidation, elimination of column chromatography, and telescoping crude material through 
multiple manipulations greatly streamlined the route. Masses shown are the amount of material that was processed 
in a single reaction. 
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Initial efforts to generate bis-epoxide 4.52 from tetraol 4.51 were based on a very similar 
transformation reported by Linclau utilizing L-(-)-arabitol (4.10).
81
 Activation of the terminal 
alcohols of 4.10 with 2,4,6-tri-isopropylbenzenesulfonyl chloride (4.54) followed by treatment 
with base afforded bis-epoxide 4.53 (Figure 4.12A). However, when these conditions were 
employed with tetraol 4.51, a one-carbon homologue of 4.10, the expected bis-epoxide 4.52 was 
not formed in any detectable amount. Instead, a mixture of tetrahydrofurans (4.56) was isolated 
(Figure 4.12B). We hypothesized that these products arise from a 1,5-cyclization of intermediate 
4.55, rather than the desired 1,3-cyclization to form bis-epoxide 4.52.
81
 Despite screening a 
variety of reaction conditions including base, solvent, and temperature, bis-epoxide 4.52 was 
never detected.  
 
 
Figure 4.12. (A) Conversion of arabitol to bis-epoxide 4.53 by Linclau and coworkers. (B) Attempted conversion of 
tetraol 4.51 to bis-epoxide 4.52. Only tetrahydrofuran products could be detected, resulting from 1,5-cyclization of 
intermediate 4.55. Application of Mitsunobu conditions suppressed tetrahydrofuran formation, possibly due to 
simultaneous alcohol activation and nucleophile generation which may stochastically favor reactivity at only one 
terminus through intermediate 4.58.  
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Strikingly, employing Mitsunobu-type conditions
83
 alternatively afforded bis-epoxide 
4.52 with no detectable formation of tetrahydrofuran byproducts. To rationalize this result, we 
have proposed a plausible mechanistic pathway shown in Figure 4.12B. Exposure of 1,2-diols to 
Mitsunobu conditions (triphenylphosphine, dialkylazodicarboxylate) generates an equilibrating 
mixture of alkoxyphosphorane 4.57 and oxyphosphonium salts 4.58.
83
 Formation of 
alkoxyphosphoranes from 1,3-diols is not observed.
83
 Cyclization occurs primarily via the 
terminal oxyphosphonium salt 4.58 to give retention of configuration at C2. This reaction 
manifold reduces or eliminates undesired 1,5-cyclization because the terminal alcohol is 
activated only transiently with concomitant release of the nucleophilic alkoxide on the 
neighboring carbon. For 1,5-cyclization to occur, both alkoxyphosphoranes in 4.57 would need 
to exist as the corresponding bis-oxyphosphonium salt 4.59 simultaneously. This species 
possesses extensive charge separation and is thus likely to be a higher energy intermediate along 
the reaction coordinate relative to oxyphosphonium salt 4.58. The lack of detectable formation of 
tetrahydrofuran byproducts is consistent with the conclusion that reaction via this pathway does 
not occur.  
Bis-epoxide 4.52 was then opened with trimethylsilylcyanide
84,85
 to give crude bis-nitrile 
4.60. Employing the Type II diastereotopic group-selective lactonization developed above, 
hydrolysis and lactonization of 4.60, followed by methyl esterification and TBS protection 
afforded lactone 4.61 as a crystalline solid, which could be purified by recrystallization in 41% 
yield over 4 steps. The configuration of the newly formed stereogenic center at C16 was 
confirmed by X-ray crystallography (Figure 4.13B). This compound proved to be a valuable 
point at which to accumulate material during the synthesis of BB2 due to its ease of handling and 
robust benchtop stability (Figure 4.13C). 
Subsequent debenzylation, oxidation
89
 (developed in collaboration with Dr. Justin 
Struble), Mitsunobu esterification, and saponification of both the lactone ring and methyl ester, 
followed by relactonization gave carboxylic acid 4.62 in 75% yield over 4 steps (Figure 4.14). 
This acid was isolated cleanly from the saponification reaction by washing the aqueous reaction 
mixture with Et2O prior to acidification in a process developed in collaboration with David 
Knapp. The corresponding bis-carboxylate salt of 4.62 remained in the aqueous phase, and other 
organic impurities were removed with the Et2O washes. Subsequent acidification afforded 4.62 
in sufficient purity to be carried forward without further purification. Additionally, although the 
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benzylation, oxidation, and Mitsunobu reactions could be performed without purification, 
execution of this sequence in immediate succession was required to avoid decomposition of the 
intermediates. The instability of these intermediates to silica gel also necessitated this 
manipulation. 
 
 
Figure 4.13. (A) Application of novel Type 2 diastereotopic group-selective lactonization to the synthesis of lactone 
intermediate 4.61. (B) X-ray crystal strucure of 4.61 confirming the stereochemistry at the newly formed stereogenic 
center. (C) Intermediate 4.61 was easily manipulated and stable to prolonged storage. It thus proved to be very 
convenient for the storage of large amounts of material during our synthetic campaign.  
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Figure 4.14. (A) Initial attempts to synthesize aglycone 4.66 were hampered by low diastereoselectivity in the 
reduction of enone 4.64. (B) Model for predicting the stereochemical outcome of the CBS reduction. We 
hypothesized that a lack of steric differentiation between the ketone substituents in 4.64 led to the observed low 
diastereoselectivity. (C) Improved CBS reduction utilizing germanium enone 4.67. Guided by the analysis in B, we 
predicted that the proximity of the sterically bulky triethylgermyl group to the ketone in 4.67 would help to 
differentiate the ketone substituents in the CBS reduction to a greater degree than in dienone 4.64. 
 
Initial efforts were made to install the diene as a single unit through Stille coupling
90
 of 
the acid chloride of 4.62 with bis-metalated diene 4.63.
49
 Though this process was successful, 
CBS reduction
91,92,93
 of dienone 4.64 proceeded with only moderate selectivity and required 
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tedious purification to separate the diastereomers. Other types of reductions, including substrate-
controlled reduction with achiral reagents, either gave low selectivity or also reduced the lactone. 
An analysis of the factors contributing to selectivity in the CBS reduction (Figure 4.14B)
94
 led to 
the hypothesis that reduction of germanium enone 4.67, in which the sterically bulky 
triethylgermanium group is in closer proximity to the ketone relative to the MIDA boronate in 
dienone 4.64, would lead to greater diastereoselectivity. This was in fact realized with the 
synthesis and reduction of 4.67 (Figure 4.14C) and ultimately allowed for the preparatively 
useful construction of the BB2 aglycone 4.68. Configuration of the new stereogenic center was 
confirmed by Mosher ester analysis.
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4-7 β-1,2-CIS GLYCOSYLATION 
The next challenge in the BB2 synthesis was the stereoselective installation of the 
mycosamine sugar via a β-1,2-cis glycosidic linkage. The discovery of a solution to this problem 
was the result of a highly productive collaboration with David Knapp and Dr. Justin Struble. As 
discussed in Chapter 1, the β-1,2-cis glycosidic linkage in polyene macrolides represents a 
formidable synthetic challenge.
96,97
 Intramolecular aglycone delivery and anchimeric assistance 
followed by stereocenter inversion represent two common strategies employed to address this 
problem.
4,20,21,45,59 
At the outset of our synthetic efforts, both the intramolecular aglycone 
delivery and anchimeric assistance strategies were proposed as possible approaches for the 
installation of mycosamine in BB2. Despite the difficulties associated with intramolecular 
aglycone delivery in the case of rimocidin,
59
 we hypothesized that the hydroxyl group of BB2 
could potentially be a more effective nucleophile than the larger and more conformationally 
restricted hydroxyl group of the rimocidin aglycone. Additionally, the lack of acid-sensitive 
functionality in BB2 suggested that issues of chemical incompatibility experienced with the 
rimocidin aglycone might be circumvented. Finally, use of the Ito benzylidene acetal method
98
 
could allow electronic tuning of the benzyl group
99,100
 and thus improve the transfer efficiency of 
the glycosyl acceptor. In the event that intramolecular aglycone delivery was ineffective, we 
proposed that anchimeric assistance could be a viable alternative given the success of its 
previous application to the synthesis of polyene macrolides.
4,20,21
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4-8 DEVELOPMENT OF A NEW TACTIC FOR FORGING β-1,2-CIS GLYCOSIDIC 
LINKAGES 
Our initial efforts focused on the development of an approach based on intramolecular 
aglycone delivery to install a mycosamine donor possessing the desired stereochemistry at C2’ 
(Scheme 4.5). In collaboration with David Knapp and Dr. Justin Struble, extensive efforts to 
tether glycosyl donors to BB2 acceptor 4.66 under the oxidative conditions required for 
benzylidene acetal formation
98,99,100,101,102,103,104,105
 were all unsuccessful due to the facile 
oxidation of the BB2 acceptor. Investigation of tethering and intramolecular aglycone delivery 
using the mixed silyl tether developed by Stork
106
 was simultaneously pursued by David Knapp. 
Though tethered intermediates (4.69) could be formed, subsequent intramolecular aglycone 
delivery was not successful. The corresponding hemiacetals and free glycosyl donors were 
isolated as byproducts, leading us to hypothesize that although anomeric activation was 
successful, the allylic alcohol 4.66 was too poor a nucleophile to intercept the resulting 
oxocarbenium ion. 
 
 
Scheme 4.5. Initial unsuccessful attempts at glycosylation of BB2 acceptor 4.66 by intramolecular aglycone 
delivery. Facile oxidation of 4.66 hampered efforts to tether this acceptor to donors using the Ito benzylidene 
methodology. Although tethered intermediates (4.69) could be formed using the Stork silyl linker, transfer could not 
be accomplished. We hypothesized that 4.66 is too poor of a nucleophile to intercept the activated glycosyl donor 
using the Stork strategy. 
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Based on these results, an approach employing anchimeric assistance was then explored. 
Initial efforts were focused on glycosylation with mycosamine donor 4.70, prepared by David 
Knapp and Dr. Justin Struble, containing a chlorodimethylacetate directing group at C2’ 
developed by Carreira and coworkers.
20,21,45
 Combination of this donor with BB2 aglycone 4.68 
under the action of 2-chloro-6-methylpyridinium triflate/2-chloro-6-methylpyridine buffer 
system
20,21,45
 afforded the desired adduct in <63% yield, along with an unidentified and 
inseparable byproduct. Subsequent attempts to remove the chlorodimethylacetate directing group 
under basic conditions
20,21,45
 resulted in decomposition of the substrate, likely due to the 
sensitivity of the lactone moiety to base. 
 
 
Scheme 4.6. Installation of mycosamine using anchimeric assistance mediated by Carreira’s chlorodimethylacetate 
directing group was successful. However, the sensitivity of the BB2 framework to base prevented removal of this 
directing group. 
 
 
Figure 4.15. Directing groups for anchimeric assistance with the potential to disfavor orthoester formation. 
 
Given this result, we considered the 4-acetoxy-2,2-dimethylbutyrate directing group 
(1.56) developed by Ensley, which is removed by acetate saponification and lactonization.
107
 
However, removal of the acetate in this directing group was anticipated to be problematic given 
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the sensitivity of the BB2 framework to base. Likewise, we considered the 2,2-dimethylbut-3-
enoate directing group (1.55) developed by Crimmins, which is removed by 
hydroboration/oxidation and lactonization.
108
 However, the BB2 substrate was expected to be 
unstable to the hydroboration/oxidation sequence required for deprotection of this directing 
group. To overcome these limitations, we considered the use of 4-tert-butyldimethylsilyloxy-2,2-
dimethylbutyrate (TDMB, 4.72) as an alternative that could be removed under mild acidic 
conditions
109
 while still retaining the steric bulk required to minimize undesired orthoester 
formation during glycosylation. Deprotection of the silyl group would generate a free alcohol, 
and subsequent acid-catalyzed lactonization would release the directing group from the substrate 
(Scheme 4.7). TDMB had been employed previously by Trost
109
 as a protecting group for 
alcohols but, to the best of our knowledge, had not previously been utilized in glycosylation.  
 
 
Scheme 4.7. Deprotection scheme for the TDMB directing group under acidic conditions. 
 
To test this directing group, mycosamine donor 4.73 was synthesized by Dr. Justin 
Struble. Exposure of donor 4.73 and acceptor 4.68 to the 2-chloro-6-methylpyridinium triflate/2-
chloro-6-methylpyridine buffer system
20,21,45
 afforded the desired adduct 4.74 in 93% yield with 
no evidence of formation of the corresponding orthoester (Scheme 4.8). Exposure of the product 
to CSA in MeCN then gave a mixture of desired product (4.75, 60%), starting material (16%), 
and the free alcohol resulting from deprotection of the primary TBS group (10%). Recycling of 
the starting material and the free alcohol once through this process gave the desired product 
(4.75) in 72% overall yield on gram scale. Choice of solvent proved critical to this reaction, as 
the use of THF gave little to no conversion under the same conditions. 
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Scheme 4.8. Glycosylation of BB2 acceptor 4.68 with mycosamine donor 4.73 bearing the TDMB directing group 
proceeded in excellent yield with no detectable orthoester formation. Subsequent deprotection under acidic 
conditions successfully generated advanced intermediate 4.75. 
 
Oxidation of alcohol 4.75 with Dess-Martin periodinane, followed immediately by 
NaBH4 reduction gave 4.77 with complete stereoselectivity, consistent with literature precedent 
on related substrates (Scheme 4.9).
4,20,21,110
 Exclusion of water was necessary in the handling of 
ketone 4.76 due to the formation of hydrate 4.78, which was unreactive in the subsequent 
reduction and thus represented an unproductive pathway. A similar challenge was noted by 
Rychnovsky in the development of a β-selective mycosaminylation of cholesterol.59,111 
 
 
Scheme 4.9. Inversion of stereochemistry at C2'. Ketone 4.76 was used immediately after generation due to its 
instability and propensty to form hydrate 4.78. 
 
98 
 
4-9 COMPLETION OF BB2 
Having installed the mycosamine sugar and established the desired stereochemistry at 
C2’, the final remaining challenge was installation of the diene and conversion of the lactone to 
the ketene acetal phosphate. TBS protection of C2’ and iododegermylation52 proceeded smoothly 
to give vinyl iodide 4.78 (Scheme 4.10). Initial efforts focused on the coupling of 4.78 with bis-
metalated olefin 4.5,
62
 followed by phosphorylation of the lactone.
56,57
 The MIDA boronate was 
cleanly deprotected in the course of phosphorylation and was reinstalled via reaction with 
Klubnick’s MIDA anhydride (4.80)112 to give BB2. 
 
 
Scheme 4.10. Initial attempts to install the ketene acetal phosphate with lactone 4.79. 
 
Although the MIDA boronate was removed cleanly and the resulting boronic acid could 
be reprotected, we sought a route which might eliminate the need for deprotection/reprotection 
and thus increase efficiency. In this vein, vinyl iodide 4.78 was first converted to ketene acetal 
phosphate 4.81. We hypothesized that conditions could be found which would selectively couple 
the vinyl iodide in the presence of the ketene acetal phosphate. In the event, coupling of 4.81 
with bis-metalated olefin 4.5 using PdCl2(MeCN)2 proceeded with complete selectivity for the 
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vinyl iodide to give BB2. This building block is stable to storage for at least 2 months and has 
the potential for integration into an ICC-based synthesis platform via selective cross-coupling of 
the ketene acetal phosphate in the presence of the MIDA boronate. 
 
 
Scheme 4.11. Selective Stille coupling of the vinyl iodide of 4.81 in the presence of the ketene acetal phosphate 
eliminates the deprotection/reprotection sequence described in Scheme 4.10 and completes the synthesis of BB2. 
 
4-10 THESIS SUMMARY 
This dissertation describes the identification, synthesis, and function of a conserved 
structural motif of mycosamine-containing polyene macrolides. Utilizing a functional group 
deletion-based approach, the contributions of the functional groups within this structural motif to 
the mechanism of action of AmB were systematically probed. These results established that, in 
stark contrast to the leading model for AmB ion channel formation, intermolecular polar 
interactions between the C41 carboxylic acid and C3’ amine of AmB are not required for 
forming ion channels or killing yeast, nor are interactions of these functional groups with 
phospholipids required for these compounds to bind to lipid bilayers. Alternatively, the 
mycosamine sugar is required for promoting a direct binding interaction with ergosterol, and 
removal of this interaction abolishes the ion channel and antifungal activities of AmB.  
To further probe the role of sterol binding in the membrane permeabilizing and antifungal 
activities of these natural products, C35deOAmB was synthesized via a semisynthetic ICC-based 
approach and its capacity to bind ergosterol, permeabilize membranes, and kill yeast was 
interrogated. These results established that this derivative retains the capacity to bind ergosterol, 
is unable to permeabilize membranes, and exhibits only a sixfold reduction in fungicidal activity 
relative to AmB. This antifungal activity was similar to natamycin, another mycosamine-
containing polyene macrolide which binds ergosterol but does not permeabilize membranes. 
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Removal of mycosamine from this natural product also abolishes its ability to bind sterol and kill 
yeast. Collectively, these results are consistent with the conclusion that mycosamine-containing 
polyene macrolides operate primarily via mycosamine-mediated sterol binding, and that 
subsequent channel formation represents a complimentary mechanism that further increases 
potency.  
The universally conserved mycosamine-containing structural element in these natural 
products was thus identified as an important target for the synthesis-enabled understanding and 
optimization of the biological and biophysical properties of these compounds. To overcome 
challenges associated with modifications of this subunit via existing degradative or semisynthetic 
approaches, a building block was envisioned with the potential for incorporation of this subunit 
into a modular ICC-based strategy for polyene macrolide synthesis. The development of a novel 
type of diastereotopic group-selective lactonization and a new tactic for the introduction of the 
mycosamine sugar enabled the synthesis of this building block.  
Collectively, the results described herein represent a significant advance in the 
understanding of the function of mycosamine-containing polyene macrolides and demonstrate 
the power of unfettered synthetic access to targeted derivatives of these compounds for 
investigating the elusive fundamental underpinnings of small molecule function. 
 
4-11 EXPERIMENTAL SECTION 
 
General methods 
Materials. Commercial reagents were purchased from Sigma-Aldrich, Strem, Alfa Aesar, and 
Fisher Scientific and used without further purification unless otherwise noted. Solvents were 
purified by passage through packed columns by the method of Pangborn and coworkers
113
 (THF, 
Et2O, CH3CN, CH2Cl2: dry neutral alumina; benzene, toluene: dry neutral alumina and Q5 
reactant; DMSO, DMF, CH3OH: activated molecular sieves). Water was obtained from a 
Millipore (Billerica, MA) MilliQ water purification system. Triethylamine was freshly distilled 
under an atmosphere of nitrogen from CaH2. (±)-10-Camphorsulfonic acid was recrystallized 
from EtOAc. The following compounds were prepared by their literature methods: 3,3-
dimethoxypentane,
79
 KCN∙18-crown-6 complex,114 bis-metalated olefin 4.5,62 (S)-CBS·BH3.
93
 
Iodobenzoic acid and oxone were generous gifts from Dr. Bill Boulanger. 
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General Experimental Procedures. All reactions were performed in flame- or oven (125 °C)-
dried glassware under an atmosphere of dry nitrogen or argon unless otherwise stated. Reactions 
were monitored by analytical thin layer chromatography (TLC) on Merck silica gel 60 F254 
plates (0.25 mm) using the indicated solvent system. Compounds were visualized by exposure to 
UV light (254 nm), or by an acidic solution of p-anisaldehyde followed by heating with a 
Varitemp heat gun. Flash column chromatography was performed as described by Still and 
coworkers
115
 using Merck silica gel 60 (230-400 mesh). Medium pressure liquid chromatography 
(MPLC) was performed using a Teledyne Isco Combiflash Rf system employing prepacked 
columns from Teledyne Isco or reusable columns from Luknova packed manually using Merck 
silica gel 60 (230-400 mesh). Compounds were loaded neat, in solution, or adsorbed onto Celite 
as described in each procedure. Specifically for the case of Celite adsorption, for a 1 g mixture of 
crude material the sample in a round bottom flask is dissolved in reagent grade acetone or Et2O 
(25 to 50 mL), and to the flask is added Celite 454 Filter Aid (5 to 15 g). The mixture is then 
concentrated in vacuo to afford a powder, which is then loaded on top of a silica gel column. The 
procedure is typically repeated with a small amount of acetone or Et2O (5 mL) and Celite (2 g) to 
ensure quantitative transfer. Ozonolysis was performed using an Ozone Solutions model VMVS-
4S ozonator supplied by an external oxygen tank. 
 
Structural Analysis. 
1
H NMR spectra were recorded at ambient temperature using one of the 
following instruments: Varian Unity 500 (500 MHz), Varian VXR 500 (500 MHz), or Varian 
Unity Inova 500NB (500 MHz). Chemical shifts are reported in parts per million (ppm) 
downfield from tetramethylsilane and referenced to residual protium in the NMR solvent 
(CDCl3, δ = 7.26; (CD3)2CO, δ = 2.05, center line). Spectral data are presented as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, sext = sextet, dd = 
doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, m = multiplet, 
b = broad, app = apparent), coupling constant (J), and integration. 
13
C NMR spectra were 
recorded at ambient temperature using one of the following instruments: Varian VXR 500 (125 
MHz), Varian Unity 500 (125 MHz), or Varian Unity 400 (101 MHz) instrument. Chemical 
shifts are reported in ppm downfield from tetramethylsilane and referenced to carbon resonances 
in the NMR solvent (CDCl3, δ = 77.16, center line; (CD3)2CO, δ = 29.84, center line). High 
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resolution mass spectra (HRMS) were acquired by Mr. Pulin Wang, Mr. Furong Sun, or Dr. 
Haijun Yao at the University of Illinois School of Chemical Sciences Mass Spectrometry 
Laboratory. Data are reported in the form of m/z. Gas chromatography analysis was conducted 
on an Agilent Technologies 7890A instrument. The diastereoselectivity of lactonization was 
determined by GC analysis with an Agilent Technologies chiral β-cyclodextrin stationary phase 
(part number 112-2532). X-ray crystallographic analysis was carried out by Dr. Scott Wilson at 
the University of Illinois George L. Clark X-Ray facility. 
 
Synthesis of intermediate 4.35. 
 
 
 
Arabitol bisketal 4.48. To a 3 L 3-neck round bottom flask containing a stir bar and outfitted 
with a septum, a reflux condenser, and a glass stopper was added 3,3-dimethoxypentane (382 g, 
2.89 mol, 4.4 equiv.) and THF (1 L). L-(-)-arabitol (100 g, 0.657 mol, 1.0 equiv.) was added via 
the stoppered sidearm, and the septum was replaced with a PTFE thermometer adapter and 
thermometer. The resulting slurry was heated to reflux with stirring for 15 minutes. Next, (±)-10-
camphorsulfonic acid (45.8 g, 0.197 mol, 0.3 equiv.) was added to the suspension at reflux 
through the stoppered sidearm. The reaction was stirred at reflux for 5 minutes, then quenched at 
reflux by the addition of 160 mL 3 M aq. NaOH. The mixture was allowed to cool to room 
temperature and was transferred to a separatory funnel. H2O (160 mL) and Et2O (550 mL) were 
added, the layers were separated, and the aqueous phase was extracted with Et2O (3 x 250 mL). 
The combined organics were washed with brine (1 L), dried over Na2SO4, and concentrated in 
vacuo, azeotropically drying with MeCN. This afforded a crude mixture of bisketals as a pale 
yellow oil. 
 This crude was added as a solution in DCM (1.5 L) to a 3 L 3-neck round bottom flask 
containing a stir bar and outfitted with a septum, a reflux condenser, and a glass stopper. Et3N 
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(100 mL, 0.723 mol, 1.1 equiv.) was added, and the solution was stirred and brought to reflux. 
Succinic anhydride (17.1 g, 0.171 mol, 0.26 equiv.) was added through the stoppered sidearm 
over approx. 1 minute. The reaction was stirred at reflux for 3 hours, then quenched at reflux by 
the addition of 1 L saturated aq. NaHCO3. After cooling to room temperature, the mixture was 
transferred to a separatory funnel, the layers were separated, and the aqueous phase was 
extracted with DCM (2 x 500 mL). The combined organics were washed with brine (1 L), dried 
over Na2SO4, and concentrated in vacuo, azeotropically drying with MeCN. The resulting 
mixture was taken up in Et2O, filtered, and concentrated in vacuo, azeotropically drying with 
MeCN. This afforded the crude product as a yellow oil (194 g). This was carried forward without 
further purification. 
  
Characterization data match that reported by Linclau and coworkers.
79
  
 
 
 
Ketone 4.82. A flame-dried 5-L round-bottomed flask was charged with a magnetic stir bar and 
IBX (780 g, 2.78 mol, 2.1 equiv). Under Ar, a solution of the crude alcohol 4.48 (380 g, 1.32 
mol, 1.00 equiv) in THF (1.65 L) was added via cannula. DMSO (1.65 L) was added via cannula 
and the solution was allowed to stir at rt for 64 h. To the reaction was added ice (600 mL) and 
water (400 mL) and the resultant mixture was allowed to stir at rt for 1 h. During this time a 
white precipitate had formed which was collected by vacuum filtration and washed with 1:1 
THF:H2O (500 mL) and Et2O (500 mL). The filtrate was transferred to a 6-L separatory funnel 
and diluted with sat NaHCO3 (750 mL). The organic layer was removed and the aqueous layer 
extracted with Et2O (2 x 1.0 L). The combined organic fractions were washed with sat NaHCO3 
(1.0 L), dried over Na2SO4, filtered and concentrated in vacuo and finally azeotroped with 
CH3CN (1 x 300 mL) to provide the crude ketone as a yellow liquid that was used without 
further purification. 
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Characterization data match that reported by Linclau and coworkers.
79
  
 
 
 
Olefin 4.49. To a 5 L 3-neck flask equipped with a stir bar, a gas adapter, a graduated pressure-
equalizing addition funnel, and a glass stopper was added methyltriphenylphosphonium bromide 
(470 g, 1.31 mol, 2.0 equiv.), followed by 1 L THF. This slurry was cooled to 0 °C with an ice 
water bath and stirred. NaHMDS (1.0 M in THF, 1.25 L, 1.25 mol, 1.9 equiv.) was added 
dropwise from the addition funnel over 1 hour. The resulting yellow slurry was stirred at 0 °C for 
10 minutes. Crude ketone 4.82 (177 g, 0.657 mol assumed, 1.0 equiv.) was then cannulated into 
the reaction vessel as a solution in 1 L THF. The resulting dark yellow slurry was stirred at 0 °C 
for 6 hours. Half of the reaction mixture was transferred to a separatory funnel. H2O (500 mL) 
was added, and the mixture was extracted with Et2O (4 x 500 mL). The combined organics were 
washed with brine (500 mL) and dried over Na2SO4. This procedure was repeated with the 
remaining half of the reaction mixture. The combined organics were concentrated in vacuo 
afforded a dark yellow sludge. To this was added hexanes (500 mL), and the resulting slurry was 
filtered. The solids were extracted with hexanes, and the combined organics were concentrated in 
vacuo. The resulting crude was purified by SiO2 chromatography (hexanes:EtOAc 10:1) to 
afford the product as a pale yellow oil (129 g, 69% from L-arabitol). 
 
Characterization data match that reported by Linclau and coworkers.
79
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Hydroxymethyl bisketal 4.35. To a 3 L 3-neck flask containing a stir bar and equipped with a 
septum, a pressure-equalizing addition funnel, and a gas adapter was added BH3·THF (1.0 M in 
THF, 167 mL, 167 mmol, 0.5 equiv.), followed by THF (1 L). The resulting solution was stirred 
and cooled to 0 °C with an ice water bath. Et3B (145 mL, 1 mol, 3.0 equiv.) was added via the 
addition funnel, and the solution was warmed to room temperature and stirred for 1 hour. Next, 
alkene 4.49 (95.0 g, 334 mmol, 1.0 equiv.) was cannulated into this solution as a solution in 690 
mL THF over 5 minutes. The resulting clear, colorless solution was stirred at room temperature 
for 48 hours. The reaction mixture was then cannulated over 1 hour into a 5 L 3-neck flask 
outfitted with a mechanical stirrer and containing 30 wt.% aq. H2O2:3M aq. NaOH:DCM (1:1:1, 
2.1 L) stirring vigorously at 0 °C. DCM (200 mL) was used as a wash and cannulated to the 5 L 
flask. This biphasic mixture was allowed to warm to room temperature and stirred vigorously for 
20 h. The mixture was then filtered through Whatman grade 4 filter paper. The filtrate was 
transferred to a separatory funnel, H2O (700 mL) was added, and the layers were separated. The 
aqueous phase was extracted with Et2O (3 x 1.4 L). The combined organics were washed with 
brine (1.4 L), dried over Na2SO4, and concentrated in vacuo to afford 97.5 g of crude 4.35 as a 
pale yellow oil. This was carried forward without purification. 
 
Characterization data match that reported by Linclau and coworkers.
80
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Synthesis of model lactonization substrates 
 
 
 
Methoxymethyl-bis-ketal 4.83. In a glovebox, NaH (3.15 g, 131.1 mmol, 3.0 equiv.), pentane 
washed) was added to a 250 mL Schlenk flask. A stir bar was added, and the flask was sealed 
with a septum and Teflon screw plug and removed from the glovebox. THF (67 mL) was added, 
and the resulting slurry was cooled to 0 °C. The substrate 4.35 (13.21 g, 43.69 mmol, 1.0 equiv.) 
was cannulated into this slurry as a solution in THF (20 mL). The ice bath was removed and the 
reaction was stirred for 1 hour. The reaction was then cooled to 0 °C, and MeI (13.6 mL, 218 
mmol, 5.0 equiv.) was added. The ice bath was removed and the reaction was stirred for 5 hours. 
The reaction was then cooled to 0 °C and quenched by the dropwise addition of MeOH (10 mL) 
over 2 minutes. The ice bath was removed, and the reaction was stirred for 15 minutes. The 
resulting mixture was diluted with brine (50 mL) and H2O (50 mL) and extracted with Et2O (3 x 
100 mL). The combined organics were dried over Na2SO4, filtered, and concentrated in vacuo to 
afford the product 4.82 as a yellow oil (13.32 g). This was of sufficient purity to be carried 
forward without further purification. 
 
 
TLC (hexanes:EtOAc 3:1) 
 Rf = 0.59, stained by p-anisaldehyde 
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1
H-NMR (500 MHz, CDCl3)  
 δ 4.17-4.13 (m, 1H), 4.12-4.09 (m, 2H), 3.97 (dt, J = 5.5, 9.0 Hz, 1H), 3.72 (t, J = 8.3 Hz, 
1H), 3.59-3.56 (m, 2H), 3.46 (dd, J = 6.5, 9.5 Hz, 1H), 3.29 (s, 3H), 1.87-1.92 (m, 1H), 
1.66-1.53 (m, 8H), 0.91-0.84 (m, 12H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 112.1, 111.6, 76.6, 75.8, 71.0, 70.2, 69.7, 59.1, 46.7, 30.0, 29.9, 29.7, 29.6, 8.3, 8.3, 8.2, 
8.1. 
 
HRMS (ESI)  
Calculated for C17H32O5Na (M+Na)
+
: 339.2147 
Found: 339.2154 
 
 
 
Methoxymethyl tetraol 4.84. To the crude bis-ketal 4.83 (6.81 g, 21.5 mmol assumed, 1.0 
equiv.) in a 500 mL round bottom flask was added MeCN (70 mL), 1 M aq. HCl (70 mL), and a 
stir bar. The flask was outfitted with a reflux condenser and stirred at 55 °C for 11 h. The 
reaction was allowed to cool to room temperature, diluted with H2O (30 mL), and washed with 
pet. ether (5 x 190 mL). The aqueous phase was basified by the addition of solid NaHCO3 and 
concentrated in vacuo at 50 °C, azeotropically removing H2O by the addition of acetone (2 x 150 
mL). The resulting colorless semisolid was diluted with acetone (190 mL) and dried over 
MgSO4. This was filtered, and the recovered solids were extracted with acetone (2 x 70 mL). The 
combined organics were concentrated in vacuo, azeotropically drying with MeCN, to give the 
product 4.84 as a pale yellow viscous oil (3.60 g). This was of sufficient purity to be carried 
forward without further purification. 
 
108 
 
 
TLC (DCM:MeOH 9:1) 
 Rf = 0.08, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, Acetone-d6) 
 δ 4.20 (bs, 1H), 4.10-3.99 (m, 2H), 3.87-3.76 (m, 3H), 3.64-3.49 (m, 6H), 3.27 (s, 3H), 
1.95 (dq, J = 3.0, 5.5 Hz, 1H). 
 
13
C-NMR (125 MHz, Acetone-d6)  
δ 73.1, 72.3, 70.9, 65.4, 65.4, 58.7, 44.0. 
 
HRMS (ESI)  
Calculated for C7H17O5 (M+H)
+
: 181.1076 
Found: 181.1085 
 
 
 
Methoxymethyl bis-epoxide 4.36. To the crude tetraol 4.84 (3.50 g, 19.4 mmol assumed, 1.0 
equiv.) in a 500 mL 3-neck flask outfitted with a glass stopper, a reflux condenser, and a septum 
was added a stir bar, toluene (56 mL), and PPh3 (12.7 g, 48.6 mmol, 2.5 equiv.). This mixture 
was stirred until all PPh3 dissolved. The mixture was then cooled to 0 °C. DIAD (9.6 mL, 48.6 
mmol, 2.5 equiv.) was added dropwise over 1-2 minutes. The reaction was then heated to 110 °C 
and stirred for 4 hours. The reaction was allowed to cool to room temperature. The reaction was 
transferred to a round bottom flask, acetone and Celite were added, and the mixture was 
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concentrated in vacuo. The resulting cake was purified by reversed-phase C18 silica gel 
chromatography (H2O:MeCN 20:1 → H2O:MeCN 4:1) to give the product as a colorless liquid 
(1.53 g, 47% over 4 steps from 4.49). 
 
 
TLC (hexanes:EtOAc 3:1)  
 Rf = 0.15, stained by p-anisaldehyde  
 
1
H-NMR (500 MHz, CDCl3)  
 δ 3.58 – 3.48 (m, 2H), 3.33 (s, 3H), 3.03 (tdd, J = 9.6, 4.0, 2.7 Hz, 2H), 2.79 (ddd, J = 
14.6, 5.0, 4.0 Hz, 2H), 2.59 (ddd, J = 23.2, 5.0, 2.7 Hz, 2H), 1.22 (tdd, J = 7.5, 5.9, 4.6 
Hz, 1H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 71.13, 59.23, 51.42, 50.99, 46.50, 46.14, 45.74. 
 
HRMS  
Calculated for C7H12O3Na (M+Na)
+
: 167.0684 
Found: 167.0689 
 
 
 
 
Bisnitrile diol 4.37. The substrate (1.236 g, 8.576 mmol, 1.0 equiv.) was concentrated into a 50 
mL round bottom 3-neck flask from Et2O. A stir bar was added, and the flask was outfitted with 
a reflux condenser with a gas adapter, a rubber septum, and a glass stopper. The apparatus was 
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evacuated under high vac and backfilled with Ar. TMSCN (3.4 mL, 25.7 mmol, 3.0 equiv.) was 
added, followed by KCN·18-crown-6 complex (0.141 g, 0.429 mmol, 0.05 equiv.). The flask 
was heated in a 110 °C oil bath with stirring for 7 hours. The reaction was allowed to cool to 
room temperature and diluted with saturated aq. NaHCO3 (50 mL). The resulting mixture was 
extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo to afford a dark red oil. This was carried forward without further 
purification. 
 To this oil in a 100 mL round bottom flask with a stir bar was added a freshly prepared 
solution of 1% TFA in MeOH (v/v, 43 mL). The flask was capped, and the reaction was stirred 
at room temperature for 1 hour. The reaction was concentrated in vacuo, azeotroping with PhMe, 
to afford the crude as a viscous dark red oil. This was purified by SiO2 chromatography 
(hexanes:EtOAc 3:1 to 1:3) to afford the product as a yellow oil (0.972 g, 57% overall) 
 
 
TLC (hexanes:EtOAc 3:1) 
 Rf = 0.40, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, Acetone-d6)  
 δ 4.89 (bs, 1H), 4.52 (bd, J = 4.5 Hz, 1H), 4.38 (bs, 1H), 4.14 (bs, 1H), 3.65 (dd, J = 5.0, 
10.5 Hz, 1H), 3.53 (dd, J = 5.0, 10.5 Hz, 1H), 3.30 (s, 3H), 2.84 (dd, J = 4.0, 17.0 Hz, 
1H), 2.78 (d, J = 6.5 Hz, 2H), 2.71 (dd, J = 7.0 Hz, 17.0 Hz, 1H), 1.92 (m, 1H). 
 
13
C-NMR (125 MHz, Acetone-d6)  
δ 119.2, 119.0, 69.7, 67.8, 67.5, 58.9, 48.3, 24.9, 24.7. 
 
HRMS (ESI)  
Calculated for C9H15N2O3 (M+H)
+
: 199.1083 
Found: 199.1078 
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Lactone methyl ester 4.40. To the bisnitrile diol 4.37 (883 mg, 4.46 mmol, 1.0 equiv.) in a 100 
mL round bottom flask was added a stir bar, aq. NaOH (3 M, 14.9 mL, 44.6 mmol, 10 equiv.), 
and aq. H2O2 (30 wt%, 9.1 mL, 89.1 mmol, 20 equiv.). The flask was outfitted with a reflux 
condenser, and the reaction was heated to 100 °C for 3.5 hours. The reaction was then cooled to 
0 °C and acidified over 5 minutes by portionwise addition of aq. HCl (6 M, 8.2 mL, 49.0 mmol, 
11 equiv.). The resulting solution was removed from the cold bath and stirred for 1.5 hours. To 
this was added NaCl (10 g), and the mixture was extracted with EtOAc (10 x 40 mL). The 
combined organics were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude 
acid as a yellow oil. This was used without further purification. 
 To the crude acid (4.46 mmol assumed) in a 100 mL round bottom flask was added 
EtOAc (8 mL) and a stir bar. This solution was cooled to 0 °C, and an ethereal solution of CH2N2 
(36 mL, 8.91 mmol, 2.0 equiv.) was added. The reaction was stirred at 0 °C for 30 minutes. 
AcOH (1 mL) was added, and the reaction was removed from the cold bath, stirred for 15 
minutes, then concentrated in vacuo, azeotroping with PhMe. This gave the crude methyl ester as 
a yellow oil (780 mg, 75% overall from bisnitrile diol 4.37). This was carried forward without 
further purification. 
 The configuration of the newly formed stereocenter was determined via a 
1
H-
1
H 
NOESY1D experiment. The diagnostic NOEs are shown below. 
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TLC (hexanes:EtOAc 1:3) 
 Rf = 0.33, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
 δ 4.58 (ddd, J = 10.3, 7.7, 3.8 Hz, 1H), 4.17 (dt, J = 6.9, 5.9 Hz, 1H), 3.70 (s, 3H), 3.57 
(dd, J = 9.7, 4.7 Hz, 1H), 3.47 (dd, J = 9.7, 4.9 Hz, 1H), 3.32 (s, 3H), 2.88 (dd, J = 16.8, 
5.6 Hz, 1H), 2.81 (dd, J = 16.3, 3.8 Hz, 1H), 2.68 (dd, J = 16.3, 7.8 Hz, 1H), 2.57 (dd, J = 
16.8, 6.0 Hz, 1H), 2.03 – 1.94 (m, 1H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 170.49, 170.28, 75.24, 71.06, 66.52, 59.42, 52.15, 46.18, 38.73, 38.50. 
 
HRMS (EI+)  
Calculated for C10H17O6 (M+H)
+
: 233.1025 
Found: 233.1021 
 
 
 
Bis-methyl ester 4.38. To the lactone (12.0 mg, 0.0517 mmol, 1.0 equiv.) in a 7 mL vial was 
added MeOH (0.52 mL), (±)-CSA (3.6 mg, 0.0155 mmol, 0.3 equiv.), and a stir bar. The vial 
was capped, and the reaction was stirred at room temperature for 45 minutes. The reaction was 
diluted with sat. aq. NaHCO3 (5 mL) and extracted with EtOAc (3 x 5 mL). The combined 
organics were dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was 
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purified by SiO2 chromatography (hexanes:EtOAc 2:1  1.5:1  1:1  1:2) to give 1.4 mg 
product and 8.2 mg recovered lactone starting material (32% BORSM). 
 
 
TLC (hexanes:EtOAc 1:3) 
 Rf = 0.23, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
δ 4.50 – 4.44 (m, 1H), 4.35 (dq, J = 9.0, 4.3 Hz, 1H), 3.72 (s, 3H), 3.71 (s, 3H), 3.64 – 
3.55 (m, 4H), 3.33 (s, 3H), 2.72 (dd, J = 16.1, 9.2 Hz, 1H), 2.68 – 2.59 (m, 2H), 2.54 (dd, 
J = 16.1, 4.3 Hz, 1H), 1.77 (qd, J = 5.3, 2.6 Hz, 1H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 173.45, 172.99, 70.39, 68.84, 67.96, 59.19, 52.05, 51.97, 46.92, 39.69, 39.47. 
 
HRMS (ESI)  
Calculated for C11H20O7Na (M+Na)
+
: 287.1107 
Found: 287.1104 
 
 
 
Bis-olefin 4.39. To a 25 mL 3-neck round bottom flask was added Mg turnings (600 mg, 25 
mmol, 5 equiv. rel. to vinyl bromide). The flask was outfitted with a glass stopper, a reflux 
condenser with gas adapter, and a rubber septum. The apparatus was evacuated on high vac, 
flame-dried, and backfilled with Ar. A solution of vinyl bromide in THF (1.0 M, 5.0 mL, 5.0 
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mmol, 1.0 equiv.) was added via syringe. The solution was heated in an oil bath at 70 °C for 1.5 
hours. The solution was allowed to cool to room temperature, titrated by no-D NMR,
116,117
 and 
found to be 0.65 M.  
 To a 10 mL Schlenk flask in the glovebox was added CuI (52.8 mg, 0.278 mmol, 0.4 
equiv.) and a stir bar. The flask was sealed with a rubber septum and Teflon screw and removed 
from the glovebox. THF (1.4 mL) was added, and the resulting slurry was cooled to -78 °C with 
stirring. The solution of vinyl magnesium bromide in THF prepared above (4.3 mL, 2.78 mmol, 
4.0 equiv.) was added dropwise, and the resulting dark grey slurry was stirred for 15 minutes. A 
solution of the substrate (100 mg, 0.694 mmol, 1.0 equiv.) in THF (0.8 mL) was added dropwise 
over 25 minutes. THF (0.5 mL) was used to wash the vessel which contained the substrate 
solution and was added to the reaction dropwise over 2 minutes. The reaction was transferred to 
a -30 °C bath and stirred for 6 hours. The reaction was quenched at -30 °C by the addition of 
MeOH (0.5 mL). The mixture was diluted with saturated aq. NH4Cl (50 mL) and extracted with 
EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 25 mL), dried 
over Na2SO4, and concentrated in vacuo. The resulting crude was purified by normal phase 
MPLC (hexanes/EtOAc) to give the product as a pale yellow oil (88 mg, 64%). 
 
 
TLC (hexanes:EtOAc 3:1) 
 Rf = 0.11, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
 δ 5.82 (dtt, J = 17.3, 10.3, 7.1 Hz, 2H), 5.18 – 5.06 (m, 4H), 4.10 (ddd, J = 8.0, 5.6, 2.3 
Hz, 2H), 4.03 (dt, J = 7.9, 4.9 Hz, 1H), 3.67 (dd, J = 9.8, 6.2 Hz, 1H), 3.59 (dd, J = 9.8, 
4.2 Hz, 1H), 3.34 (s, 3H), 3.21 (bs, 1H), 2.81 (bs, 1H), 2.44 – 2.20 (m, 3H), 1.70 (dtd, J = 
6.7, 4.4, 2.4 Hz, 1H). 
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13
C-NMR (125 MHz, CDCl3)  
δ 135.24, 135.03, 118.22, 117.61, 71.03, 70.65, 70.33, 59.21, 45.78, 39.80. 
 
HRMS (ESI)  
Calculated for C11H20O3Na (M+Na)
+
: 223.1300 
Found: 223.1310 
 
Lactonization studies 
 To accurately determine the d.r. of lactonization, both possible lactone diastereomers 
were synthesized, purified, and used as GC standards for analysis of the model lactonization 
reactions. The synthesis of each is shown in Scheme 4.2 
 
 
 
Lactone methyl ether 4.41. In the glovebox, to a 7 mL vial containing the crude substrate (22.0 
mg, 0.0947 mmol, 1.0 equiv.) in DCM (4.7 mL) was added a stir bar, followed by proton sponge 
(81.0 mg, 0.379 mmol, 4.0 equiv.), then Me3OBF4 (42.0 mg, 0.284 mmol, 3.0 equiv.). The vial 
was capped and removed from the glovebox. The reaction was stirred at room temperature for 
5.5 hours. The reaction mixture was diluted with 1 M aq. HCl (12 mL) and brine (12 mL), and 
the resulting mixture was extracted with EtOAc (3 x 25 mL). The combined organic layers were 
dried over Na2SO4, filtered, and concentrated to give the crude as a yellow solid. This was 
purified by SiO2 chromatography (hexanes:EtOAc 10:1  7:1  5:1  3:1) to give the product 
as a pale yellow oil (7.9 mg, 26% over 3 steps from bisnitrile diol 4.37). 
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TLC (hexanes:EtOAc 3:1) 
 Rf = 0.46, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
 δ 4.66 (ddd, J = 10.1, 8.1, 3.7 Hz, 1H), 3.75 – 3.68 (m, 4H), 3.51 (dd, J = 9.8, 4.6 Hz, 
1H), 3.45 (dd, J = 9.8, 3.7 Hz, 1H), 3.33 (s, 3H), 3.31 (s, 3H), 2.81 (dd, J = 16.3, 3.7 Hz, 
1H), 2.78 – 2.65 (m, 3H), 1.99 (ddd, J = 9.9, 8.6, 4.5 Hz, 1H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 170.56, 170.05, 75.31, 75.11, 70.87, 59.37, 56.59, 52.16, 44.90, 38.68, 34.75. 
 
HRMS  
Calculated for C11H19O6 (M+H)
+
: 247.1182 
Found: 247.1183 
 
The product was analyzed by GC using a Cyclodex B column: 
tr 22.4 min; temperature 170 °C for 10 minutes, then 2 °C/min to 230 °C for 10 minutes. 
 
 
 
Fully protected lactone 4.42. To a 10 mL Schlenk flask was added the crude alcohol 4.40 (107 
mg, 0.462 mmol, 1.0 equiv.) and a stir bar. The flask was capped with a rubber septum and 
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evacuated on high vac, backfilling with Ar. DMF (2.3 mL) was added, followed by imidazole 
(126 mg, 1.85 mmol, 4.0 equiv.), then TBSCl (139 mg, 0.923 mmol, 2.0 equiv.). The reaction 
was heated to 45 °C for 16 hours, then allowed to cool to room temperature, diluted with H2O (5 
mL) and brine (15 mL), and extracted with EtOAc (3 x 20 mL). The combined organics were 
dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude was purified by SiO2 
chromatography (hexanes:EtOAc 20:1  10:1  5:1  3:1) to afford the product as a clear, 
colorless oil (109 mg, 51% over 3 steps from bis-nitrile 4.37). 
 
 
TLC (hexanes:EtOAc 1:1) 
 Rf = 0.62, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
 δ 4.63 (ddd, J = 10.0, 7.8, 3.9 Hz, 1H), 4.12 (td, J = 6.6, 5.3 Hz, 1H), 3.69 (s, 3H), 3.53 
(dd, J = 9.7, 4.3 Hz, 1H), 3.39 (dd, J = 9.7, 3.5 Hz, 1H), 3.27 (s, 3H), 2.83 (dd, J = 10.6, 
4.6 Hz, 1H), 2.79 (dd, J = 11.1, 4.6 Hz, 1H), 2.68 (dd, J = 16.2, 7.8 Hz, 1H), 2.49 (dd, J = 
16.7, 6.5 Hz, 1H), 1.89 (ddt, J = 10.4, 6.8, 3.9 Hz, 1H), 0.86 (s, 9H), 0.06 (s, 3H), 0.05 (s, 
3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 170.49, 169.85, 75.41, 69.62, 66.03, 59.18, 52.03, 46.81, 39.55, 38.64, 25.73, 17.93, -
4.46, -4.95. 
 
HRMS (ESI)  
Calculated for C16H31O6Si (M+H)
+
: 347.1890 
Found: 347.1890 
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Bis(methyl ester) 4.43. To a 25 mL round bottom flask containing the substrate 4.42 (136 mg, 
0.392 mmol, 1.0 equiv.) was added THF (5.2 mL) and a stir bar. The resulting solution was 
cooled to 0 °C with stirring. To this was added a solution of NaOH (17 mg, 0.43 mmol, 1.1 
equiv.) in H2O (2.6 mL) dropwise over 1 minute. The resulting solution was stirred at 0 °C for 10 
minutes. AcOH (0.025 mL, 0.43 mmol, 1.1 equiv.) was added all at once, and the reaction was 
stirred at 0 °C for 3 minutes. The reaction was then diluted with brine (20 mL) and extracted 
with EtOAc (4 x 20 mL). The combined organics were dried over Na2SO4 and concentrated in 
vacuo to give the crude hydroxyacid 4.85 as a pale yellow oil. This was carried forward 
immediately without further purification. 
 To the crude hydroxyacid 4.85 (0.196 mmol, 1.0 equiv., assumed 50% conversion from 
saponification) in a 10 mL Schlenk flask was added a stir bar, THF (3.9 mL), and HMPA (0.085 
mL, 0.49 mmol, 2.5 equiv.). The resulting solution was cooled to -78 °C with stirring. LiHMDS 
(1.0 M in THF, 0.41 mL, 0.41 mmol, 2.1 equiv.) was added down the side of the flask over 2 
minutes, producing a bright yellow solution. This was stirred at -78 °C for 15 minutes. Next, 
MeOTf (0.067 mL, 0.59 mmol, 3.0 equiv.) was added all at once, producing a pale yellow 
solution. The reaction was warmed to -30 °C and stirred for 1.5 hours. The reaction was then 
quenched by pouring into saturated aqueous NaHCO3 (15 mL). The resulting mixture was 
extracted with EtOAc (3 x 15 mL), and the combined organics were dried over Na2SO4 and 
concentrated in vacuo. The resulting pale yellow crude oil was purified by SiO2 chromatography 
(hexanes:EtOAc 15:1) to afford the product 4.43 as a pale yellow oil (23 mg, 29%). 
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TLC (hexanes:EtOAc 3:1) 
 Rf = 0.30, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
 δ 4.44 (dt, J = 3.5, 6.5 Hz, 1H), 3.85 (ddd, J = 4.3, 5.8, 7.8 Hz, 1H), 3.69 (s, 3H), 3.66 (s, 
3H), 3.51 (dd, J = 5.0, 10.0 Hz, 1H), 3.35 (dd, J = 6.0, 10.0 Hz, 1H), 3.33 (s, 3H), 3.26 (s, 
3H), 2.66-2.53 (m, 4H), 2.01 (dq, J = 3.5, 5.5 Hz, 1H), 0.87 (s, 9H), 0.078 (s, 3H), 0.046 
(s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 172.8, 172.1, 77.5, 69.6, 68.0, 58.7, 57.1, 51.7, 51.6, 47.0, 41.1, 37.5, 26.0, 18.2, -4.5,   
-4.7. 
 
HRMS (ESI)  
Calculated for C18H37O7Si (M+H)
+
: 393.2309 
Found: 393.2296 
 
 
 
Lactone diastereomer 4.44. To the substrate in a 7 mL vial was added a stir bar, MeOH (1.1 
mL), and (±)-CSA (13 mg, 0.057 mmol, 1.0 equiv.). The resulting pale yellow solution was 
stirred at room temperature for 5.5 hours, at which point the reaction was concentrated in vacuo. 
Saturated aqueous NaHCO3 (2 mL) was added, and the resulting mixture was extracted with 
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EtOAc (4 x 2 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo to 
afford a mixture of desilylated starting material and desired lactone product. This material was 
transferred to a 7 mL vial as a solution in EtOAc and concentrated. To this was added a stir bar, 
THF (1.1 mL), and (±)-CSA (4.0 mg, 0.017 mmol, 0.3 equiv.). This was stirred at room 
temperature for 30 minutes. The reaction was recharged with CSA (14 mg, 0.060 mmol, 1.1 
equiv.), and the reaction was stirred for 1 hour. The reaction was then diluted with EtOAc and 
passed through a plug of SiO2, eluting with EtOAc. Concentration afforded an oily crystalline 
residue contaminated with (±)-CSA. To this was added EtOAc (1 mL) and saturated aqueous 
NaHCO3 (1 mL). The layers were separated, and the aqueous phase was extracted with EtOAc (2 
x 1 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo. This 
afforded the product as a pale yellow oil (13 mg, 90%). 
The configuration of the newly formed stereocenter was verified via a 
1
H-
1
H NOESY1D 
experiment. The diagnostic NOEs are shown below. 
 
 
 
 
TLC (hexanes:EtOAc 1:1) 
 Rf = 0.25, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
 δ 4.84 (ddd, J = 3.3, 5.8, 8.3 Hz, 1H), 3.79 (ddd, J = 4.4, 6.6, 9.1 Hz, 1H), 3.72 (s, 3H), 
3.55-3.48 (m, 2H), 3.37 (s, 3H), 3.30 (s, 3H), 2.93 (dd, J = 8.3, 16.8 Hz, 1H), 2.84 (dd, J 
= 6.8, 18.3 Hz, 1H), 2.77 (dd, J = 6.0, 17.0 Hz, 1 H), 2.52-2.47 (m, 2 H). 
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13
C-NMR (125 MHz, CDCl3)  
δ 170.9, 169.4, 75.9, 74.2, 66.3, 59.1, 56.6, 52.1, 38.7, 37.6, 34.5. 
 
HRMS (ESI)  
Calculated for C11H19O6 (M+H)
+
: 247.1182 
Found: 247.1173 
 
The product was analyzed by GC using a Cyclodex B column: 
tr 22.0 min; temperature 170 °C for 10 minutes, then 2 °C/min to 230 °C for 10 minutes. 
 
Determination of d.r.: To determine the d.r. of lactonization (Figure 4.11), each substrate was 
subjected to the corresponding lactonization procedure as described below. The crude reaction 
mixtures were then analyzed by GC using compounds 4.41 and 4.44 as standards. 
 
 
 
General procedure for lactonization of bis-methyl ester 4.38 in Figure 4.11, entries 1-2:  
To the bis-methyl ester 4.38 (1.1 mg, 0.0042 mmol, 1.0 equiv.) in a 2 mL vial with a stir 
bar was added CSA (0.29 mg, 0.0013 mmol, 0.3 equiv.) in THF (0.083 mL). The vial was 
capped, and the reaction was stirred for the appropriate amount of time. The reaction was diluted 
with saturated aq. NaHCO3 (0.5 mL) and extracted with EtOAc (3 x 0.5 mL). The combined 
organics were dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude 
material was immediately carried forward without further purification. 
 In a glovebox, to the crude lactone 4.40 (0.0042 mmol assumed, 1.0 equiv.) in a 7 mL 
vial was added proton sponge (3.6 mg, 0.0168 mmol, 4.0 equiv.), Me3OBF4 (1.9 mg, 0.0126 
mmol, 3.0 equiv.), and a stir bar. The vial was capped with a septum cap and PTFE septum and 
removed from the glovebox. DCM (0.14 mL) was added, and the reaction was stirred at room 
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temperature for 3 hours. The crude reaction mixture was passed through a 1 cm plug of SiO2 gel 
in a Pasteur pipette, washing with EtOAc (3 mL). The resulting solution was concentrated in 
vacuo, then redissolved in EtOAc (2 mL), passed through a plug of glass wool, and analyzed by 
GC. 
 
Figure 4.11A, Entry 1. 
Following the general procedure, the lactonization reaction was stirred for 3 hours. 
 
Based on the average of two runs: 
The d.r. was determined to be 69:1 by GC using a Cyclodex B column: 
tr 22.4 min (major, compound 4.41), tr 22.0 min (minor, compound 4.44) ; temperature 170 °C 
for 10 minutes, then 2 °C/min to 230 °C for 10 minutes.  
 
Figure 4.11A, Entry 2. 
Following the general procedure, the lactonization reaction was stirred for 48 hours. 
 
Based on the average of two runs: 
The d.r. was determined to be 60:1 by GC using a Cyclodex B column: 
tr 22.4 min (major, compound 4.41), tr 22.0 min (minor, compound 4.44) ; temperature 170 °C 
for 10 minutes, then 2 °C/min to 230 °C for 10 minutes.  
 
Figure 4.11A, Entry 3. 
 
 
 
A solution of NaOH in MeOH/DCM was made by dissolving NaOH (540 mg) in MeOH 
(5.6 mL), then adding DCM (5.6 mL). A portion of this solution (2.9 mL, 3.52 mmol NaOH, 40 
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equiv.) was added to the bis-olefin 4.39 (17.6 mg, 0.0663 mmol, 1.0 equiv.) in a 7 mL vial. The 
vial was capped with a septum cap and PTFE septum and cooled to -78 °C. The septum was 
punctured with a PTFE needle, and the tip of the needle was submerged completely into the 
reaction mixture. The needle was connected to the output of an ozonator (Ozone Solutions model 
VMVS-4S). A 20 ga. Needle was inserted into the septum of the reaction vial, and this was 
connected via tubing to a bubbler containing aq. KI. The ozonator was activated (power level 10, 
oxygen flow adjusted to give flow reading of 1 L/min), and O3 was bubbled through the reaction. 
The needle would periodically become clogged with frozen solid material, so when this 
occurred, the needle was removed and warmed with gloved fingers until the frozen material 
thawed and was expelled by the gas flow. The needle was then replaced through the septum into 
the reaction vial. After 90 minutes, N2 was bubbled through the reaction for 3 minutes. The 
reaction was diluted with brine (10 mL) and H2O (1 mL) and extracted with EtOAc (6 x 10 mL). 
The combined organics were dried over Na2SO4, filtered, and concentrated in vacuo. This was 
carried forward immediately without further purification. 
 In a glovebox, to the crude lactone 4.40 (15.4 mg, 0.0663 mmol assumed, 1.0 equiv.) in a 
7 mL vial was added proton sponge (56.8 mg, 0.265 mmol, 4.0 equiv.), Me3OBF4 (29.4 mg, 
0.199 mmol, 3.0 equiv.), and a stir bar. The vial was capped with a septum cap and PTFE septum 
and removed from the glovebox. DCM (2.2 mL) was added, and the reaction was stirred at room 
temperature for 3 hours. The reaction was diluted with 1 M aq. HCl (5 mL) and brine (5 mL) and 
extracted with EtOAc (3 x 10 mL). The combined organics were dried over Na2SO4, filtered, and 
concentrated in vacuo. The resulting residue was passed through a 1 cm plug of SiO2 gel in a 
Pasteur pipette, washing with EtOAc (3 mL). The resulting solution was concentrated in vacuo, 
then redissolved in EtOAc (10 mL), passed through a plug of glass wool, and analyzed by GC. 
 
Based on the average of two runs: 
The d.r. was determined to be 22:1 by GC using a Cyclodex B column: 
tr 22.4 min (major, compound 4.41), tr 22.0 min (minor, compound 4.44) ; temperature 170 °C 
for 10 minutes, then 2 °C/min to 230 °C for 10 minutes.  
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Figure 4.11B 
 
 
 
To the bis-nitrile 4.37 (12.0 mg, 0.0605 mmol, 1.0 equiv.) in a 2 mL vial was added a stir 
bar, 3 M aq. NaOH (0.2 mL, 0.6 mmol, 10 equiv.), then 30% wt. aq. H2O2 (0.12 mL, 1.2 mmol, 
20 equiv.). The vial was capped with a septum cap and PTFE septum, and the septum was 
punctured with an 18 ga. needle for venting gas pressure. The reaction was heated in a 100 °C oil 
bath with stirring. After 5 minutes, the vent needle was removed. After a total of 3.5 hours, the 
reaction was allowed to cool to room temperature. The reaction was split into five equal portions, 
and each portion was added to another 2 mL vial with a stir bar. Next, 6 M aq. HCl (0.022 mL, 
0.132 mmol, 11 equiv.) was added to each vial. The vials were capped and stirred. Each vial was 
stirred a different amount of time before proceeding: 1 min, 5 min, 10 min, 30 min, and 60 min. 
After this time had elapsed, brine (0.5 mL) was added, and the mixture was extracted with 
EtOAc (1 x 0.5 mL). The organic phase was dried over Na2SO4, filtered, and concentrated in 
vacuo. 
The following procedure was performed for each of the five crude lactone samples. In a 
glovebox, to the crude lactone (0.0121 mmol assumed, 1.0 equiv.) in a 7 mL vial was added 
proton sponge (10.4 mg, 0.0484 mmol, 4.0 equiv.), Me3OBF4 (5.4 mg, 0.0363 mmol, 3.0 equiv.), 
and a stir bar. The vial was capped with a septum cap and PTFE septum and removed from the 
glovebox. DCM (0.4 mL) was added, and the reaction was stirred at room temperature for 3 
hours. The crude reaction mixture was passed through a 1 cm plug of SiO2 gel in a Pasteur 
pipette, washing with EtOAc (3 mL). The resulting solution was concentrated in vacuo, then 
redissolved in EtOAc (2 mL), passed through a plug of glass wool, and analyzed by GC. 
 
Based on the average of five runs: 
The d.r. was determined to be 74:1 by GC using a Cyclodex B column: 
tr 22.4 min (major, compound 4.41), tr 22.0 min (minor, compound 4.44) ; temperature 170 °C 
for 10 minutes, then 2 °C/min to 230 °C for 10 minutes. 
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Synthesis of aglycone 4.67 
 
 
 
 
Benzyloxymethyl bisketal 4.86. In a glovebox, NaH (23.2 g, 967 mmol, 3.0 equiv., pentane 
washed) was added to a 500 mL Schlenk flask. A stir bar was added, and the flask was sealed 
with a septum and Teflon screw plug and removed from the glovebox. DMF (300 mL) was then 
added. To a 3 L 3-neck round bottom flask containing crude alcohol 4.35 (97.5 g, 322 mmol 
assumed, 1.0 equiv.) and a stir bar and outfitted with a stopper, a gas adapter, and a septum was 
added 800 mL DMF. The resulting clear, colorless solution was cooled to 0 °C with an ice water 
bath and stirred. The NaH slurry was cannulated over to the substrate solution dropwise over 10 
minutes, producing a cream-colored cloudy solution. In two portions, 190 mL DMF was used to 
transfer residual NaH to the substrate flask via cannula. The ice water bath was removed, and the 
reaction mixture was stirred for 1 hour. Next, the reaction mixture was again cooled to 0 °C with 
an ice water bath, and BnBr (42 mL, 355 mmol, 1.1 equiv.) was added dropwise over 5 minutes. 
Tetrabutylammonium iodide (11.9 g, 32.2 mmol, 0.1 equiv.) was then added in one portion 
through a sidearm under positive Ar pressure. The ice bath was removed, and the reaction was 
stirred for 15 hours. The reaction mixture was then cooled to 0 °C with an ice water bath, and the 
flask was outfitted with a pressure-equalizing addition funnel. The reaction was quenched by the 
dropwise addition of 200 mL MeOH from the addition funnel over 20 minutes. After addition 
was complete, the ice water bath was removed and the reaction mixture was stirred for 
approximately one hour. The reaction mixture was partitioned between 1.3 L H2O and 1.3 L 
Et2O. The layers were separated, and the aqueous phase was extracted with Et2O (3 x 1.3 L). The 
combined organics were dried over Na2SO4, filtered, and concentrated, azeotropically drying 
with MeCN. The resulting brown oil was carried forward without further purification. 
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TLC (hexanes:EtOAc 5:1) 
 Rf = 0.61, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
 δ 7.36-7.27 (m, 5H), 4.48 (app dd, J = 12, 14 Hz, 2H), 4.17 (m, 2H), 4.11 (dd, J = 6.0, 
8.5 Hz, 1H), 4.03 (dt, J = 5.5, 8.5 Hz, 1H), 3.73 (m, 1H), 3.68 (dd, J = 3.5, 10 Hz, 1H), 
3.60 (m, 2H), 1.90 (m, 1H), 1.64-1.54 (m, 8H), 0.91-0.84 (m, 12H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 138.3, 128.5, 127.7, 127.6, 112.2, 111.6, 76.6, 75.9, 73.5, 70.3, 69.8, 68.7, 46.9, 30.0, 
29.9, 29.7, 29.7, 8.4, 8.3, 8.2, 8.2. 
 
HRMS (ESI)  
Calculated for C23H36O5Na (M+Na)
+
: 415.2460 
Found: 415.2448 
 
 
 
 
Tetraol 4.51. To a 3 L round-bottom flask containing crude bisketal 4.86 (322 mmol assumed, 
1.0 equiv.) was added a freshly prepared solution of 1M aq. HCl:MeCN (1:1, 2.1 L). The flask 
was outfitted with a reflux condenser, and the reaction mixture was stirred at 55 °C for 22 hours. 
The reaction was allowed to cool to room temperature and split into two approximately equal 
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portions. Each portion was washed with pet. ether (5 x 1.5 L). The aqueous phases were then 
combined and neutralized by the portionwise addition of NaHCO3 (104 g). This solution was 
concentrated to approximately half volume in vacuo at 40 °C – 50 °C. Acetone was added, and 
the mixture was concentrated in vacuo. Acetone was again added, and the mixture was 
concentrated to afford a viscous semi-solid material. To this was added acetone (2 L) and MgSO4 
(250 g), and the resulting slurry was stirred at room temperature and filtered through Whatman 
grade 42 filter paper, washing with acetone. The solids were extracted with acetone (2 x 500 
mL), and the combined organics were concentrated in vacuo to afford 83.4 g of tetraol 4.51 as a 
highly viscous dark yellow oil. This was carried forward without purification. 
 
 
TLC (DCM:MeOH 9:1) 
 Rf = 0.11, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, (CD3)2CO) 
δ 7.39-7.32 (m, 4H), 7.30-7.26 (m, 1H), 4.50 (s, 2H), 4.26 (bs, 1H), 4.09 (bs, 1H), 4.06 
(bm, 1 H), 3.92 (q, J = 5.5 Hz, 1H), 3.90 (bs, 1H), 3.75 (dd, J = 5.5, 9.5 Hz, 2H), 3.69-
3.56 (m, 6H), 2.05 (m, 1H). 
 
13
C-NMR (125 MHz, (CD3)2CO)  
δ 139.6, 129.1, 128.4, 128.2, 73.6, 73.1, 72.3, 68.8, 65.5, 65.4, 44.1. 
 
HRMS (ESI)  
 Calculated for C13H21O5 (M+H)
+
: 257.1389 
 Found: 257.1388 
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Bis-epoxide 4.52. Crude tetraol 4.51 (50.2 g, 196 mmol assumed, 1.0 equiv.) was transferred to a 
3 L 3-neck round bottom flask containing a stir bar and outfitted with a septum, a pressure-
equalizing addition funnel, and a reflux condenser. This apparatus was evacuated on high 
vacuum and backfilled with Ar. PhMe (1.78 L) was added, followed by Ph3P (128 g, 490 mmol, 
2.5 equiv.) with stirring. The septum was replaced with a PTFE thermometer adapter and 
thermometer, and the reaction mixture was cooled to 0 °C with an ice water bath and stirred. 
DIAD (81 mL, 411 mmol, 2.1 equiv.) was added dropwise from the addition funnel over 10 
minutes such that the temperature of the reaction mixture did not exceed 10 °C. When addition 
was complete, the ice bath was removed and replaced with a heating mantle, and the addition 
funnel was replaced with a glass stopper. The reaction was heated to 110 °C and stirred for 13 
hours. The reaction was allowed to cool to room temperature and concentrated in vacuo. The 
resulting crude was taken up in hexanes (500 mL) and filtered. The solids were extracted with 
hexanes (3 x 250 mL), and the combined organics were concentrated in vacuo. This was partially 
purified by SiO2 chromatography (hexanes:EtOAc 19:1 → hexanes:EtOAc 14:1 → 
hexanes:EtOAc 9:1). The resulting yellow liquid was further purified by Kugelrohr distillation 
(160 °C, 1 Torr) to give the product as a pale yellow liquid (15.3 g, 35% over 4 steps). 
 
 
TLC (hexanes:EtOAc 3:1) 
 Rf = 0.26, stained by p-anisaldehyde 
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1
H-NMR (500 MHz, CDCl3) 
δ 7.37-7.27 (m, 5H), 4.55 (d, J = 12 Hz, 1H), 4.53 (d, J = 12 Hz, 1H), 3.70-3.60 (m, 2H), 
3.10 (m, 2H), 2.84 (dd, J = 4.3, 4.8 Hz, 1H), 2.80 (dd, J = 4.0, 5.0 Hz, 1H), 2.66 (dd, J = 
2.5, 5.0 Hz, 1H), 2.60 (dd, J = 2.5, 5.0 Hz, 1H), 1.30 (ddt, J = 4.8, 6.1, 7.4 Hz, 1H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 138.2, 128.5, 127.6, 127.5, 73.4, 68.7, 51.5, 51.0, 46.5, 46.2, 45.9. 
 
HRMS (ESI) 
 Calculated for C13H16O3Na (M+Na)
+
: 243.0997 
 Found: 243.1004 
 
 
 
 
Bisnitrile diol 4.60. To a 100 mL 3-neck round bottom flask was added bis-epoxide 4.52 (15.0 
g, 68.1 mmol, 1.0 equiv.) and a stir bar. The flask was outfitted with a glass stopper, a septum, 
and a reflux condenser and evacuated on high vacuum, backfilling with Ar. KCN·18-crown-6 
complex (1.12 g, 3.41 mmol, 0.05 equiv.) was added, followed by trimethylsilylcyanide 
(TMSCN, 27 mL, 204 mmol, 3.0 equiv.). This mixture was stirred at 110 °C for 7 hours. The 
heating bath was removed, and the reaction was cooled to room temperature and partitioned 
between saturated aqueous NaHCO3 (250 mL) and EtOAc (250 mL). The layers were separated, 
and the aqueous phase was extracted with EtOAc (3 x 250 mL). The combined organic extracts 
were dried over Na2SO4, filtered, and concentrated in vacuo to afford a viscous black oil (27.7 
g). To this material in a 2 L round bottom flask was added a stir bar and a freshly prepared 
solution of 1% trifluoroacetic acid (TFA) in MeOH (340 mL). After stirring for 1 hour, the 
reaction mixture was concentrated in vacuo. Celite and acetone were added, and the mixture was 
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concentrated and purified by SiO2 chromatography (Et2O:pet. ether 1:1 → Et2O:pet. ether 5:1 → 
Et2O:pet. ether 8:1) to afford the product 4.60 as a brown oil (13.2 g, 70% over 2 steps). 
 
 
TLC (hexanes:EtOAc 1:3) 
 Rf = 0.59, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.42-7.33 (m, 3H), 7.32-7.28 (m, 2 H), 4.51 (q, J = 11.8 Hz, 2H), 4.39 (bs, 1H), 4.33 
(bm, 1H), 3.74 (dd, J = 4.5, 10.5 Hz, 1H), 3.64 (dd, J = 4.0, 10.5 Hz, 1H), 3.44 (bs, 1H), 
3.08 (bs, 1H), 2.74-2.52 (m, 4H), 1.96 (m, 1H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 136.8, 128.9, 128.5, 128.2, 118.1, 117.9, 73.8, 67.8, 66.9, 66.7, 46.7, 24.6, 24.3. 
 
HRMS (ESI)  
 Calculated for C15H19N2O3 (M+H)
+
: 275.1396 
 Found: 275.1397 
 
 
 
 
Lactone methyl ester 4.87. All of the following manipulations were carried out under air. To a 1 
L round bottom flask containing the substrate (13.0 g, 47.7 mmol, 1 equiv.) and a stir bar was 
added 3 M aq. NaOH (158 mL, 474 mmol, 10 equiv.) from a graduated cylinder, followed by 
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30% wt. aq. H2O2 (97 mL, 948 mmol, 20 equiv.) from a graduated cylinder. The flask was 
outfitted with a reflux condenser open to air and heated to 100 °C with stirring. After 3.5 hours, 
the reaction was cooled to 0 °C and acidified by the addition of 6 N aq. HCl (87 mL). The 
resulting solution was allowed to warm to room temperature and stirred for 1.5 hours. NaCl (75 
g) was added, and the reaction was extracted with EtOAc (6 x 350 mL). The combined organics 
were dried over Na2SO4 and concentrated in vacuo, azeotropically drying with MeCN (100 mL) 
to give the crude acid as an amber oil (12.7 g). This was taken forward without further 
purification. 
To the crude lactone acid in a 2 L round bottom flask was added a stir bar and EtOAc (75 
mL). The resulting solution was cooled to 0 °C and stirred. A freshly prepared ethereal solution 
of CH2N2 (350 mL, 86.3 mmol, 2.0 equiv.) was added to the flask and stirred for 30 minutes. 
AcOH (5 mL) was then added, and the reaction was allowed to warm to room temperature and 
stirred for 15 minutes. The reaction was then concentrated in vacuo to afford the crude product 
4.87 as a yellow solid (12.2 g). This was taken forward without further purification. 
 
 
TLC (hexanes:EtOAc: 1:1) 
 Rf = 0.21, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.38-7.27 (m, 5H), 4.72 (ddd, J = 3.5, 7.8, 10.5 Hz, 1H), 4.52 (d, J = 12 Hz, 1H), 4.49 
(d, J = 12 Hz, 1H), 4.21 (q, J = 6.3 Hz, 1H), 3.69 (s, 1H), 3.68 (dd, J = 5.0, 10 Hz, 1H), 
3.53 (dd, J = 5.0, 10 Hz, 1H), 2.90 (dd, J = 5.8, 16.8 Hz, 1H), 2.75 (dd, J = 3.8, 16.3 Hz, 
1H), 2.65 (dd, J = 7.8, 16.3 Hz, 1H), 2.58 (dd, J = 6.3, 16.8 Hz, 1H), 2.02 (m, 1H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 170.5, 170.4, 137.4, 128.6, 128.1, 127.8, 75.2, 73.5, 68.0, 66.3, 52.1, 46.1, 38.7, 38.3. 
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HRMS (ESI) 
Calculated for C16H21O6 (M+H)
+
: 309.1338 
Found: 309.1327 
 
 
 
TBS-protected lactone methyl ester 4.61. To a 500 mL 3-neck round bottom flask containing 
crude lactone methyl ester 4.87 (12.2 g, 39.5 mmol assumed, 1.0 equiv.) and a stir bar and 
outfitted with a stopper, a reflux condenser, and a septum was added DMF (200 mL), imidazole 
(10.8 g, 158 mmol, 4.0 equiv.), and TBSCl (11.9 g, 79.0 mmol, 2.0 equiv.). The resulting 
solution was heated to 45 °C and stirred for 10 hours. The reaction was allowed to cool to room 
temperature, and 1 M aq. HCl (800 mL) was added. This was extracted with EtOAc (3 x 800 
mL), and the combined organics were dried over Na2SO4 and concentrated in vacuo, 
azeotropically drying with PhMe (3 x 500 mL). This afforded the crude as an amber solid which 
was purified by recrystallization from Et2O/pentane to afford the product as a pale yellow solid 
(7.1 g, 49% from bisnitrile diol 4.60). 
 
 
TLC (hexanes:EtOAc 3:1) 
 Rf = 0.25, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.36-7.27 (m, 5H), 4.72 (ddd, J = 4.0, 8.0, 10 Hz, 1H), 4.53 (d, J = 12 Hz, 1H), 4.40 (d, 
J = 12 Hz, 1H), 4.17 (dt, J = 5.5, 6.5 Hz, 1H), 3.69 (s, 1H), 3.62 (dd, J = 4.3, 10 Hz, 1H), 
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3.49 (dd, J = 3.8, 10 Hz, 1H), 2.82 (dd, J = 5.5, 16.5 Hz, 1H), 2.76 (dd, J = 3.8, 16 Hz, 
1H), 2.64 (dd, J = 8.0, 16 Hz, 1H), 2.52 (dd, J = 6.5, 16.5 Hz, 1H), 1.93 (m, 1H), 0.86 (s, 
9H), 0.054 (s, 3H), 0.025 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 170.6, 170.0, 137.6, 128.7, 128.1, 127.9, 75.5, 73.5, 67.0, 66.2, 52.1, 46.8, 39.6, 38.6, 
25.8, 18.0, -4.4, -4.9. 
 
HRMS (ESI) 
Calculated for C22H35O6Si (M+H)
+
: 423.2203 
Found: 423.2201 
 
 
 
 
Hydroxymethyl lactone 4.88. Benzyl ether 4.61 (4.51 g, 10.7 mmol, 1.0 equiv.) was added to a 
100 mL recovery flask as a solution in EtOAc (100 mL). A stir bar was added, followed by Pd/C 
(5.93 g, 1.28 mmol, 0.12 equiv., 5% wt. on wet (55.15% H2O) Degussa type E101 NO/W). The 
flask was placed in a steel bomb, which was then purged by pressurizing with H2 gas to 50 psi, 
then venting the atmosphere of the bomb. This process was performed a total of 7 times. Next, 
the bomb was pressurized with H2 to 25 psi, and the reaction was stirred vigorously for 50 min. 
Na2SO4 (15 g) was added, and the reaction mixture was stirred under air for 10 min, then filtered 
through a pad of Celite, washing with EtOAc. Concentration afforded 3.58 g of crude product 
which was carried forward without further purification. 
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TLC (1:1 hexanes:EtOAc) 
 Rf = 0.47, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 4.67 (ddd, J = 4.7, 6.9, 10.1 Hz, 1H), 4.23 (dt, J = 5.2, 6.6 Hz, 1H), 3.83 (dd, J = 3.8, 
11.3 Hz, 1H), 3.72 (s, 3H), 3.71 (dd, J = 4.0, 11.0 Hz, 1H), 2.88 (dd, J = 4.8, 16.8 Hz, 
1H), 2.83 (dd, J = 5.0, 17.0 Hz, 1H), 2.79 (dd, J = 6.8, 16.8 Hz, 1H), 2.53 (dd, J = 6.5, 
16.5 Hz, 1H), 1.83 (m, 1 H), 0.87 (s, 9H), 0.086 (s, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 171.3, 170.1, 75.1, 66.1, 59.8, 52.3, 48.6, 39.6, 38.9, 25.7, 18.0, -4.4, -4.8. 
 
HRMS (ESI) 
Calculated for C15H29O6Si (M+H)
+
: 333.1733 
Found: 333.1725 
 
 
 
 
Lactone acid 4.89. The lactone alcohol 4.88 (3.58 g, 10.7 mmol, 1.0 equiv.) was added as a 
solution in MeCN (54 mL) to a 250 mL 3-neck round bottom flask. A stir bar was added, 
followed by aq. potassium phosphate buffer (0.67 M, pH = 6.0, 41 mL). The solution was stirred, 
and TEMPO (0.117 g, 0.749 mmol, 0.07 equiv.) was added. The flask was outfitted with a reflux 
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condenser with a gas adapter, and two pressure-equalizing addition funnels. The reaction mixture 
was heated in a 35 °C oil bath. To one of the addition funnels was added aq. NaClO2 (2.0 M, 
10.8 mL, 21.4 mmol, 2.0 equiv.). A solution of NaOCl was prepared by adding commercial 
bleach (6 % w/w, 0.54 mL) to H2O (5.4 mL). All of this solution was added to the other addition 
funnel. Approximately 20% of each of the solutions in the addition funnels was added 
simultaneously to the reaction, producing a dark red solution. Next, the flow-rate of each 
addition funnel was adjusted such that the remainder of each solution was added dropwise over 
15 minutes. After addition of both solutions was complete, the addition funnels were replaced 
with stoppers, and the reaction was maintained in the 35 °C oil bath with stirring for 17 hours. 
The reaction was allowed to cool to room temperature, and NaCl (12 g) was added with stirring. 
The reaction was transferred to a separatory funnel containing EtOAc (55 mL) and 1 M aq. HCl 
(55 mL). The layers were separated, and the aqueous phase was extracted with EtOAc (4 x 90 
mL). The combined organics were dried over Na2SO4, filtered, and concentrated in vacuo to 
afford the crude as a colorless solid. This was carried forward without purification. 
 
 
TLC (1:1 hexanes:EtOAc, 1% AcOH) 
 Rf = 0.39, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
4.84 (ddd, J = 10.1, 6.4, 5.3 Hz, 1H), 4.45 (td, J = 6.8, 4.9 Hz, 1H), 3.72 (s, 3H), 2.93 – 
2.84 (m, 2H), 2.83 – 2.75 (m, 2H), 2.58 (dd, J = 16.8, 6.9 Hz, 1H), 0.85 (s, 9H), 0.08 (s, 
3H), 0.06 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 175.51, 169.93, 168.70, 73.81, 67.23, 53.07, 52.44, 38.91, 38.70, 25.60, 17.90, -4.55, -
5.04. 
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HRMS (ESI)  
Calculated for C15H27O7Si (M+H)
+
: 347.1526 
Found: 347.1522 
 
 
 
 
TMSE ester 4.3. The lactone carboxylic acid 4.89 (10.7 mmol assumed) was added as a solution 
in THF (215 mL) to a 500 mL 2-neck round bottom flask. A stir bar was added, and the flask 
was outfitted with a reflux condenser with a gas adapter. PPh3 (7.00 g, 26.7 mmol, 2.5 equiv.) 
was added, followed by TMSEtOH (4.6 mL, 32.1 mmol, 3.0 equiv.). The solution was cooled to 
0 °C with stirring, and DIAD (4.6 mL, 23.4 mmol, 2.2 equiv.) was added dropwise over 10 min. 
The reaction was warmed to 45 °C and thus stirred for 4 h. The reaction was allowed to cool to 
room temperature, then transferred to a 500 mL recovery flask and concentrated in vacuo. A stir 
bar was added, followed by Et2O (50 mL) and petroleum ether (200 mL). The flask was sealed 
with a rubber septum and stirred overnight at room temperature. The resulting mixture was 
filtered through a fritted funnel, and the yellow filtrate was concentrated in vacuo to give a clear 
yellow oil. This was carried forward without further purification. 
 
 
TLC (3:1 hexanes:EtOAc) 
 Rf = 0.40, stained by p-anisaldehyde 
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1
H-NMR (500 MHz, CDCl3)  
δ 4.81 (ddd, J = 10.9, 7.3, 4.5 Hz, 1H), 4.41 (td, J = 6.9, 5.2 Hz, 1H), 4.22 – 4.16 (m, 
2H), 3.71 (s, 3H), 2.87 (dd, J = 16.8, 5.1 Hz, 1H), 2.77 (dd, J = 10.4, 6.8 Hz, 1H), 2.75 – 
2.65 (m, 2H), 2.54 (dd, J = 16.8, 7.0 Hz, 1H), 1.03 – 0.97 (m, 2H), 0.84 (s, 9H), 0.07 (s, 
3H), 0.05 (s, 12H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 170.79, 169.68, 168.88, 74.16, 67.29, 64.34, 53.61, 52.33, 38.89, 25.61, 17.89, 17.49, -
1.43, -4.48, -5.02. 
 
HRMS (ESI)  
Calculated for C20H38O7Si2Na (M+Na)
+
: 469.2054  
Found: 469.2057 
 
 
 
 
Lactone acid 4.62. The lactone 4.3 (10.7 mmol assumed) was added as a solution in THF (170 
mL) to a 500 mL round bottom flask. A stir bar was added, and the solution was cooled stirring 
to 0 °C. Aq. NaOH (0.3 M, 170 mL) was added dropwise over 20 min. The reaction was allowed 
to warm to room temperature and stirred for an additional 4 h. The reaction was transferred to a 
separatory funnel and washed with Et2O (3 × 100 mL). The remaining aqueous phase was 
transferred to a 500 mL round bottom flask and cooled to 0 °C. THF (170 mL) was added, and 
aq. HCl (1 M, ca. 80 mL) was added until the pH of the mixture was between 0 and 1, as 
measured by pH paper. The mixture was allowed to warm to room temperature, transferred to a 
separatory funnel, and extracted with EtOAc (4 × 100 mL). The combined organics were dried 
over Na2SO4, filtered, and concentrated in vacuo to afford the crude as a pale yellow oil that 
crystallized under vacuum (3.44 g, 75% yield from 4.60). 
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TLC (1:1 hexanes:EtOAc, 1% AcOH) 
 Rf = 0.49, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
δ 4.80 (ddd, J = 5.5, 6.5, 10.5 Hz, 1H), 4.43 (dt, J = 5.5, 7.0 Hz, 1H), 4.21 (m, 2H), 2.87 
(dd, J = 5.0, 16.5 Hz, 1H), 2.79 (dd, J = 7.0, 10.5 Hz, 1H), 2.75 (m, 2H), 2.54 (dd, J = 
7.0, 17.0 Hz, 1H), 1.01 (m, 2H), 0.85 (s, 9H), 0.076 (s, 3H), 0.052 (s, 12H). 
 
13
C-NMR (101 MHz, CDCl3)  
δ 174.17, 170.71, 168.98, 73.99, 67.30, 64.44, 53.49, 38.86, 38.78, 25.64, 17.91, 17.55,   
-1.43, -4.49, -4.99. 
 
HRMS (ESI)  
Calculated for C19H36O7Si2Na (M+Na)
+
: 455.1897 
Found: 455.1891 
 
 
 
 
Germanium enone 4.67. To a 50 mL round bottom flask was added the carboxylic acid 4.62 
(1.111 g, 2.568 mmol, 1.0 equiv.) and a stir bar, and the flask was outfitted with a reflux 
condenser with a gas adapter. The apparatus was evacuated on high vac, backfilling with Ar. 
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DCM (26 mL) was added, followed by (COCl)2 (2.2 mL, 25.68 mmol, 10 equiv.). The reaction 
was heated in a 45 °C oil bath and stirred for 3 hours. The reaction was allowed to cool to room 
temperature and concentrated in vacuo. To another 50 mL round bottom flask was added 
NaHCO3 (5.0 g). The flask was evacuated on high vac and flame-dried until gas evolution 
ceased. The resulting solid was allowed to cool to room temperature and added to the crude acyl 
chloride along with DCM (20 mL). The resulting slurry was stirred for 20 minutes, then vacuum 
filtered into a 50 mL Schlenk flask. The filtrate was concentrated in vacuo to give a tan solid. 
 In the glovebox, DMF (15.9 mL) and THF (5.3 mL) were added to the acyl chloride, 
along with a stir bar. This solution was stirred until homogeneous. PdCl2(MeCN)2 (0.033 g, 
0.128 mmol, 0.05 equiv.) was added, followed by the stannane (1.83 g, 3.85 mmol, 1.5 equiv.). 
The Schlenk flask was sealed, removed from the glovebox, heated in a 45 °C oil bath, and stirred 
for 16.5 hours. The reaction was allowed to cool to room temperature, diluted with H2O (50 mL), 
and extracted with Et2O (3 x 50 mL). The combined organics were dried over Na2SO4, filtered, 
adsorbed onto Celite, and purified by reversed-phase MPLC (MeCN:H2O) using C18 silica gel. 
This afforded the product as a yellow crystalline solid (1.107 g, 72%). 
 
 
TLC (5:1 hexanes:EtOAc) 
 Rf = 0.39, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.31 (d, J = 19.5 Hz, 1H), 6.48 (d, J = 19.5 Hz, 1H), 4.98 (ddd, J = 4.0, 7.0, 10.0 Hz, 
1H), 4.46 (dt, J = 5.0, 6.0 Hz, 1H), 4.18 (m, 2H), 3.17 (dd, J = 7.0, 17.0 Hz, 1H), 2.87 (m, 
2H), 2.77 (dd, J = 6.5, 10.0 Hz, 1H), 2.54 (dd, J = 6.0, 16.5 Hz, 1H), 1.03 (t, J = 8.0 Hz, 
9H), 0.99 (m, 2H), 0.87 (q, J = 8.0 Hz, 6H), 0.85 (s, 9H), 0.074 (s, 3H), 0.051 (s, 3H), 
0.042 (s, 9H). 
 
140 
 
13
C-NMR (125 MHz, CDCl3) 
δ 194.26, 170.79, 169.06, 149.31, 142.59, 73.76, 67.46, 64.21, 53.97, 43.07, 38.80, 25.69, 
17.94, 17.54, 8.97, 4.32, -1.42, -4.51, -4.94. 
 
HRMS (ESI) 
Calculated for C27H52O6Si2GeNa (M+Na)
+
: 625.2412 
Found: 625.2410 
 
 
 
Allylic alcohol 4.68. NOTE: This reaction is extremely sensitive to the presence of H2O. All 
manipulations were performed with flame- or oven-dried glassware using freshly purified 
solvents with good Schlenk technique.  
(S)-CBS·BH3 (4.65) stock solution preparation: In the glovebox, (S)-CBS·BH3 (4.65)
93
 
(27.8 mg) was added to a 20 mL ICHEM vial. The was capped with a PTFE-lined septum cap 
and removed from the glovebox. THF (9.3 mL) was added, followed by BH3·THF (1.0 M in 
THF, 0.27 mL). The mixture was agitated manually until homogeneous. The resulting solution 
was used immediately in the following procedure. 
Reduction: The substrate (220 mg, 0.366 mmol, 1.0 equiv.) in a 50 mL Schlenk flask 
with stir bar was azeotroped with PhMe (2 x 1.5 mL) on high vac, backfilling with Ar. THF 
(9.15 mL) was added, and the solution was cooled in a -40 °C bath. The stock solution prepared 
above (9.15 mL, 0.0914 mmol (S)-CBS·BH3, 0.25 equiv., 0.256 mmol BH3·THF, 0.7 equiv.) was 
added dropwise via a syringe pump from a glass airtight Hamilton syringe over 20 minutes. The 
reaction was stirred for 23 hours. MeOH (5 mL) was added all at once, and the solution was 
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stirred for 5 minutes. The reaction flask was then removed from the cold bath and stirred for 10 
minutes. The reaction was diluted with H2O (50 mL) and extracted with EtOAc (3 x 50 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
was purified by SiO2 chromatography (hexanes:EtOAc 8:1) to afford the product as a pale 
yellow solid (124 mg, 94% based on 60% conversion). 
 
 
TLC (3:1 hexanes:EtOAc) 
 Rf = 0.52, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
δ 6.02 (d, J = 18.6 Hz, 1H), 5.90 (dd, J = 18.6, 6.0 Hz, 1H), 4.45 – 4.37 (m, 2H), 4.34 (td, 
J = 7.0, 5.2 Hz, 1H), 4.23 – 4.17 (m, 2H), 2.83 (dd, J = 16.8, 5.1 Hz, 1H), 2.75 (dd, J = 
10.4, 6.8 Hz, 1H), 2.51 (dd, J = 16.7, 7.2 Hz, 1H), 1.99 (ddd, J = 14.3, 8.7, 6.8 Hz, 1H), 
1.79 (ddd, J = 14.4, 6.5, 3.2 Hz, 1H), 1.03 – 0.98 (m, 11H), 0.85 (s, 9H), 0.78 (q, J = 7.8 
Hz, 6H), 0.07 (s, 3H), 0.05 (s, 9H), 0.04 (s, 3H). 
 
HRMS (ESI)  
Calculated for C27H55O6Si2Ge (M+H)
+
: 605.2749 
Found: 605.2748  
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Synthesis of BB2 
 
 
Glycoside 4.74. To a 7 mL vial was added a stir bar, allylic alcohol 4.68 (35.0 mg, 0.058 mmol, 
1.0 equiv.), and mycosamine donor 4.73 (59.0 mg, 0.087 mmol, 1.5 equiv.). The components 
were azeotropically dried with PhMe (0.5 mL). Hexane (2.9 mL) was added, followed by 2-
chloro-6-methylpyridine (7.4 mg, 0.058 mmol, 1.0 equiv.) and 2-chloro-6-methylpyridinium 
triflate (8.1 mg, 0.029 mmol, 0.5 equiv). The reaction was stirred vigorously at room temperature 
for 30 minutes. The reaction was transferred to a separatory funnel containing saturated aq. 
NaHCO3 (7 mL), and the mixture was extracted with hexane (2 x 5 mL). The combined organics 
were dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude was purified by 
SiO2 chromatography (Hex:EtOAc 20:1) to give the product as a pale yellow oil (60.5 mg, 93%). 
 
 
TLC (5:1 hexanes:EtOAc) 
 Rf = 0.73, stained by p-anisaldehyde 
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1
H-NMR (500 MHz, CDCl3)  
δ 5.99 (d, J = 18.6 Hz, 1H), 5.79 (dd, J = 18.6, 8.0 Hz, 1H), 4.80 (dd, J = 10.2, 7.9 Hz, 
1H), 4.42 (d, J = 8.0 Hz, 1H), 4.28 (td, J = 6.9, 5.1 Hz, 1H), 4.21 (ddd, J = 11.4, 7.9, 3.7 
Hz, 1H), 4.18 – 4.09 (m, 2H), 3.75 – 3.60 (m, 3H), 3.31 (t, J = 9.7 Hz, 1H), 3.29 – 3.22 
(m, 1H), 3.15 (t, J = 9.0 Hz, 1H), 2.76 (dd, J = 16.7, 5.2 Hz, 1H), 2.56 (dd, J = 10.5, 6.8 
Hz, 1H), 2.47 (dd, J = 16.7, 7.1 Hz, 1H), 1.96 (ddd, J = 14.5, 11.1, 3.8 Hz, 1H), 1.85 (t, J 
= 7.1 Hz, 2H), 1.71 – 1.62 (m, 1H), 1.26 (s, 3H), 1.25 (s, 3H), 1.21 (d, J = 6.1 Hz, 3H), 
1.06 – 0.97 (m, 11H), 0.90 (s, 9H), 0.88 (s, 9H), 0.84 (s, 9H), 0.79 (q, J = 7.9 Hz, 6H), 
0.17 (s, 3H), 0.084 (s, 3H), 0.054 (s, 9H), 0.047 (s, 9H), 0.023 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 176.19, 170.75, 169.09, 144.28, 132.92, 126.20, 100.40, 81.98, 75.07, 74.61, 73.52, 
72.11, 68.94, 67.54, 64.10, 59.98, 54.90, 42.45, 41.43, 39.35, 39.09, 26.09, 25.98, 25.66, 
25.63, 25.45, 18.39, 18.37, 18.20, 17.89, 17.65, 9.12, 4.39, -1.45, -4.17, -4.26, -4.51, -
5.03, -5.18. 
 
HRMS (ESI)  
Calculated for C51H102N3O11Si4Ge (M+H)
+
: 1118.5803 
Found: 1118.5796 
 
 
 
Free alcohol 4.75. To the substrate 4.74 (2.17 g, 1.94 mmol, 1.0 equiv.) in a 250 mL round-
bottomed flask was added MeCN (195 mL), followed by CSA (0.496 g, 2.14 mmol, 1.1 equiv.). 
The reaction was stirred at room temperature for 72 hours, during which the solution gradually 
became darker yellow. The reaction was poured into a separatory funnel containing saturated aq. 
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NaHCO3 (500 mL) and extracted with Et2O (3 x 500 mL). The combined organics were dried 
over Na2SO4, filtered, and concentrated in vacuo. The crude was purified by MPLC using a 40 g 
RediSep GOLD silica gel column to afford the product 4.75 as a colorless solid (1.033 g, 60%) 
along with recovered 4.74 (345 mg, 16%) and the product resulting from deprotection of the 
primary TBS group (4.90, 192 mg, 10%). Recycling of this intermediate and the recovered 
starting material once through the same reaction conditions gave a total of 1.236 g (72%) product 
overall. 
 
 
TLC (5:1 hexanes:EtOAc) 
 Rf = 0.53, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
δ 6.05 – 5.90 (m, 2H), 4.48 – 4.44 (m, 1H), 4.30 (dt, J = 5.0, 7.0 Hz, 1H), 4.28 (d, J = 7.5, 
1H), 4.25 (m, 1H), 4.21 (m, 2H), 3.56 (d, J = 2.5 Hz, 1H), 3.40 (m, 1H), 3.27 – 3.22 (m, 
2H), 3.03 (t, J = 9.0 Hz, 1H), 2.85 (dd, J = 5.0, 16.5 Hz, 1H), 2.81 (dd, J = 7.0, 10.0 Hz, 
1H), 2.52 (dd, J = 7.0, 16.5 Hz, 1H), 2.13 (td, J = 7.0, 15.0 Hz, 1H), 1.84 (td, J = 4.5, 
15.0 Hz, 1H), 1.19 (d, J = 6.0 Hz, 3H), 1.03 – 0.99 (m, 11H), 0.89 (s, 3H), 0.86 (s, 3H), 
0.78 (q, J = 7.5 Hz, 6H), 0.17 (s, 3H), 0.075 (s, 3H), 0.066 (s, 3H), 0.060 (s, 9H), 0.040 
(s, 3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 171.48, 169.38, 145.33, 130.54, 102.83, 81.75, 75.44, 74.96, 73.86, 73.46, 69.66, 67.74, 
64.47, 54.06, 39.63, 39.13, 26.04, 25.66, 18.44, 18.30, 17.92, 17.55, 9.09, 4.36, -1.44, -
3.98, -4.22, -4.42, -5.02. 
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HRMS (ESI) 
Calculated for C39H78N3O9Si3
70
Ge (M+H)
+
: 886.4288 
Found: 886.4302 
 
 
 
Alcohol 4.77. The substrate 4.75 (398.7 mg, 0.4485 mmol, 1.0 equiv.) was concentrated into a 
25 mL round bottom flask from DCM. A stir bar was added, and the flask was outfitted with a 
rubber septum and evacuated on high vac, backfilling with Ar. DCM (4.5 mL) was added, 
followed by Dess-Martin periodinane (228.3 mg, 0.5382 mmol, 1.2 equiv.). The reaction was 
stirred at room temperature for 5 hours. The reaction was then diluted with Et2O (25 mL) and 
washed sequentially with saturated aq. NaHCO3 (25 mL) and brine. The organic phase was dried 
over Na2SO4, filtered, and concentrated into a 100 mL recovery flask to give the corresponding 
crude ketone 4.90 as a cloudy oil. Et2O was used for all manipulations as this was found to help 
reduce formation of the corresponding hydrate. The crude ketone 4.91 was used immediately in 
the next step.  
A stir bar was added to flask containing the substrate 4.91, and the flask was outfitted 
with a rubber septum. The flask was evacuated on high vac, backfilling with Ar. EtOH (22 mL) 
was added, and the solution was cooled to -78 °C using a dry ice/IPA bath. The septum was 
removed, and NaBH4 (8.5 mg, 0.22 mmol, 0.5 equiv.) was added. The septum was replaced, and 
the reaction was stirred for 30 minutes. The reaction was then poured into a separatory funnel 
containing half-saturated aq. NaHCO3 (100 mL) and extracted with Et2O (2 x 100 mL). The 
combined organic phases were washed with brine (1 x 100 mL), dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified by MPLC using a 40 g ResiSep GOLD 
silica gel column to afford the product 4.77 as a colorless foam (267.2 mg, 67% overall). 
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TLC (5:1 hexanes:EtOAc) 
 Rf = 0.29, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 5.99 (d, J = 18.5 Hz, 1H), 5.89 (dd, J = 7.5, 18.5 Hz, 1H), 4.49 (s, 1H), 4.36 – 4.29 (m, 
3H), 4.18 (m, 2H), 4.09 (d, J = 3.0 Hz, 1H), 3.57 (t, J = 9.0 Hz, 1H), 3.21 – 3.13 (m, 2H), 
2.82 (dd, J = 5.0, 16.5 Hz, 1H), 2.69 (dd, J = 7.0, 10.5 Hz, 1H), 2.50 (dd, J = 7.0, 17.0 
Hz, 1H), 2.09 (ddd, J = 6.0, 8.5, 14.5 Hz, 1H), 1.81 (ddd, J = 3.0, 8.0, 14.5 Hz, 1H), 1.25 
(d, J = 6.0 Hz, 3H), 1.02 – 0.98 (m, 11H), 0.89 (s, 9H), 0.85 (s, 9H), 0.78 (q, J = 7.5 Hz, 
6H), 0.20 (s, 3H), 0.092 (s, 3H), 0.059 (s, 3H), 0.052 (s, 9H), 0.036 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 170.97, 169.33, 144.32, 132.10, 98.87, 80.56, 75.08, 73.87, 71.71, 71.25, 67.71, 67.02, 
64.28, 54.75, 39.25, 39.12, 26.03, 25.66, 18.46, 18.28, 17.93, 17.64, 9.09, 4.41, -1.44, -
4.11, -4.22, -4.47, -4.98. 
 
HRMS (ESI)  
Calculated for C39H78N3O9Si3Ge (M+H)
+
: 890.4258 
Found: 890.4257 
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Persilylated lactone 4.92. The substrate (620 mg, 0.698 mmol, 1.0 equiv.) was azeotroped in a 
40 mL ICHEM vial with PhMe (2 x 10 mL). A stir bar was added, and the vial was evacuated on 
high vac with stirring, backfilling with Ar. DMF (2.3 mL) was added, followed by imidazole 
(715 mg, 10.5 mmol, 15.0 equiv.), then TBSCl (1050 mg, 6.98 mmol, 10.0 equiv.). The vial was 
sealed with a PTFE-lined cap under an Ar funnel, placed in a 45 °C heating block, and stirred for 
12 hours. The reaction was allowed to cool to room temperature and poured into a separatory 
funnel containing saturated aq. NH4Cl (50 mL). This was extracted with Et2O (2 x 50 mL), and 
the combined organic phases were washed with brine (1 x 25 mL), dried over Na2SO4, and 
concentrated in vacuo. The resulting crude oil was purified by MPLC using a 40 g RediSep 
GOLD silica gel column to afford the product as a colorless viscous oil (660 mg, 94%). 
 
 
TLC (5:1 hexanes:EtOAc) 
 Rf = 0.60, stained by p-anisaldehyde 
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1
H-NMR (500 MHz, CDCl3)  
δ 5.96 (d, J = 18.6 Hz, 1H), 5.84 (dd, J = 18.6, 7.7 Hz, 1H), 4.35 (s, 1H), 4.31 (td, J = 7.1, 
5.4 Hz, 1H), 4.28 – 4.24 (m, 1H), 4.24 – 4.11 (m, 3H), 3.96 (d, J = 2.5 Hz, 1H), 3.47 (t, J 
= 9.1 Hz, 1H), 3.20 (dd, J = 9.5, 2.6 Hz, 1H), 3.14 (dq, J = 8.7, 6.1 Hz, 1H), 2.78 (dd, J = 
16.7, 5.3 Hz, 1H), 2.61 (dd, J = 10.4, 6.8 Hz, 1H), 2.48 (dd, J = 16.7, 7.0 Hz, 1H), 2.08 
(ddd, J = 14.5, 10.6, 4.2 Hz, 1H), 1.71 (ddd, J = 14.0, 10.3, 2.1 Hz, 1H), 1.20 (d, J = 6.2 
Hz, 3H), 1.00 (t, J = 8.0 Hz, 9H), 0.91 (s, 9H), 0.89 – 0.87 (m, 11H), 0.84 (s, 9H), 0.77 
(q, J = 8.1 Hz, 6H), 0.15 (s, 3H), 0.11 (s, 3H), 0.085 (s, 3H), 0.064 (s, 3H), 0.050 (s, 
12H), 0.026 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 170.83, 169.32, 144.78, 132.19, 99.60, 80.72, 74.99, 74.00, 72.05, 71.96, 68.85, 67.55, 
64.05, 55.01, 39.25, 39.09, 26.10, 26.07, 25.67, 18.68, 18.60, 18.29, 17.93, 17.72, 9.11, 
4.43, -1.43, -3.56, -4.03, -4.19, -4.48, -4.92, -4.99. 
 
HRMS (ESI)  
Calculated for C45H92N3O9Si4Ge (M+H)
+
: 1004.5122 
Found: 1004.5116 
 
 
 
Vinyl iodide 4.78. A 50 mL round bottom flask containing the substrate (586 mg, 0.584 mmol, 
1.0 equiv.) and a stir bar was outfitted with a rubber septum, and the flask was evacuated on high 
vac and backfilled with Ar. DCM (6.5 mL) was added, and the solution was cooled to 0 °C and 
stirred. To a 40 mL ICHEM vial was added I2 (757 mg) and a stir bar. A spatula was used to 
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crush the I2 into small pieces. The vial was capped with a septum cap and briefly evacuated on 
high vac, backfilling with Ar. This process was repeated two more times. DCM (16.6 mL) was 
added, and the solution was stirred at room temperature for 10 minutes. Next, 13.0 mL of this 
solution (593 mg I2, 2.34 mmol, 4.0 equiv.) was added dropwise over 12 minutes down the side 
of the flask containing the substrate using a syringe pump. After addition was complete, the dark 
purple reaction was stirred at 0 °C for 5 hours. The reaction was diluted with Et2O (50 mL) and 
poured into a separatory funnel containing saturated aq. Na2S2O3 (50 mL). The contents of the 
funnel were shaken until no color remained in the organic layer, and the layers were separated. 
The aqueous layer was extracted with Et2O (1 x 50 mL), and the combined organic layers were 
washed with brine (1 x 30 mL), dried over Na2SO4, and concentrated in vacuo. The resulting 
crude material was purified by MPLC using a 40 g RediSep GOLD silica gel column to afford 
the product as a pale yellow oil (496 mg, 88%). 
 
 
TLC (5:1 hexanes:EtOAc) 
 Rf = 0.50, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
δ 6.47 (dd, J = 14.5, 7.9 Hz, 1H), 6.40 (d, J = 14.5 Hz, 1H), 4.37 (td, J = 7.2, 5.4 Hz, 1H), 
4.33 (s, 1H), 4.30 (ddd, J = 10.0, 7.9, 4.3 Hz, 1H), 4.26 – 4.13 (m, 3H), 3.97 (d, J = 2.6 
Hz, 1H), 3.47 (t, J = 9.1 Hz, 1H), 3.22 – 3.12 (m, 2H), 2.86 (dd, J = 16.9, 5.4 Hz, 1H), 
2.60 (dd, J = 10.4, 7.2 Hz, 1H), 2.50 (dd, J = 16.9, 7.2 Hz, 1H), 2.05 (ddd, J = 14.6, 10.7, 
4.3 Hz, 1H), 1.73 (ddd, J = 14.1, 10.0, 2.2 Hz, 1H), 1.25 (d, J = 6.2 Hz, 3H), 1.04 – 0.96 
(m, 2H), 0.91 (s, 9H), 0.89 (s, 9H), 0.85 (s, 9H), 0.16 (s, 3H), 0.10 (s, 3H), 0.076 (s, 3H), 
0.068 (s, 3H), 0.066 – 0.056 (m, 12H), 0.043 (s, 3H). 
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13
C-NMR (125 MHz, CDCl3)  
δ 170.70, 168.98, 145.55, 99.97, 79.66, 79.26, 74.32, 73.97, 71.94, 71.83, 68.75, 67.32, 
64.19, 54.95, 39.15, 39.06, 26.06, 26.00, 25.63, 18.59, 18.56, 18.25, 17.89, 17.69, -1.39, -
3.74, -4.04, -4.27, -4.45, -4.89, -4.99. 
 
HRMS (ESI) 
Calculated for C39H77N3O9Si4I (M+H)
+
: 970.3782 
Found: 970.3798 
 
 
Ketene acetal phosphate 4.81. To a 7 mL vial containing a stir bar was added THF (0.14 mL), 
(PhO)2P(O)Cl (0.027 mL, 0.13 mmol, 2.5 equiv.), and HMPA (0.022 mL, 0.13 mmol. 2.5 
equiv.). This solution was cooled to -78 °C and a solution of LHMDS in THF (1.0 M, 0.13 mL, 
0.13 mmol, 2.5 equiv.) was added. Next, a solution of the lactone 4.78 (50.0 mg, 0.0515 mmol, 
1.0 equiv.) in THF (0.15 mL) was added down the side of the vial over 8 minutes. An additional 
amount of THF (0.1 mL) was used as a wash and added to the reaction over 1 minute. The 
reaction was stirred at -78°C for 3.5 hours. The vial was removed from the ice bath, and aq. 
potassium phosphate buffer (0.5 M, pH 7.0, 1 mL) was added, followed by Et2O (0.5 mL). The 
mixture was stirred at room temperature for 10 minutes. The layers were separated, and the 
aqueous phase was extracted with Et2O (2 x 1 mL). The combined organics were dried over 
Na2SO4, filtered, and concentrated in vacuo. The resulting crude was purified by reversed phase 
MPLC (MeCN  EtOAc) to afford the recovered starting material (8.1 mg) and the desired 
product (28.5 mg, 55% BORSM). 
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TLC (5:1 hexanes:EtOAc, 1% Et3N) 
 Rf = 0.56, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3)  
δ 7.41 – 7.35 (m, 4H), 7.28 – 7.21 (m, 6H), 6.41 (dd, J = 14.5, 8.1 Hz, 1H), 6.30 (d, J = 
14.5 Hz, 1H), 4.77 (dt, J = 6.8, 3.0 Hz, 1H), 4.49 – 4.46 (m, 1H), 4.25 – 4.16 (m, 3H), 
4.16 – 4.10 (m, 2H), 3.86 (d, J = 2.6 Hz, 1H), 3.44 (t, J = 9.1 Hz, 1H), 3.11 – 3.04 (m, 
2H), 2.62 (dd, J = 8.8, 7.2 Hz, 1H), 2.18 (ddd, J = 14.7, 11.1, 4.2 Hz, 1H), 1.60 (ddd, J = 
13.6, 10.2, 2.6 Hz, 1H), 1.21 (d, J = 6.1 Hz, 3H), 1.01 – 0.96 (m, 2H), 0.90 (s, 18H), 0.85 
(s, 9H), 0.16 (s, 3H), 0.086 (s, 3H), 0.071 (s, 3H), 0.058 – 0.051 (m, 9H), 0.048 (s, 3H), 
0.035 (s, 3H), 0.009 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3)  
δ 171.27, 150.19, 150.13, 145.47, 130.08, 130.07, 125.99, 125.94, 120.28 (d, JC-P = 1.9 
Hz), 120.24 (d, JC-P = 2.1 Hz), 100.02, 86.72 (d, JC-P = 5.8 Hz), 79.80, 79.63, 74.78, 
73.87, 71.96, 71.83, 68.78, 66.54, 63.81, 52.88, 37.13, 26.09, 26.01, 25.78, 18.58, 18.28, 
18.02, 17.60, -1.36, -3.69, -4.04, -4.23, -4.33, -4.90, -4.96. 
 
HRMS (ESI) 
Calculated for C51H85N3O12Si4PINa (M + Na)
+
: 1224.3890 
Found: 1224.3859 
152 
 
 
 
BB2. To a 7 mL vial was added vinyl iodide 4.81 (19.4 mg, 0.0161 mmol, 1.0 equiv.), bis-
metalated olefin 4.5 (10.7 mg, 0.0226 mmol, 1.4 equiv.), and a stir bar. This was brought into the 
glovebox, and a solution of PdCl2(MeCN)2 (0.21 mg, 0.00081 mmol, 0.05 equiv.) in DMF (0.16 
mL) was added. The vial was capped with a PTFE-lined cap, removed from the glovebox, placed 
in a 65 °C heating block, and stirred for 4 hours. The reaction was then allowed to cool to room 
temperature and taken back into the glovebox. PdCl2(MeCN)2 (0.21 mg, 0.00081 mmol, 0.05 
equiv.) in DMF (0.16 mL) was added. The vial was capped with a PTFE-lined cap, removed 
from the glovebox, placed in a 65 °C heating block, and stirred for 17 more hours. The reaction 
was allowed to cool to room temperature, diluted with Et2O, filtered through Celite, and 
concentrated in vacuo, azeotroping with DMF. The crude material was adsorbed onto C18 silica 
gel from acetone and purified by reversed phase MPLC (MeCN  EtOAc). This gave 22.2 mg 
of a mixture of desired product and vinyl MIDA boronate in a 1:0.34 ratio. This was repurified 
by SiO2 chromatography (Hex:EtOAc 3:1  1:1  1:3, 1% Et3N in each eluent system) to give 
BB2 as a pale yellow oil (8.9 mg, 44%). 
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TLC (1:3 hexanes:EtOAc, 1% Et3N) 
 Rf = 0.28, stained by p-anisaldehyde 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.40 – 7.33 (m, 4H), 7.27 – 7.20 (m, 6H), 6.58 (dd, J = 17.5, 10.3 Hz, 1H), 6.21 (dd, J = 
15.3, 10.3 Hz, 1H), 5.62 (dd, J = 15.4, 8.3 Hz, 1H), 5.45 (d, J = 17.4 Hz, 1H), 4.75 (dt, J 
= 7.4, 3.1 Hz, 1H), 4.46 (t, J = 2.4 Hz, 1H), 4.25 (d, J = 0.9 Hz, 1H), 4.25 – 4.10 (m, 4H), 
3.88 – 3.86 (m, 1H), 3.82 – 3.63 (m, 4H), 3.43 (t, J = 9.2 Hz, 1H), 3.12 – 3.05 (m, 2H), 
2.76 (s, 3H), 2.66 – 2.61 (m, 1H), 2.22 (ddd, J = 14.6, 11.0, 4.0 Hz, 1H), 1.64 (ddd, J = 
13.5, 10.0, 2.4 Hz, 1H), 1.16 (d, J = 6.2 Hz, 3H), 0.98 (dd, J = 9.6, 7.7 Hz, 2H), 0.90 (s, 
9H), 0.89 (s, 9H), 0.84 (s, 9H), 0.15 (s, 3H), 0.09 (s, 3H), 0.07 (d, J = 1.1 Hz, 3H), 0.06 
(s, 3H), 0.05 (s, 9H), 0.02 (s, 3H), -0.002 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 171.54, 167.16, 167.07, 150.35, 143.79, 134.74, 134.34, 130.11, 126.03, 120.27, 
120.23, 99.58, 86.82 (d, JC-P = 5.8 Hz), 77.57, 75.10, 73.89, 71.95, 71.89, 68.82, 66.73, 
63.84, 61.56, 61.51, 53.01, 46.67, 37.94, 26.08, 26.05, 25.76, 18.60, 18.26, 18.00, 17.58, 
-1.37, -3.61, -4.05, -4.25, -4.32, -4.93, -4.96. 
 
HRMS (ESI) 
Calculated for C58H94BN4O16Si4PNa (M+Na)
+
: 1279.5470 
Found: 1279.5463 
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